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Demyelination disrupts neuronal signalling and can have profound effects on 
neurological control. No therapies currently exist to encourage remyelination and 
treatment options are based on preventing further demyelination highlighting the 
need to develop effective therapies for demyelinating diseases. Recent trials aimed 
at the leucine rich repeat (LRR) protein, LINGO1 to encourage remyelination have 
shown promising preclinical data however phase II clinical trials have been 
unsuccessful. The analogous LRR protein, AMIGO3 is predicted to overcome 
LINGO1 inhibition and therefore needs to be investigated for its role in 
oligodendroglia. We have investigated the expression profile of AMIGO3 in 
myelination and demyelinating disease. AMIGO3 is upregulated rapidly in 
oligodendrocyte precursor cells (OPCs) following trauma and in experimental 
autoimmune encephalomyelitis (EAE). Downregulation of AMIGO3 also corresponds 
with development myelination however AMIGO3 mRNA levels do not change 
following induction of OPC maturation in vitro. As AMIGO3 is raised following trauma, 
AMIGO3 could provide a pathological inhibition of OPC maturation in demyelinating 
diseases. We have also identified the NgR1 receptor complex on OPCs highlighting 
a potential biding partner that AMIGO3 could function through in disease. These data 
suggest that therapies aimed at inhibiting AMIGO3 will be promising in encouraging 
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1.1 Myelin and the mammalian nervous system 
1.1.1 The role of myelin in saltatory conduction and the metabolic and 
trophic support of axons 
Myelin is an insulating substance found in segments along axons, predominantly 
but not exclusively in white matter. Each myelin segment tends to be roughly 150μm 
in length (Aggarwal et al., 2011). Arguably, the primary role of myelin is to maintain 
proper saltatory conduction. This is achieved by increasing the electrical resistance 
across the axonal membrane inhibiting the passage of ions, preventing the loss of 
depolarisation, therefore allowing the charge to flow along the axon (Arancibia-
Carcamo and Attwell, 2014). Despite the insulation, as the action potential (AP) 
travels down the axon, there will always be some loss of charge across the 
membrane and myelin ensheathment. Small gaps between myelinated segments, 
known as nodes of Ranvier, and the surrounding paranodal regions, contain the 
voltage gated Na+ and K+ channels respectively that are necessary to replenish the 
AP. This process of insulation and recharging is known as saltatory conduction, and 
can upregulate the conduction speed of the APs up to twenty times (Waxman, 1982; 
Bear et al., 2007; Neishabouri and Faisal, 2014; Carroll, 2017) (fig 1.1). Additionally, 
because the charge is only replenished at the nodes of Ranvier, regenerative 






Figure 1.1: Saltatory conduction. (A) An AP is generated at the cell body or at a 
node of Ranvier through the influx of Na+. This in turn starts to flow down the axon. 
(B) With an unmyelinated axon, a large amount of the Na+ and therefore charge 
would flow out of the axon back in to the extracellular space. Myelin however 
increases the resistance to flow across the membrane, therefore more of the charge 
flows down the axon, increasing the rate of propagation of the charge down said 
axon. K+ will flow out through K+ voltage gated channels, allowing for the 
repolarisation and hyperpolarisation, preventing backflow of the AP. Although the 
rate of propagation has increased, some of the charge will leak across the membrane 
through the myelin sheath. (C) To overcome the inevitable loss of charge the AP is 
topped up at the subsequent node of Ranvier and the AP can continue to fire along 
the axon at the increased propagation rate. 
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Myelin may be important in plasticity, providing a method of speeding up and 
slowing conduction speeds to allow for proper coordination between neurons (Liu et 
al., 2012; Seidl, 2014; Saab and Nave, 2017). For example, it has been suggested 
that oligodendrocytes (OLs) may alter internode length and node of Ranvier sizes to 
alter the rate of propagation (Waxman et al., 1972; Waxman, 1997; Bakiri et al., 
2011; Fields, 2014; Hill et al., 2018).  Myelin is also known to play an important role 
in axonal survival, providing both trophic and metabolic support (Yin et al., 2006; 
Bercury and Macklin, 2015; Purger et al., 2016; Hill et al., 2018). Pyruvate and 
lactate generated during OL glycolysis can migrate to the ensheathed axon and aid 
in axonal metabolism supporting these cells in anaerobic conditions (Funfschilling et 
al., 2012; Morrison et al., 2013; Saab and Nave, 2017). Additionally, OLs produce 
MMP9, an angiogenic factor, thereby helping to provide vascularisation to the axon 
(Pham et al., 2012). It should also be noted that myelination helps to reduce axonal 
metabolic demand as well by reducing the area of the membrane requiring 
adenosine triphosphate (ATP) dependent Na+/K+ transporters to maintain the ion 
gradients required for the action potential. Denuded axons have to distribute voltage 
gated sodium and potassium channels across the entire membrane, rather than just 
at the nodes of Ranvier, to maintain an action potential. This requires a greater 
number of channels, and therefore a greater amount of ATP to maintain the same 
function (Nave, 2010; Frühbeis et al., 2013; Freeman et al., 2016). Trophic support is 
provided through the production of neurotrophic factors and cytokines, such as glial 
cell line-derived neurotrophic factor (GDNF) and insulin-like growth factor 1 (IGF1) 
(Wilkins et al., 2003; Miyamoto et al., 2014). 
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1.1.2 Structure of myelin 
Myelin forms in concentric rings around an axon, to make multi-layered and 
densely packed ensheathing segments around an axon. Two distinct layers have 
been identified through electron microscopy (EM), a dense cytoplasmic layer known 
as the major dense line, and a less dense intercellular layer, known as the 
interperiodic line (fig 1.2). Lipids make up to 81% of the dry weight of myelin’s final 
structure, accounting for 50% of the total lipids in the white matter (Aggarwal et al., 
2011; Chrast et al., 2011; Michalski and Kothary, 2015; Saab and Nave, 2017). The 
high hydrophobicity of myelin causes the proteins and lipids to densely pack together 
and repel the aqueous cytoplasm and extracellular fluids (O'Brien, 1965; Aggarwal et 
al., 2011). A high proportion of these lipids have long hydrocarbon chains, increasing 
the Van der Waal’s interactions between local lipids and proteins and therefore 
increasing the density of the structure (Aggarwal et al., 2011). Myelin also contains a 
high proportion of hydrophobic proteins/proteolipids. This results in a highly insulative 
ensheathing material, which makes myelin especially well suited for its role in 
saltatory conduction. 
A number of proteins are included in the structure of myelin, with the predominant 
proteins being myelin basic protein (MBP) and proteolipid protein (PLP). The 
cytoplasmic layers of the lipids are held together with MBP, whilst PLP plays a role in 
zipping the extracellular surfaces together, although it is not integral for this role 




Figure 1.2: Diagram demonstrating the structure of myelin. Dense layers of 
membranes are held together. Two major layers are observed, the major dense line 






protein (MOG), myelin-associated glycoprotein (MAG) and 2’3’-cyclic-nucleotide 3’-
phosphodiesterase (CNP) are also integral components of myelin although they are 
present at much lower levels than MBP and PLP. 
1.1.3 Myelin production in mammals 
1.1.3.1 Myelin in the central nervous system 
In the central nervous system (CNS), myelin is created by OLs (Seidl, 2014). As 
oligodendrocyte precursor cells (OPCs) mature, they create multiple processes which 
search for and bind to local axons. This is done in a similar manner as the axon’s 
growth cone, in that lamellipodia and filopodia explore the environment and extend 
towards their targets (Shao et al., 2017) (fig 1.3). 
 Once in contact with an axon, the processes extend radially inwards around the 
axon creating multiple concentric layers which are held together by gap junctions and 
other myelin proteins (Michailidou et al., 2014; Saab and Nave, 2017). The leading 
end of the process, known as the inner tongue, pushes underneath the previous 
layer to produce this effect (Michalski and Kothary, 2015). Once the concentric layers 
are produced, the cytoplasm of the process is compacted, largely through the action 
of MBP which binds to and draws the cytoplasmic membranes together (Aggarwal et 
al., 2011; Michalski and Kothary, 2015). Longitudinal expansion also occurs during 
this process to produce the full length myelin internode (Michalski and Kothary, 
2015). Each OL can produce multiple processes which adhere and ensheath a 




Figure 1.3: (A) OPCs migrate into a nerve in multiple waves during development. 
(B) Once OPCs are present, they proliferate and adhere to neighbouring axons. (C) 
After adhering to axons, some OPCs will differentiate, create myelin and ensheath 
the axons. Multiple axons can be myelinated by a single OL. Not all OPC will mature 
and a population of OPC will reside to provide a source for further myelination 
throughout life. (D) When the OL adheres, the process will begin to ensheath the 
axon. (E) Once the myelinated process has performed one full revolution, the leading 
end of the process, the inner tongue, will advance underneath the previous layer. (F)  
Concentric rings of myelinated processes wrap around the axon as the inner tongue 
continues to push underneath the previous layers. These layers will then become 
compacted together to create dense ensheathing layers.
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 Origins and development of OLs 
OPCs the multipotent stem cell line which differentiate to mature OLs, are found 
throughout the CNS of adults. These OPCs have a consistent turnover in the adult 
CNS, with local OPCs being able to propagate and differentiate as required (Hill et 
al., 2018). OPCs are also referred to as NG2+ cells due to the presence of NG2 on 
the cell membrane which is downregulated as the cells mature. It should also be 
noted that there is evidence that NG2+ cells also have the ability to differentiate into 
certain neurons and astrocytes (Nishiyama et al., 2009; Michalski and Kothary, 
2015). 
As well as NG2, a number of markers have been identified that are useful for 
determining the stage of differentiation of oligodendroglia (OLG). Markers that have 
been identified for immature OPCs include platelet-derived growth factor α receptor 
(PDGFαR) and A2B5, as well as NG2 itself (Polito and Reynolds, 2005; Miron et al., 
2011). O4 and O1 are markers of developing OPC. O4 appears to be a sign of OLs 
which have begun to differentiate, reaching a pro-OL stage, whereas O1 is 
expressed in the later stages of OPC differentiation, prior to full maturation (Sypecka 
et al., 1995; Polito and Reynolds, 2005; Abbaszadeh et al., 2014). 
Galactocerebroside (GalC) has also been identified as a marker of differentiating 
OPCs (Kuhlmann et al., 2008). Finally, a number of marker proteins have been 
identified in the CNS that are useful for identifying mature OLs. Firstly as myelin is 
present in high levels only in mature OLs, proteins such as MBP, MOG and PLP are 
predominantly in mature OL. Other commonly used markers of mature OLs include 
adenomatous polyposis coli (with the main antibody against the protein also known 
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as CC1), carbonic anhydrase 2 (CAII) and 2’, 3’-cyclic-nucleotide 3’-
phosphodiesterase (CNPase) (Kida et al., 2006; Crawford et al., 2016). These 
markers, although they have their various weaknesses, all are useful for monitoring 
the changing phenotypes. Additionally, morphology provides a useful criteria in vitro 
for assessing maturation in OLG cell lines and in primary cultures. Primary OPCs 
present as small cells with two processes, which transition into more complex stellate 
forms as differentiation proceeds. It is not until the latter stages of differentiation that 
myelin is produced, which in culture appears as a membranous layer, known as the 
myelin sheath, that surrounds the processes (fig 1.4) (O'Meara et al., 2011).  
OPCs in both the developing spinal cord and cerebrum, originate from neural 
precursor cells (NPCs) in the ventral ventricular zone of the medial ganglionic 
eminence (MGE) (Mitew et al., 2014; Bergles and Richardson, 2015; Takebayashi 
and Ikenaka, 2015). This appears to be a Sonic Hedgehog derived reaction that 
induces this differentiation and migration (Nishiyama et al., 2009; Takebayashi and 
Ikenaka, 2015). A second wave then appears from the lateral ganglionic eminence. 
These OPC in turn migrate across the developing CNS of the embryonic mouse, 
although it should be noted that myelination is not achieved during this time (Mi et al., 
2004; Bergles and Richardson, 2015). After birth, new OPCs are derived from the 
cortical ventricular zone. Over time these cortical derived OPCs become the majority 





Figure 1.4: Representative images of OLG in culture. (A) OPC cultures before 
differentiation. OPCs can be seen to have large bright nucleus and are bipolar or 
multipolar with few processes. (B) OLG further along the differentiation process can 
be seen to have a more stellate appearance as process expand and diverge to 
searching for axons to myelinate. Scale bars represent 50μm.
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1.1.3.2 Peripheral nervous system 
Myelin is also created in the peripheral nervous system (PNS) to insulate and 
protect peripheral axons. A separate cell line is used to generate myelin in the PNS, 
known as Schwann cells (SCs). There are two forms of Schwann cells, myelinating 
and non-myelinating (Monk et al., 2015). Unlike OLs, myelinating Schwann cells are 
only able to interact with a single axon, although the ensheathing process is very 
similar in that they adhere to and then wrap multiple layers around the axon to 
ensheath the axon. Similarly, the cytoplasm of the ensheathing layers contains the 
myelin to insulate the axon (Belin et al., 2017). Both cells types demonstrate 
metabolic and trophic support however only the myelinating SCs provide the 
insulation required for saltatory conduction (Monk et al., 2015; Salzer, 2015). The 
non-myelinating SCs pack in more densely along the axons, presumably as nodes of 
Ranvier and saltatory conduction is irrelevant. These cells also are able, like OLs, to 
bind with multiple axons (Monk et al., 2015). Unlike OPCs, SC precursors derive from 
the trunk neural crest and can only partially mature to immature SCs until postnatal 
stages of development. The precursor forms are migratory and disperse throughout 
the PNS following the developing axons (Dong et al., 1995). These precursors settle 
with PNS axons and differentiate to the immature form before continuing 
development postnatally into the myelinating or non-myelinating form, depending on 
which type of axons they contact. For example, the non-myelinated C-fiber 
nociceptor neurons signal for non-myelinating SCs (Bhatheja and Field, 2006; Monk 
et al., 2015). Interestingly, unlike OLG, when both myelinating and non-myelinating 
SCs lose contact with axons, they are able to de-differentiate back to the immature 
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form allowing them to be recycled when axonal contact is re-established (Bhatheja 
and Field, 2006). 
1.2 Demyelination and demyelinating diseases 
Demyelination is the loss of the myelin sheath that surrounds the axon (Kutzelnigg 
and Lassmann, 2014). A number of demyelinating diseases exist, which are varied 
and can be associated with the CNS as well as the PNS, or in rare cases, can affect 
both (Love, 2006; Zephir et al., 2008). The effects of demyelination can be severe, 
through the loss of proper signalling, which has been reported produce up to a 20 
fold reduction in propagation rate, if not ablating the signal entirely (Waxman, 1982). 
Additionally, focal damage can result in a lack of synchronicity between neurons, 
preventing appropriately timed summation or inhibition between neuronal signalling 
(Cover et al., 2006; Pan et al., 2017). 
Demyelination can occur in acute forms through damage to myelin producing cells 
or through specific diseases. These diseases are varied, and cases exist of CNS, 
PNS or both simultaneously being affected (Love, 2006; Menon et al., 2014). On top 
of demyelinating diseases, dysmyelinating diseases are also prevalent, where the 
myelin is still produced, but it is not produced correctly (Love, 2006; Vanderver et al., 
2015). Examples of these include Krabbe’s disease, Canavan’s disease and 
Pelizaeus Merzbacher’s disease (Torii et al., 2014; Graziano and Cardile, 2015). This 
could happen through the improper production of the myelin such that it does not 
produce the dense ensheathing layer, resulting in similar inefficiencies for the 
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affected axons (Sarbu et al., 2016; Gregath and Lu, 2018). The most prevailing 
myelin disorder is multiple sclerosis (MS) (Goldenberg, 2012). 
1.2.1 Remyelination 
Remyelination is the process whereby myelin is restored to neurons following 
pathological demyelination. This is separate from the act of myelination which is 
simply the original addition and maintenance of myelin in healthy nervous systems. 
OLs that survive the demyelination are not able to develop new processes and 
engage in remyelination. This is clear from labelled endogenous OLs and 
transplanted OLs that fail to induce any degree of remyelination in models of 
demyelination (Targett et al., 1996; Crawford et al., 2016). Furthermore, when 
demyelination occurs however mature OLs survive, the areas of demyelination 
develop greater number of OLs than before the focal demyelination (Blakemore and 
Keirstead, 1999; Anastasiadis et al., 2000). Furthermore, labelled mature OLs have 
been demonstrated to fail to migrate in to focal demyelinated sites in murine spinal 
cord or even to produce processes from the periphery of the lesion. Instead all novel 
remyelination was produced by OLs that had been derived from OPCs (Crawford et 
al., 2016). This demonstrates that there is a drive to create new OLs for novel 
remyelination rather than activating the surviving OLs to engage in remyelination. 
OPC are considered to be the principal source of remyelinating OL in the CNS. In 
acute forms of demyelination, when the axons remain relatively healthy, 
remyelination will occur as local OPCs mature and adhere to the surviving axons 
(Franklin and Ffrench-Constant, 2008). OPCs are also able to migrate to the site of 
demyelination to produce the new OLs and myelin. These OPC create processes 
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which start to develop expression of myelin. Subsequently, they adhere to and 
ensheath the surviving axons with a new coat of myelin (Boyd et al., 2013; Bercury 
and Macklin, 2015). 
1.2.2 Multiple sclerosis 
MS is primarily considered an immunopathologic disease which is associated with 
break-down of the blood brain barrier and invasion of immune cells which attack and 
destroy the myelinating OLs (Goldenberg, 2012). Destruction and phagocytosis of 
the myelin as well as the denuding of local axons occurs as a result of the 
autoimmune attack. Inefficient propagation of action potentials and axonal 
damage/death follows, eventually leading to the development of localised plaques. 
These plaques and lesion sites are predominantly located at white matter tracts, and 
are sites of axonal loss and reactive glial scars (Lassmann et al., 2007; Goldenberg, 
2012; Kutzelnigg and Lassmann, 2014; Lopes Pinheiro et al., 2016). The exact 
distribution is somewhat random and does not show an obvious progression pattern, 
however the regions affected predominantly are the optic nerve, cervical spinal cord, 
cerebellar white matter and the pons and medulla (Kutzelnigg and Lassmann, 2014). 
As a result, the disease is characterised by progressive CNS demyelination (Satoh et 
al., 2005; Patrikios et al., 2006; Patani et al., 2007). In rare cases, and in early stages 
of MS, minimal disability may be observed, but the majority of patients experience 
progressive CNS disability and loss of motor control. MS can also result in a number 
of direct or indirect symptoms including acute/chronic pain, ataxia vertigo, bladder 
dysfunction, depression, paralysis, visual defects as well as numerous others 
(Goldenberg, 2012; Jadasz et al., 2012; Boeschoten et al., 2017).  
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Owing to the limited understanding of MS aetiology, there are a number of clinical 
classifications of the disease. The earliest form of MS is clinically isolated syndrome 
(CIS). CIS is defined as the first clinical and symptomatic presentation of MS. This 
can be further categorised as active or inactive depending on the presentation of 
lesions identified through magnetic resonance imaging (MRI) (Lublin et al., 2014). 
Three further forms exist of the ‘active’ form of the disease, with the most common 
form of MS being relapsing remitting MS (RRMS). Patients exhibit acute relapses 
with rapid onset of symptoms, before periods of remission where the symptoms 
lessen and can ablate entirely in early stages of the disease. The remission rarely 
returns to symptomatic levels before the relapse, however some degree of recovery 
is observed until the next relapse (fig 1.5A). This form tends to progress on to 
secondary progressive (SPMS) where the symptoms continually develop without 
periods of relapse or remission anymore. Remissions can appear however patients 
always exert a progressive degree of disability (fig 1.5B). Primary Progressive 
(PPMS) is similar to SPMS, however patients do not exhibit any form of relapses or 
remission and show a constant degradation, therefore it does not progress from a 
relapse and remission stage (fig 1.5C). A further subcategory, known as ‘PPMS with 
activity’, or previously as progressive relapsing (PRMS), is similar to PPMS, except 
that patients also exhibit relapse periods with severe worsening of symptoms but do 
not observe any degree of recovery (Goldenberg, 2012; Jadasz et al., 2012; Lublin, 
2014; Nelson et al., 2016). The final form, radiologically isolated syndrome (RIS) 
exists, where lesions are observed though MRI, however there are no clinical signs 




Figure 1.5: Representation of the progression of the different forms of MS. (A) 
RRMS, where relapses lead to a progression in disease state. Some degree of 
recover occurs but not returning to the baseline before the relapse. (B) SPMS, where 
relapses progress on to a constant progressive dehabilitation. (C) PPMS, where 
constant disease progression occurs independent of a previous relapsing-remission 
stage of the disease. (D) PPMS with activity, which is similar to RRMS, however 
disease progression occurs both in the form of remissions and relapses, as well as 
constantly during the remission stage of disease.
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As previously stated, MS is the most prevalent CNS demyelinating disease. 
Modern estimates are difficult to find due to a lack of studies (Marrie et al., 2015), 
however MS affected 0.54 million people in Europe in 2010 and over 2.5 million 
worldwide in 2017, as well as up to 100,000-200,000 people in the UK (Multiple 
Sclerosis International Federation, 2013; Tullman, 2013; DiLuca and Olesen, 2014; 
Mackenzie et al., 2014; Ponzio et al., 2015). MS has a peak onset of 20-25 years 
(Lindsay et al., 1997) and is much more prevalent in women than men, with an 
approximate prevalence ratio of 3:1 for women to men (Wallin et al., 2012; Harbo et 
al., 2013). Interestingly, there appears to be a geographical distribution, with far more 
cases observed in Europe and Northern America 100/100,000, compared to 
5/100,000 in South America, Africa and Asia (Simpson et al., 2011). Although a 
genetic factor has been associated, linking Caucasians to a higher risk, latitude also 
presents an environmental risk factor with family members at a higher risk in northern 
latitudes (Love, 2006; O'Gorman et al., 2012; Khan et al., 2015). A number of other 
risk factors have been identified for MS including viruses, specifically the Epstein-
Barr virus, vitamin D levels and genetics, through major histocompatibility complex 
(MHC) modifications as well as proteins involved with the action of vitamin D (Lucas 
et al., 2011; O'Gorman et al., 2012; Alharbi, 2015). 
The prevalence and symptoms of MS alone, without taking account of 
demyelinating and dysmyelinating diseases, demand further investigation both for the 
social and economic impacts. Treatment in Europe alone for MS accounted for £12.5 
billion in 2010 (Ponzio et al., 2015). Additionally, it should be highlighted that both 
loss of productivity and employment following MS diagnosis also has a major 
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socioeconomic impact, estimated to result in production losses almost costing as 
much as treating the disease itself (van der Hiele et al., 2015). Finally, a number of 
studies note an increasing incidence of MS, highlighting the need for an effective 
treatment to be developed (Pugliatti et al., 2006; Jennum et al., 2012; Olesen et al., 
2012; Ponzio et al., 2015). These factors validate the need to develop novel 
treatments to effectively treat patients and prevent the loss of function associated 
with disease progression. 
1.2.2.1 Aetiology of MS 
MS is predominantly considered an immunopathologic autoimmune disease, 
whereby patient’s immune system attacks OLs, leading to chronic demyelination 
(Patani et al., 2007; Goldenberg, 2012; Matveeva et al., 2018). Although 
remyelination does occur acutely, the remyelination is inadequate and eventually fails 
resulting in the chronic demyelination observed in developed plaques (Patani et al., 
2007). MS is believed to be driven by the activation of T helper (Th) cells, also known 
as CD4+ cells, by antigen presenting cells which have incorrectly taken up epitopes 
from myelin proteins (Ghasemi et al., 2017). CD4+ T cells differentiate in to Th1 or 
Th17 cells which produce interferon-gamma (IFN-γ) and interleukin-17 (IL-17) 
respectively. These cells have then been shown to mediate the autoreactivity in 
experimental autoimmune encephalomyelitis (EAE), the leading rodent model for 
inflammatory demyelination (see section 2.1.2 for more details) and have been found 
within lesions and plaques of MS patients in post-mortem tissue (Grigoriadis et al., 
2015). Furthermore, preventing the development of these cells in EAE induced mice 
reduces disease incidence and clinical score, demonstrating the role of these cells in 
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disease development in EAE (Komiyama et al., 2006; Beurel et al., 2013). Originally 
believed to be a predominantly Th1 driven disease, studies have shown raised IL-17 
transcripts in MS plaques as well as an increased ability of transplanted, activated 
Th17 cells to induce EAE, compared to Th1 cells (Lock et al., 2002; Langrish et al., 
2005; Aranami and Yamamura, 2008). Additionally, mice deficient in components of 
the Th1 differentiation pathway still maintain the ability to develop EAE (Korn et al., 
2009), whereas mice deficient in components of the Th17 pathway differentiation are 
protected from the disease (Veldhoen et al., 2006). This demonstrates that Th17 
cells may be the predominant immune cell type in immune pathogenesis in the EAE 
model of MS. Th17 cells produce a number of pro-inflammatory cytokines, which 
draw inflammatory cells to the CNS and exacerbate symptoms. B cells and cytotoxic 
T cells (CD8+) have also been implemented in the development of EAE and MS 
(Ghasemi et al., 2017). 
One theory is that autoreactive T-cells are generated through a failure of the 
immune system to prevent their production or potentially due to antigen presenting 
cells (APCs) taking up and presenting foreign proteins which share similar epitopes 
to myelin proteins following an infectious agent, such as the Epstein-Barr virus 
(Baker and Amor, 2014). The autoreactive APCs activate the T cells in secondary 
lymph tissue, priming the T cells to recognise myelin derived proteins (Podbielska et 
al., 2013). The now autoreactive T cells manage to breach the blood brain barrier 
(BBB), reaching perivascular spaces where they re-encounter autoreactive APCs 
(Podbielska et al., 2013; Baker and Amor, 2014; Lopes Pinheiro et al., 2016). Once 
activated by these APCs, they induce a pro-inflammatory cascade which disrupts the 
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BBB and draws further immune cells to the CNS leading to direct damage, as well as 
indirect damage through inflammatory conditions, to myelin sheaths and the mature 
oligodendrocytes. Axons may be directly damaged directly by the inflammation, or 
indirectly due to loss of the myelin and the metabolic and trophic support it provides 
(Trapp and Nave, 2008). Chronic effects of the repeated inflammation results in 
reactive gliosis which develops plaques, causing further damage and obstruction of 
local axons (Podbielska et al., 2013). 
It should be noted however that there is evidence, at least in some cases, that 
oligodendrocyte degradation and apoptosis precedes the immune response (Barnett 
and Prineas, 2004; Bhat and Steinman, 2009). It is argued that the onset of disease 
is due to an original neurodegenerative event, presumably due to oligodendrocyte 
death. The death and abundance of myelin derived proteins then induces the auto-
immune response, leading to further degradation (Stys et al., 2012). If this is the 
case, it is not clear whether the original neurodegeneration is brought about by an 
intrinsic abnormality or an extrinsic input, again such as a virus or traumatic event. 
For the majority of patients, some degree of remyelination will originally occur, 
leading to a degree of recovery, although the remyelinated sheaths are not as thick 
as the original layers (Hanafy and Sloane, 2011; Podbielska et al., 2013). Over time 
however, the remyelination process fails, with only partial myelination observed after 
450 days in a murine model of spinal cord induced demyelination (Totoiu and 
Keirstead, 2005). It is clear that despite the loss of myelin and the development of 
plaques within the CNS, OPCs survive. Even in the most developed plaques OPCs 
are still observed (Chang et al., 2002; Harlow et al., 2015). In fact there appears to 
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be a greater number of OPCs in acute plaques suggesting that OPCs are able to 
proliferate (Guest et al., 2005; Nakahara et al., 2009). These observations have led 
to the hypothesis that the failure to remyelinate results from a deficit in OPC 
differentiation. As remyelination is observed in early stages of disease, progression 
of MS may be correlated with a progressive impairment of OPC maturation rather 
than in their migration or proliferation (Compston and Coles, 2008; Hanafy and 
Sloane, 2011). 
It has not been determined exactly why OPC fail to mature and remyelinate. Acute 
inflammation appears to be an integral promoter of remyelination in acute 
neuroinflammation, due to the release of neurotrophic factors and the removal of 
inhibitory factors (Foote and Blakemore, 2005). Preventing the action of local 
cytokines results in impaired remyelination during murine EAE and toxin induced 
demyelination (Hanafy and Sloane, 2011; Stone et al., 2017). Despite this, it is likely 
that the extent of neuroinflammation and subsequent plaque formation create an 
inhibitory environment for OPC maturation and myelin production following repeated 
bouts of demyelination (Fitch and Silver, 2008). Additionally, a build up of myelin 
debris, as a result of repeated attacks combined with incomplete removal by 
macrophages could also drive the environment towards one that is more inhibitory to 
OPC maturation and remyelination (Fancy et al., 2010). As such either modifying the 
environment or modifying the responses of OPC to said environment would be an 





1.2.2.2 Current treatments 
1.2.2.2.1 Immunomodulation 
Although the aetiology of MS is not fully understood, the disease is predominantly 
considered an immunopathologic disease (Hemmer et al., 2002; Wu and Alvarez, 
2011). As such, all of the available treatments are aimed towards immunomodulation. 
This is to reduce the number of autoimmune attacks (and subsequent relapses), thus 
slowing the progression of the disease (Goldenberg, 2012). There are a number of 
examples of this approach. IFN-β has been a commonly used molecule as a therapy 
for MS. IFN-β appears to directly lead to anti-inflammation actions by decreasing 
MHCII expression, altering interleukin transcripts on in APCs and decreasing Th1 
and Th17 production, which together leads to a general anti-inflammatory effect 
(Castro-Borrero et al., 2012; Waschbisch et al., 2014). Glatiramer acetate is another 
commonly used drug which appears to interact with APCs and change their 
interactions with T cells, such that they preferentially stimulate the anti-inflammatory 
Th2 cells (Castro-Borrero et al., 2012). More modern and more effective 
immunomodulatory therapies include Cladribine; a selective lymphocyte suppressor, 
Alemtuzumab; a depletory of CD52 expressing lymphocytes, and Ocrelizumab; a 
recombinant anti CD-20 antibody which was designed to effectively deplete B cells 
(Olek, 2018). Other medications targeting the immune system include Mitoxantrone, 
Natalizumab and to a lesser extent Fingolimod (Goldenberg, 2012).  
Despite the success of immunomodulatory therapies in modulating and slowing 
the progression of MS, disease progression still occurs and eventually leads to the 
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characteristic plaque formation and disability. Additionally, although treatments are 
effective in the early stages, the immunomodulation is of limited benefit during later, 
progressive stages of the disease (Lassmann et al., 2007). Presumably, 
immunodulation therapies do not encourage remyelination or repair of the damaged 
CNS, therefore once the damage has occurred, these therapies lose their value. 
There is also the risk of increased opportunistic infections, although this is more of an 
issue in broad immunosuppressants than direct immunomodulation therapies  
(Castro-Borrero et al., 2012; Olek, 2018). Furthermore, if MS does follow a 
neurodegenerative disease profile, then immunomodulation would only be treating 
the subsequent symptoms rather than helping to prevent the degeneration. 
1.2.2.2.2 Neuroprotection 
A new therapeutic approach being tested involves the use of neuroprotective 
agents (Brück, 2005; Wu and Alvarez, 2011; Goldenberg, 2012). Although this 
treatment won’t cure the disease or remove the acute symptoms of demyelination, 
they could in theory prevent or reduce the damage to axons. However in any nerve 
when demyelination prevents all signalling then this approach will be unproductive on 
its own. It is likely that this type of treatment will be useful in combination with other 
therapeutics, such as targeting the immune system to limit the chronic damage to the 
CNS. A number of therapeutic drugs are under development following this approach 
targeting different protective measures. These include direct delivery of neurotrophic 
factors, oxidative stress protection, mitochondrial maintenance and efficiency, as well 
as a number of others (Villoslada, 2016). 
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1.2.2.2.3 Stem cell transplantation 
It has been shown that implanted OPCs produce neurotrophic factors however 
whether they actively engage in remyelination is not clear (Priest et al., 2015). As 
such, this approach may simply promote neuronal survival. This in turn could 
indirectly promote endogenous remyelination from local OPCs rather than directly 
inducing remyelination. Neural stem cells (NSCs), have also shown to have a local 
immunomodulation effect, providing local protection to their delivery site, which has 
recently been attributed to regulation of cerebrospinal fluid (CSF) succinate. 
Succinate has been shown to be an effective biomarker of CNS metabolic stress and 
inflammation (Mills and O'Neill, 2014; Littlewood-Evans et al., 2016; Peruzzotti-
Jametti et al., 2018). Despite a lack of tumour development observed in rats injected 
with human induced OPCs (Priest et al., 2015), there is always a concern with this 
approach that unanticipated tumorigenesis could develop. Although this approach 
may be beneficial, specific sites of demyelination are required to be identified and the 
transplantation would be invasive, especially if autologous OPCs are required.  
Although the neuroprotective and immunomodulation approaches can control 
progression of the disease, there is currently no procedure that can aid the 
restoration of damaged neurons or oligodendrocytes in vivo (Goldenberg, 2012). As 
such, it is clear that there is a need to develop alternative therapies which can repair 





1.2.2.2.4 Remyelinating therapies involving endogenous OPCs 
A recent area of investigation is looking at the ability to encourage remyelination 
directly by stimulating local OPCs to differentiate. Despite a number of successful 
pre-clinical studies demonstrating improved remyelination, a viable drug capable of 
promoting OPC remyelination has not become available (Goldenberg, 2012; Harlow 
et al., 2015). Two clinically approved drugs for unrelated conditions; miconazole, a 
topical antifungal and clobetasol, a topical corticosteroid, are capable of promoting 
remyelination in mouse EAE studies (Najm et al., 2015). Both drugs were capable of 
increasing the number of CC1 positive, mature OLG in mouse EAE, as well as 
increasing the extent of MBP positive staining in lesions. Furthermore, similar results 
were observed with human OPCs derived from embryonic stem cells (ESCs). These 
data were also correlated to improved clinical observations in the mouse EAE model 
(Najm et al., 2015). These results show that stimulating endogenous remyelination 
can aid in restoring the myelin sheath and that this can be beneficial in a preclinical 
context. Despite this promising data, only two remyelination agents have made it to 
phase 2 clinical trials. Clemastine, a medication originally produced as an 
antihistamine, has been shown to encourage OPC differentiation and clinical trials 
have demonstrated reduced visual-evoked potentials (Green et al., 2017). A further 
trial will be discussed later (see section 1.4.2.2). 
Just as with neuroprotection and immunomodulation, remyelination has been 
investigated through the direct transplantation of OPCs into focal lesions. Rodent 
models of traumatic demyelination have produced a degree of success, where 
animals showed reduced clinical symptoms, higher levels of myelin and reduced 
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latencies in electrophysiological recordings (Cao et al., 2010; Wu et al., 2011). 
Despite this success, transplantation is unlikely to be clinically useful due to the 
difficulty locating focal lesions, the invasiveness required to implant the cells and the 
risk of tumorigenesis. Additionally demyelination occurs prior to plaque or lesion 
development, therefore by the time the focal site has been identified for treatment, 
there is likely to already to be significant damage (Wu and Alvarez, 2011) 
1.3 Leucine rich repeat molecules in the mammalian CNS 
Leucine rich repeat (LRR) containing proteins are a family of proteins containing a 
region of multiple LRR motifs. Each motif is made up of a consistent pattern of amino 
acids which create a horseshoe structure. The amino acid pattern consists of a 
section containing LxxLxLxxN/CxL, where L represents leucine but can be substituted 
for a valine, isoleucine or a phenylalanine, x can be any amino acid, N is an 
asparagine and C is a cysteine. Each motif consists of 20-30 amino acids including 
this pattern. It has been hypothesised that by creating a horseshoe structure, the 
LRR segment leads to a larger surface area for greater protein interaction, with 
multiple examples of interactions on both the convex and concave surface of the 
structure (Kobe and Kajava, 2001; Matsushima et al., 2005; Bella et al., 2008; de Wit 
et al., 2011). 
1.3.1 LRR Molecules in Central Nervous System Disorders 
A number of LRR proteins have been identified to play a role within the healthy 
CNS, and correspondingly have been linked with a number of neuronal disorders 
(Chen et al., 2006; Söllner and Wright, 2009; de Wit et al., 2011; Ledda and 
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Paratcha, 2016). Netrin-G-ligand and Slit are both involved with axon guidance and 
synaptic development through interactions between Netrin-G1/2 and receptor protein 
tyrosine phosphatase respectively in cultured neurons (Chen et al., 2006; Takahashi 
et al., 2012; Yim et al., 2013; de Wit and Ghosh, 2014). Neurite outgrowth inhibitor-
66 receptor 1 (NgR1) and its receptor complex inhibit axon extension through 
interactions with myelin derived proteins (Mi et al., 2004; Ahmed et al., 2013). 
Tyrosine kinase (Trk) receptors have been identified to bind with neurotrophic factors 
and regulate axon growth and synaptic development (Chen et al., 2006; Ahmed et 
al., 2013; de Wit and Ghosh, 2014; Ledda and Paratcha, 2016). From these 
interactions, LRRs have been associated with CNS plasticity as well as a number of 
neuronal disorders, including schizophrenia, bipolar disorder, Alzheimer’s disease, 
autism, Rett syndrome and attention-deficit/hyperactivity disorder (ADHD) (de Wit 
and Ghosh, 2014). 
1.4 LINGO1 and AMIGO3 
More recently there has been interest in two proteins of the LRR protein family, 
leucine rich repeat and Ig domain containing 1 (LINGO1) and amphoterin-induced 
gene and open reading frame 3 (AMIGO3). Both proteins were originally found to be 
an important component of the NgR1 receptor complex and have since been 
observed to be important proteins within the CNS (Mi et al., 2004; Ahmed et al., 
2013; Mi et al., 2013). LINGO1 and AMIGO3 are structurally analogous proteins of 
the LRR protein family. The proteins are type 1 transmembrane proteins consisting of 
a short cytosolic tail, a transmembrane domain, an Ig-like domain and an 
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extracellular LRR, horseshoe shaped domain, with a signal peptide on the 
extracellular tail (Kuja-Panula et al., 2003; Chen et al., 2006; Zhang et al., 2009; 
Zhou et al., 2012; Foale et al., 2015). The only major difference between the 
structures of the two proteins is the variation in the number of LRR that they possess, 
with LINGO1 having 12 LRR domains and AMIGO3 having 6 (fig 1.6) (Kuja-Panula et 
al., 2003; Jepson et al., 2012; Foale et al., 2015). 
1.4.1 Endogenous expression 
LINGO1 is specifically expressed within the CNS, however levels of mRNA for 
LINGO1 stay low during embryonic development in murine models (Mi et al., 2004; 
Haines and Rigby, 2008). It is not until the end of prenatal development, that mRNA 
for LINGO1 is substantially upregulated, before dropping again after postnatal day 
(P)1 in mice and rats (Mi et al., 2004; Mi et al., 2005). Similarly, in zebrafish, LINGO1 
expression is maintained at low levels during embryogenesis but rises 5 days after 
fertilisation in early larval stages (Yin and Hu, 2014). There is a debate regarding the 
peak expression of LINGO1 mRNA during murine postnatal development. While it is 
agreed that there is an increase postnatally, the peak of expression has been 
reported variously at P1, P4 and P21. A substantial decrease in expression is 
observed before stabilisation during adulthood (Mi et al., 2004; Llorens et al., 2008; 
Shao et al., 2017). A similar pattern is observed with protein levels, which increase to 
a peak at P21 in mice (Llorens et al., 2008). CNS LINGO1 protein is observed at its 
highest levels within the axons of neurons, however LINGO1 is also expressed at 
significant levels in oligodendrocytes, albeit at lower levels (Mi et al., 2005; Satoh et 




Figure 1.6: Representation of the structures of AMIGO3 and LINGO1. Both 
structures contain the characteristic components of LRR proteins, a small cytosolic 
tail, a transmembrane domain and an extracellular structure. The extracellular 
structure contains an Ig-like domain, the LRR region as well as a signal peptide. The 
main structural difference between the proteins is that AMIGO3 has 6 LRR compared 
to 12 for LINGO1 in the LRR domain.
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1.4.2 LINGO1: CNS disease 
1.4.2.1 CNS Trauma 
The first role attributed to LINGO1 in the CNS was the inhibition of axonal 
regeneration. Mi et al (2004) showed that inhibiting LINGO1 through knockdown or 
treatment with anti-LINGO Fc fusion proteins resulted in an increase in neurite 
outgrowth of cultured cerebellar granule cells. The reverse was observed when 
LINGO1 expression was increased. This demonstrates that LINGO1 acts an inhibitor 
of neurite growth in vitro (Mi et al., 2004). 
LINGO1 is able to bind to the NgR1 receptor complex and is required for the 
complex to transduce its signal. The NgR1 receptor complex is able to bind to myelin 
derived proteins including neurite outgrowth inhibitor A (Nogo-A), oligodendrocyte 
myelin glycoprotein (OMGP) and myelin associated glycoprotein (MAG), as well 
chondroitin sulphate proteoglycans (CSPGs) produced by reactive astrocytes 
(Ahmed et al., 2005; Yiu and He, 2006; Dickendesher et al., 2012; Ahmed et al., 
2013; Saha et al., 2014b; Iobbi et al., 2017). Interactions between these proteins and 
the NgR1 receptor complex leads to downstream signalling through activation of Ras 
homolog gene family, member A (RhoA)/Rho-associated protein kinase (ROCK) by 
Rho guanosine diphosphate-dissociation inhibitor (RhoGDI) anchored to the 
intracellular components of the NgR1 receptor complex. In axons, this leads to 
activation of cofilin, actin filament reorganisation and ultimately collapse of growth 
cone and inhibition of axonal extension (Ahmed et al., 2013). Furthermore, Nogo-A 
knockout mice show greater inactivation of cofilin, as well as greater levels of actin 
polymerisation in the growth of neurites. This was also correlated with longer 
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neurites, highlighting the importance of the NgR1 receptor complex for axon 
regeneration (Sandvig et al., 2004; Montani et al., 2009).  
The NgR1-neurotrophin receptor complex consists of NgR1, p75 neurotrophin 
receptor (p75NTR)/tumor necrosis factor receptor superfamily, member 19 (TROY) 
and a third integral protein which was first found to be LINGO1. COS7 cells 
transfected with the components of the NgR1 complex were only able to cause RhoA 
activation when also transfected with LINGO1 (Mi et al., 2004; Ahmed et al., 2013; 
Kwon et al., 2014). Antagonising LINGO1 with LINGO1-Fc leads to decreased 
activated RhoA in spinal cords and correlates with greater axon regeneration (Mi et 
al., 2013) in vivo after spinal cord injury. As such, it was found that LINGO1 
expression must allow for the activation of the NgR1 receptor complex by myelin 
derived proteins, resulting in the inhibition of axon extension (Mi et al., 2004; Inoue et 
al., 2007; Jepson et al., 2012) (fig 1.7). Interestingly, LINGO1 mRNA and protein 
levels do not appear to rise until D10 following spinal cord injury (SCI) in murine 
models, therefore it appears unlikely that LINGO1 is performing a major function 
during the acute stages in the injury response (Ahmed et al., 2013). 
1.4.2.2 Demyelinating diseases 
LINGO1 has also been reported to have an impact on OLG, preventing the full 
differentiation of OPC and myelination of OL (Mi et al., 2013). LINGO1 knockout mice 




Figure 1.7: The method of action for LINGO1 and AMIGO3 in Neurons. (A) Both 
AMIGO3 and LINGO1 are able to form a complex with NgR1 and P75/TROY, known 
as the NgR1 receptor complex. (B) When bound, the tripartite receptor can respond 
and activate to myelin derived proteins, Nogo, OMgp and MAG. (C) It has also been 
hypothesised that AMIGO3 and LINGO1 could interact with neighbouring molecules 
intercellularly. (D) Activation of the NgR1 receptor complex leads to the intracellular 
activation of RhoA by local RhoGDI, leading to (E) ROCK signalling and further 
activation of LIMK and myosin light chain (MLC) on actin filaments. (F) LIMK inhibits 
cofilin resulting in actin depolymerisation (Fujita and Yamashita, 2014). (G) Activation 
of MLC also leads to shortening of actin filaments. These effects lead to growth cone 
collapse. Due to similar observations of RhoA activation following LINGO1 
upregulation in OPC, it is possible that this method of action could also be present in 
OLG, affecting process extension and neuron adhesion (Foale et al., 2017).
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Furthermore, a number of studies have linked LINGO1 directly to OLs both in vitro 
and in vivo. Overexpression of LINGO1 in cultured OLG and treating cultured OLG 
with soluble LINGO1, leads to a decrease in the production of MBP, with similar 
observations observed in rodents (Lee et al., 2007; Jepson et al., 2012). 
Correspondingly, inhibiting LINGO1 appears to have pro-myelinating effects. 
Inhibition, and genetic knock out, of LINGO1 leads to a greater production of MBP, 
promotes branching, promotes the production of myelin containing sheets, and 
correlates with greater OL/OPC ratios in in vitro rodent OPC cultures (Mi et al., 2005; 
Lee et al., 2007; Mi et al., 2008; Bourikas et al., 2010; Mi et al., 2013; Lee et al., 
2014). 
Furthermore, the inhibitory effects of LINGO1 on remyelination can be observed 
in disease states as well. In EAE, LINGO1 knock-out mice and mice treated with 
LINGO1 inhibitors demonstrated improved signs of remyelination compared to 
untreated and sham controls. This has been shown through greater levels of MBP as 
well as a larger count of axons ensheathed with myelin and reduced signs of axonal 
damage in CNS lesions (Mi et al., 2007; Mi et al., 2009; Bourikas et al., 2010; Li et 
al., 2017). EAE mice also have reduced clinical scores in the disease model and 
demonstrate greater spatial learning when treated with LINGO1 inhibitors (Bourikas 
et al., 2010; Mi et al., 2013; Sun et al., 2015). Finally, treating lysolethicin induced 
demyelinated C57BL/6 mice with anti-LINGO1, led to shorter latencies in the signal 
from transcranial magnetic motor-evoked potentials (tcMMEPs) 4 weeks after 
demyelination, indicating an improvement in signal propagation in descending axons 
of the spinal cord. This demonstrates the functional restoration induced by inhibiting 
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LINGO1 in the acute demyelinating model (Zhang et al., 2015a). These data provide 
a strong link between LINGO1 and an inhibitory effect of this protein on remyelination 
in demyelinating conditions. 
1.4.2.2.1 Mechanism of action in oligodendroglia 
Various mechanisms of action have been proposed for how LINGO1 is able to 
produce an inhibitory effect on OPC differentiation and OL myelin production (fig 1.7 
& 1.8). Firstly it was proposed that LINGO1 functions in OLG just as in neurons, 
through activation of the NgR1 complex and subsequent activation of RhoA (fig 1.7). 
This would theoretically interfere with actin filaments involved with both differentiation 
of OPC and the creation of processes for myelin production and axon ensheathment. 
This hypothesis is supported by the fact that myelin debris inhibits OPC maturation 
and myelin production, a likely response to prevent too much myelin being produced 
in one area (Plemel et al., 2013). Additionally, higher levels of LINGO1 have been 
correlated with higher levels of activated RhoA in OPC (Mi et al., 2005; Jepson et al., 
2012; Kwon et al., 2014) and LINGO1 has also been found to regulate actin filament 
formation in cultured rat OPC through the phosphorylation of cofilin (Fujita and 
Yamashita, 2014; Brown and Verden, 2017; Shao et al., 2017). Despite this data, 
there is evidence that NgR1 is not expressed on OLG, raising questions to the 
validity of this hypothesis. The evidence behind this claim is not concrete however, 
and is from low power images of tissue samples or from hybrid human cancer cell 




Figure 1.8: Potential methods of action for LINGO1 and AMIGO3 in OLG. (A) 
LINGO1 binds to ErbB2 and prevent its translocation to the lipid rafts on OLG 
membranes. ErbB2 is phosphorylated by local kinases and phosphatases at lipid 
rafts. Phosphorylated ErbB2 induces OPC differentiation by an unknown pathway (Mi 
et al., 2013; Lee et al., 2014). By inhibiting the translocation of ErbB2, LINGO1 
indirectly blocks OPC differentiation. (B) Activated gelsolin is correlated with 
increased OPC differentiation, presumably through interactions with actin filaments. 
LINGO1 binds to and inhibits gelsolin, inhibiting its action (Shao et al., 2017). (C) 
LINGO1 signals through the PI3K/AKT/m-TOR pathway in dopaminergic neurons 
and OLG. LINGO1 directly inhibits EGFR signalling, preventing EGFR from activating 
PI3K (Inoue et al., 2007). This in turn prevents phosphorylation and activation of 
PIP2, consequently preventing the activation of AKT and m-TOR. Both activated AKT 
and m-TOR are implicated in OPC survival and differentiation, therefore the LINGO1 
induced inhibition of EGFR will also lead to inhibition of OPC maturation and could 
lead to apoptosis (Dienstmann et al., 2014). The homologous structures and roles in 
neurons suggest that AMIGO3 has the potential to function through the same 




(Satoh et al., 2005; Bourikas et al., 2010; Jepson et al., 2012; Mei et al., 2013). As 
such, the NgR1 signalling pathway could still be a valid mechanism for LINGO1 
actions in OLG. 
A number of other signalling pathways have also been identified for LINGO1 in 
OLG. Gelsolin (GSN), another protein related to the actin cytoskeleton has been 
linked with LINGO1. LINGO1 decreases the levels of gelsolin (GSN), an actin 
severing protein. GSN has been associated with myelin production, as demonstrated 
in both rat OPC cultures and Sprague Dawley rats following lysolethicin induced 
demyelination. Inhibiting LINGO1 in rat OPCs when simultaneously encouraged to 
differentiate leads to higher levels of GSN protein and mRNA suggesting a role for 
GSN in LINGO1’s inhibition (Shao et al., 2017) (fig 1.8A). 
LINGO1 has been demonstrated to be able to interact homophically with 
neighbouring LINGO1 molecules. It has been proposed that due to this homophilic 
interaction between LINGO1 molecules, that LINGO1 may be able to interact 
intercellularly between neighbouring glia/axons. Rat OLs demonstrate an increased 
myelin production when cultured with soluble LINGO1 as well as with 
astrocytes/neurons that were induced to overexpress LINGO1 (Jepson et al., 2012). 
Conversely, COS7 cells transfected with solely LINGO1 do not show a rise in 
activated RhoA levels, suggesting that LINGO1 self-interactions do not produce the 
necessary downstream effects (Mi et al., 2004). Of course, this could simply be a 




Lee et al (2014) suggested a convincing pathway, through interactions with the 
tyrosine kinase, human epidermal growth factor receptor 2 (ErbB2). Phosphorylated 
ErbB2 has been correlated with OPC maturation as well as MBP expression (Mi et 
al., 2013; Lee et al., 2014). LINGO1 appears to bind to the unphosphorylated ErbB2 
and prevent its translocation to lipid rafts on the membrane. As ErbB2 is 
phosphorylated at the lipid rafts, LINGO1 indirectly prevents the phosphorylation and 
subsequent MBP production and OPC maturation (Lee et al., 2014) (fig 1.8B). 
The AKT/m-TOR, WNK1 and BDNF/TrkB pathways have all also been implicated 
with LINGO1 signalling in OLG (Sun et al., 2015; Zhang et al., 2015b; Meabon et al., 
2016) (fig 1.8C). PIP3 leads to the phosphorylation and activation of the AKT/m-TOR 
pathway, which appears to be integral in promoting the ensheathing of the axon 
through regulating the wrapping via the inner surface of the ensheathing process. 
(Snaidero et al., 2014; Purger et al., 2016). Furthermore, phosphorylated mTOR and 
constitutively activated AKT have both been correlated with enhanced myelination 
and OPC differentiation in vivo (Flores et al., 2008; Narayanan et al., 2009; Sun et 
al., 2015). LINGO1 prevents the phosphorylation of both AKT and mTOR, thereby 
blocking the pro-myelinatory effects of PIP3 (Sun et al., 2015). 
WNK1 is an inhibitory protein for both OPC maturation and OL myelin production 
and incorporating siRNA against WNK1 leads to greater MBP production and a 
greater number of NG2+ processes visible in cultured rat OPCs. Similarly, WNK1 is 
able to form precipitates with LINGO1 in vitro, and inhibiting the action of WNK1 
leads to greater levels of RhoA, admittedly in neurons. Exactly how the interaction 
between WNK1 and LINGO1 would lead to changes in levels of RhoA is unclear but 
39 
 
this interaction remains another potential method of action for LINGO1 to function 
within oligodendrocytes. 
Finally TrkB has been demonstrated to be integral in OLG, with knockout mice 
showing a reduced ability to create mature OLs, resulting in unviable pups, as well as 
conditional knockout mice demonstrating a decrease in myelinated axons (Klein et 
al., 1993; Wong et al., 2013). LINGO1 has been shown to be able to interact with 
TrkB, which in turn appears to lead to a reduction in TrkB. It is suggested that 
LINGO1 aids the translocation of TrkB to lysosomes, resulting in the degradation of 
TrkB (Meabon et al., 2016). Although this has not been demonstrated to lead to 
demyelination, it does present another potential pathway for the action of LINGO1 in 
OL. 
1.4.2.2.2 Clinical trials 
LINGO1 based therapies have advanced to clinical trials to treat demyelination, 
with phase 2 trials showing moderate signs of success. Antagonising LINGO1 with 
an anti-LINGO1 antibody, opicinumab, in patients suffering from optic neuritis led to a 
greater propagation rate along the retinal nerves following treatment for 24 weeks. 
However retinal thinning still occurred and there was no significant improvement in 
disease symptoms (Ledford, 2015; MS-Society, 2016; Cadavid et al., 2017). 
1.5 AMIGO3 
Another LRR protein of relevance to myelination/demyelination, and one which 
has recently become of interest to our group is the LINGO1 analogue protein, 
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AMIGO3. All three proteins of the AMIGO family have been identified in the CNS. 
Interestingly, AMIGO1 and 2 both appear to have neuroprotective properties, 
whereas AMIGO3 has recently been shown to inhibit repairing mechanisms of the 
damaged CNS (Ahmed et al., 2013). 
1.5.1 Endogenous expression 
Unlike LINGO1, in the adult mouse, AMIGO3 is observed outside of the CNS. 
Significant levels are found within the adult murine liver, intestines and lungs, 
although much higher levels are observed in the adult CNS (Kuja-Panula et al., 2003; 
Hossain et al., 2011; Ahmed et al., 2013). Interestingly, AMIGO1, another protein of 
the AMIGO family of proteins is purely expressed in the CNS, indicating a possible 
family specificity for CNS functions (Kuja-Panula et al., 2003). AMIGO3 mRNA has 
not been detected in embryonic mice (Homma et al., 2009), however unpublished 
data from our laboratory (Ahmed et al, unpublished), shows the presence of the 
AMIGO3 protein in the white matter of post-natal rodents indicating that AMIGO3 is 
present, and likely active, in the murine CNS during the critical stages of 
developmental myelination. Furthermore, in zebrafish, the transcripts for AMIGO3 are 
upregulated from day 4 post-fertilisation (dpf4), appearing to stabilise by dpf8 in the 
zebrafish brain (Zhao et al., 2014). This shows that AMIGO3 expression appears to 
be upregulated during the same stages of myelination which begins at dpf2 with the 
majority completed by dpf10 in zebrafish (Brosamle and Halpern, 2002; Strachan et 
al., 2017). AMIGO3 has been identified most significantly in neurons, but is also 
present in astrocytes and OLG (Ahmed et al., personal communication). There is 
currently no evidence to support its expression in inflammatory cells (Tickle, 2013). 
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1.5.2 Expression profile in disease 
Just as with LINGO1, AMIGO3 is upregulated in rodents following CNS injury. A 
significant increase (four-fold) in AMIGO3 mRNA levels is observed 1 day following 
SCI, which rises to eight-fold by 10 days. LINGO1 levels however remain unaltered 
until 10 days following SCI (Ahmed et al., 2013). Similarly, EAE models demonstrate 
a lag between responses when LINGO1 levels are altered. LINGO1 KO rats and anti-
LINGO1 treated rats do not show variation from control rats until the disease is 
developed, indicating that LINGO1 is unlikely to be playing a role in the acute stages 
of inflammatory demyelinating disease (Mi et al., 2007). 
As well as being upregulated in murine SCI, our group has previously identified 
AMIGO3 expression in cultured murine OPCs, cultured OPC cell lines, as well as in 
both chronic progressive and secondary progressive MS samples. Notably, AMIGO3 
mRNA expression appears to be increased in both forms of the disease compared to 
healthy controls, and levels of AMIGO3 mRNA appear to be greater than LINGO1 
levels in all forms of the disease (fig 1.9) (Ahmed et al., personal communication; 
Foale et al,. 2014). This suggests that AMIGO3 is playing a more important role than 




Figure 1.9: AMIGO3 and LINGO1 expression in (A) cultured murine OPC and (B) 
human MS post-mortem brain samples as measured by RT-PCR after 26 cycles. (A) 
AMIGO3 expression is found at higher levels in mature OL but also in relatively high 
levels in OPC. AMIGO3 expression is also observed at higher levels in chronic 
RRMS and secondary progressive MS than in healthy controls. LINGO1 levels also 
increase but are not as noticeable compared to AMIGO3 increases. GAPDH used as 
a housekeeper. Images produced by Ahmed et al (unpublished).
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co-localised through immunohistochemistry (IHC) to markers of astrocytes and OLs, 
in murine EAE and optic neuritis models, demonstrating that AMIGO3 is not purely 
associated with neurons in demyelinating disease models (fig 1.10) (Ahmed et al., 
personal communication). These data support the hypothesis that AMIGO3 is playing 
a more active role than LINGO1 during inflammatory CNS disease states, and that its 
inhibitory actions in OLs may be relevant to strategies aiming to promote 
remyelination. 
It is believed that the expression of AMIGO3 in astrocytes and, arguably more 
interestingly, in OLG, indicates that AMIGO3 must have a more diverse role in the 
injured CNS. Furthermore, as AMIGO3 interacts with the NgR1 receptor complex and 
functions without LINGO1 in neurons, it is possible that AMIGO3 replicates this 
function in OLG as similarly hypothesised with LINGO1 (Ahmed et al., 2013; Saha et 
al., 2014a; Foale et al., 2015). However, due to the conflicting reports of NgR1 
expression on OLG, the exact mechanism that AMIGO3 would function through in 
OLG is unclear. Just as with LINGO1, AMIGO3 is able to form homodimers (Kuja-
Panula et al., 2003; Chen et al., 2006; Kajander et al., 2011). It is therefore possible 
that it is able to bind to and activate itself, whether intercellularly or intracellularly. As 
OLGs have not been tested with raised AMIGO3 levels, it is unknown whether 
AMIGO3 self-interactions could modify OPC development. It is also possible that 
AMIGO3 could signal through any of the pathways that have been hypothesised for 
LINGO1 (fig 1.7 & 1.8) or even through any of the other pathways that are involved 




Figure 1.10: AMIGO3 colocalisation staining. (A-C) AMIGO3 (A) and Glial fibrillary 
acidic protein (B) as well as merged with DAPI (C), shows colocalisation of AMIGO3 
with markers of astrocytes in murine samples. (D) AMIGO3 (green) and carbonic 
anhydrase II (CAII), a marker of mature OL, in EAE samples. (E) AMIGO3 and CAII 
in murine optic neuritis samples. AMIGO3 can be seen colocalised with markers of 




1.6 Study rationale 
As AMIGO3 is raised during CNS disease and shares a number of similarities to 
the inhibitory protein LINGO1, AMIGO3 is likely to be performing similar roles within 
the murine CNS. This has already been shown to be the case with the axonal NgR1 
receptor therefore it is likely that AMIGO3 could perform similar co-interactions in 
other cell types as well. Along with the preliminary evidence that AMIGO3 is 
expressed by OLG, it is very likely that AMIGO3 has a function within OLG. 
Considering that AMIGO3 induces similar actions as LINGO1 in CNS neurons, it is 
likely that AMIGO3 will have an inhibitory role in OLG, inhibiting their maturation and 
myelin production. 
Despite the promising signs for LINGO1 therapies, there have been a number of 
recent setbacks. Firstly, a lag of 14 days has been observed between anti-LINGO1 
treatment and subsequent effects on clinical score EAE (Mi et al., 2007). This as well 
as the lag time between CNS injury and increases in LINGO RNA suggest that 
although LINGO therapies are able to alter OLG generation both in vitro and in vivo, 
they do not appear to make any change in the acute stages of demyelination (Ahmed 
et al., 2013). Secondly, although anti-LINGO1 therapies have also resulted in 
statistically significant increases in myelin thickens when compared to both IgG 
controls and untreated animals, as measured by the G-ratio, the changes were 
minuscule and not clearly beneficial to treated animals (Zhang et al., 2015a). 
Furthermore, despite anti-LINGO1 antibodies being utilised in clinical trials for 
treating demyelinating disorders, specifically in optic neuritis, the results have not 
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been as promising as predicted by the pre-clinical studies in rodents. Anti-LINGO1 
antibodies enabled an increase in the propagation rate down the optic nerve, 
however this did not correlate with any symptomatic relief (Ledford, 2015; MS-
Society, 2016; Cadavid et al., 2017). Unfortunately the study was not able to examine 
direct signs of myelin and OLG health and therefore it is difficult to confirm whether 
the moderate success was related to remyelination.  
It is likely that due to the observed lag time between injury and LINGO1 
expression changes, that LINGO1 based therapies will not act in sufficient time to 
encourage remyelination after the original demyelination. As such, LINGO1 is 
unlikely to be involved in inhibiting remyelination in acute stages following 
demyelination and therefore therapies aimed at inhibiting LINGO1 will not be 
sufficient to encourage rapid and efficient remyelination. Although LINGO1 based 
therapies may be able to eventually induce remyelination, this delay to remyelination 
will leave the axons vulnerable, limiting the effectiveness of these therapies. 
Due to the much more rapid rise in AMIGO3 expression in the injured CNS, the 
preliminary evidence that AMIGO3 is expressed in OLG and the preliminary signs of 
AMIGO3 in MS, it is very possible that AMIGO3 is able to compensate for the 
function of LINGO1 in the acute stages of OLG disease. As such, examining the role 
that AMIGO3 plays in acute stages of demyelination could be a promising approach 
to develop novel therapies for remyelination and address a severe deficit in the 
treatment for MS and other demyelinating and dysmyelinating disorders. 
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1.7 Hypothesis and aims 
We hypothesise that AMIGO3 is able to exert an inhibitory effect on OLG, 
preventing their differentiation into mature OLG, and creating the myelin sheath 
around axons. Additionally we hypothesise that AMIGO3 levels will be high in 
undifferentiated OPC and that trauma, such as that observed during inflammatory 
attacks in MS, will lead to an increase in the expression of AMIGO3 in vivo and in 
vitro. This in turn will lead to inhibition of remyelination during acute stages following 
demyelination. Furthermore, we hypothesise that the NgR1 receptor complex will be 
present on murine OLG and will provide a mechanism of action for AMIGO3 in these 
cells. 
In this study, we aim to: 
- Examine AMIGO3 expression during myelination, demyelination and 
remyelination. 
- Examine AMIGO3 expression in OLG trauma and demyelinating disease.  










Materials and Methods 
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2.1 In vivo procedures 
2.1.1 Animals 
All animals used in this study, unless stated otherwise, were cared for at the 
Biomedical Services Unit (BMSU) at the University of Birmingham. Animals were kept 
in a 12-hour light-dark cycle with food ad libitum. All animal procedures used were 
approved by the University of Birmingham’s Ethical Review Committee. All 
procedures were also in accordance with the UK Home Office Animals (Scientific 
Procedures) Act (ASPA) 1986 under Home Office Project Licence provided by Dr 
Zubair Ahmed. Various strains of mice were used in the study, as specified 
throughout.  
2.1.2 Experimental autoimmune encephalomyelitis 
2.1.2.1 Principles of EAE 
To examine in vivo remyelination, demyelination has to be induced. The model 
used in this study is EAE. EAE evokes autoimmunity to CNS proteins to induce 
neuroinflammation. It has been used with varying degrees of efficiency to investigate 
CNS auto-immunity. The primary use of EAE is to investigate MS as it shares a 
number of clinical and histological features with the human disease (Baker et al., 
2011; Robinson et al., 2014b). Similarly to MS, EAE is an autoimmune disease 
where myelin derived proteins are targeted by the host’s immune system, leading to 
neuroinflammation, oligodendrocyte degradation, and plaque formation within the 
CNS (Constantinescu et al., 2011). 
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EAE is induced through the priming of the animal’s immune system to target 
myelin proteins. This can be done by injecting various myelin components, including 
PLP, MBP and MOG, as well as entire spinal cord homogenates. This is usually done 
with an adjuvant to activate the immune system (Robinson et al., 2014b). Depending 
on the exact model, the disease course can be chronic or acute as well as 
progressive or with relapses (Baker et al., 2011). Models have also been developed 
to focus on acute stages and only induce optic neuritis so that both early and late 
stages of the disease can be investigated (Furlan et al., 2009; Constantinescu et al., 
2011). 
Although rats were the predominate model traditionally used, recent 
advancements have led to mice being used more commonly, with the C57BL/6 strain 
the model of choice for most MS researchers (Constantinescu et al., 2011; Croxford 
et al., 2011; van der Star et al., 2012; Bittner et al., 2014). EAE models have also 
been described in marmosets and rhesus macaques, where disease course more 
closely follows MS progression and thus can more directly mimic the human disease 
(Slierendregt et al., 1995; Kap et al., 2010; Constantinescu et al., 2011; Baker and 
Amor, 2014). Additionally, a number of variations of the model have been described, 
inducing varying disease timeframes and courses (Baker and Amor, 2014). 
In the early stages of disease, both EAE and MS are T cell mediated (Langrish et 
al., 2005; Aranami and Yamamura, 2008; Baker and Amor, 2014). CD4+ T cells 
interact with MHC class II molecules and become primed to react to myelin derived 
proteins. Additionally Th1 and Th17 cells have been shown to mediate EAE 
progression in a similar manner to MS (Korn et al., 2009). Furthermore, both EAE 
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and MS produce the characteristic CNS plaques with loss of myelin, a depletion of 
OLs/OPCs, axonal loss and infiltration of T cells, macrophages and in later stages, B 
cells (McCarthy et al., 2012). 
Despite the similarities, it should be noted that the aetiology of MS is not clear. 
EAE however is an artificial disease, through induced immunity to CNS derived 
proteins and their antigens. As such, the model cannot truly compare the onset of 
disease. This difference in disease onset is also likely to result in discrepancies in 
disease progression. One of the major differences is that despite the complexity of 
the immune response in MS, the majority of immune cells found in MS lesions are 
CD8+ T cell derived whereas in EAE, lesions demonstrate a higher concentration of 
CD4+ T cells. Further criticism for EAE comes from the number of successful 
treatments for EAE that have not translated to MS (Constantinescu et al., 2011; 
Baker and Amor, 2014). There is a debate as to whether this is due to improper 
scientific activity by researchers, such as a lack of reproducibility or from making 
inflated claims from data (Baker and Amor, 2014), however it could also be that the 
disease course differs due to their variations (Sriram and Steiner, 2005) and may 
simply be due to the incompatibilities between murine and human immune systems 
(Baker and Amor, 2014). 
Despite these differences, EAE has been instrumental in understanding the 
pathology of T-cell induced neuroinflammation and demyelination and has had a 
number of successes in producing therapies for MS demonstrating its value for 
further research. If used correctly, EAE parameters can be set to appropriately 
investigate certain features of MS. In this study, we are investigating OPC and OL 
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responses, rather than the immune response itself. As such, the exact mechanisms 
in the immune response should not be vital, rather just an inflammatory condition 
should be sufficient to provide an environment that is not conducive with OPC 
survival and maturation. 
2.1.2.2 Advantages of EAE over other models of demyelination 
A number of other models of demyelination have been developed and are efficient 
for inducing and investigating demyelination and remyelination. Those most 
predominantly used are the cuprizone model (Blakemore, 1974; Torkildsen et al., 
2008), the lysophosphatidyl choline/lysolethicin (LPC) model (Praet et al., 2014; 
Keough et al., 2015)  and Theiler’s murine encephalitis virus (TMEV) model 
(Torkildsen et al., 2008; Nathoo et al., 2014). 
The cuprizone model uses the copper chelator, bis-cyclohexanone-
oxaldihydrazone (cuprizone). Addition of cuprizone in the animals’ drinking water is 
believed to lead to inhibition of copper dependent mitochondrial enzymes, which 
disproportional affecting oligodendrocytes. This is turn leads to an inhibition of myelin 
protein synthesis, myelin lipid metabolism and OL death, effectively inducing 
demyelination (Wergeland et al., 2012; Praet et al., 2014). The model observes 
consistent cortical demyelination and subsequent axonal loss. Spontaneous 
remyelination can then be reliably observed as early as 4 days after the toxin is no 
longer applied, with extensive remyelination by 4 weeks (Matsushima and Morell, 
2001; Lindner et al., 2008; Torkildsen et al., 2008). 
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Although a number of advancements have been with the cuprizone model, it 
maintains its weakness in that the exact mechanism behind demyelination remains 
unclear. Although the mitochondrial disruption theory is likely, it is not clear why this 
would lead exclusively to OL disruption and not a more global effect. It is very 
possible that uncertain side effects could be interrupting results obtained from the 
model. Additionally, as the model is more akin to toxic demyelination rather than 
autoreactive demyelination (Torkildsen et al., 2008) in that T cells are negligible to 
disease progression (Matsushima and Morell, 2001), and the BBB remains 
undisrupted (McMahon et al., 2002), the model cannot be viewed in relation to a 
neuro-inflammatory disease. 
The LPC model requires precise injection of LPC into the white matter tracts of the 
spinal cord (Jeffery and Blakemore, 1995). This produces reliable focal 
demyelination, akin to MS plaques. This is thought to be brought about by a direct 
toxic effect due to the detergent properties of LPC (Denic et al., 2011; Lassmann and 
Bradl, 2017). An immediate response of demyelination, accompanied by acute 
inflammation is produced, followed by OPC migration and proliferation (Denic et al., 
2011; Lau et al., 2012; Keough et al., 2015). One of the main advantages of the LPC 
model over EAE is that the site of demyelination is precisely where the injection was 
administered. This is also advantageous over EAE as although the sites of 
demyelination are predictable, they are not precise and require searching for 
following tissue collection. However due to the nature of the LPC injections, only 
larger rodents can be used and therefore mice, and the extensive genetic resources 
already developed, are excluded, complicating research (Keough et al., 2015). 
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Additionally, the inflammation is rapidly cleared thus remyelination therapies 
developed through this model may not be translatable, especially in the case of MS, 
as a similar environment to that observed in human demyelination, is unlikely to be 
found. 
TMEV takes advantage of the RNA viruses’ ability to induce demyelination in a 
monophasic or biphasic manner, after intracerebral injection (Nathoo et al., 2014). 
Intracerebral injections of this virus induce reproducible chronic demyelination which 
only affects the CNS and affects the animal for the remainder of its lifespan. It is not 
exactly clear how demyelination occurs, whether it introduces autoimmunity, directly 
attacks OLs, or through indirect effects due to CNS inflammation (Denic et al., 2011). 
Despite the advantages of these models for easily and reproducibly inducing 
demyelination, it was decided that in this investigation, EAE would be used. This is 
primarily so that we could compare the demyelination and remyelination processes to 
that of a major human disease and therefore hopefully investigate a more 
translatable disorder. Additionally, due to our LINGO1 co-interaction hypothesis, we 
wanted to utilise the same models to directly compare our investigations to those 
involving LINGO1 based therapies. 
2.1.2.3 EAE protocol 
Two models of EAE were used for this project. Firstly, an acute disease model 
was used in our facilities to investigate the role of AMIGO3 in the acute stages of 
demyelination. Additionally, a monophasic model of EAE was used to examine the 
progression of disease and responses in the chronic disease state. 
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2.1.2.3.1 Acute EAE and optic neuritis 
For the acute model, C57BL/6 mice were maintained at the BMSU as previously 
described. Animals were injected subcutaneously with 100μl of MOG35-55/CFA 
emulsion (1mg/ml; Hooke Laboratories). The animals received a clinical score based 
on progression of the disease (table 2.1). In the early stage disease, animals were 
euthanised at treatment day 10 (D10) for optic neuritis and D14/19 for early EAE 
samples. Daily clinical scores were taken from D14 up until date of collection. 
2.1.2.3.2 Relapsing-remitting EAE 
A relapsing-remitting model of EAE was also performed and samples generously 
supplied by Professor David Baker and Dr Gareth Pryce (Blizzard Institute, Barts and 
London Medical School, UK). The model used 6-8 week old, male and female ABH 
Biozzi mice. Mice were specific pathogen free. The mice were maintained in a 12 
hour dark/light cycle at 21°C with 55% relative humidity. Food and water was 
available ad libitum, with moist food provided during clinical stages of the model to 
prevent undereating. 
The animals were treated and collected as previously described (Al-Izki et al., 
2012). Briefly, at 6-8 weeks, the mice received 2, 150μl subcutaneous injections of 
spinal cord homogenate/ complete Freund’s adjuvant as defined by Al-Izka et al 




Score Clinical observation 
0 Normal. 
0.5 A limp tail, characterised by some tone but the mouse is unable to 
hold its tail upright. When the tail is lifted by a finger, it can partially 
curve around said finger. 
1 Flaccid tail. 
1.5 Difficulty with righting reflex. Mice when placed on their backs will 
struggle to right themselves and will do so slowly. 
2 Impaired righting reflex. Mice are fully unable to right themselves 
when inverted. 
2.5 Hind-limb gait disturbance. Mice demonstrate difficulty with their 
walk. 
3 Hind-limb paresis. Clear signs of partial paralysis and weakness in 
the hindlimbs. 
3.5 Effective paralysis of hind-limbs, although some minor movement. 
4 Hind-limb paralysis. Usually with signs of fore-limb paresis. 
5 Paralysis of all limbs 
Table 2.1: EAE scores and their corresponding clinical observations.
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mice. The first injection was deemed on D0, with a repeat injection following the 
same procedure on D7, however injections were made below and more posteriorly 
than the previous. The animals were maintained until progressing to a score of 4 for 
2 consecutive days. At this stage, animals were euthanised and samples collected. 
2.2 Ex vivo procedures 
2.2.1 Cell culture 
2.2.1.1 Primary OLG 
2.2.1.1.1 Preparation of primary OPC 
Primary mixed glial cultures were obtained from C57BL/6 mice at postnatal day 0-
2 (P0-2). P2 pups are the optimum collection age to obtain the highest number of 
OPCs before substantial differentiation occurs (O'Meara et al., 2011). Mixed glial 
cultures were obtained as previously described (O'Meara et al., 2011), with some 
modifications as described below. 
Brains were dissected and isolated neocortices were disrupted physically by 
slicing, and enzymatically by trypsinisation containing DNAseI (0.2% v/v; Thermo 
Fisher Scientific) to prevent aggregation of cells. Cells were triturated and strained 
through a 70μm filter before centrifuging at 200xg, 10°C for 7 minutes. The cells were 
then seeded into 3 poly-L-lysine (PLL; Sigma-Aldrich) coated T25 flasks with 6ml 
Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies) containing foetal 
bovine serum (FBS; Sigma-Aldrich) (10% v/v) and incubated at 37°C, 5% CO2. 
Following 24 hours, the media was replaced to remove excess debris. The cells were 
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then maintained for two days before replacing 2/3 of the media with sterile N2 media, 
consisting of DMEM:F12 (Life Technologies), penicillin-streptomycin (1X; Thermo 
Fisher Scientific), L-glutamine (200mM; Sigma-Aldrch), insulin (50μg/ml; Sigma-
Aldrich), apo-transferrin (100ng/ml; Sigma-Aldrich), putrescine (100μM; Sigma-
Aldrich), progesterone (20nM; Sigma-Aldrich) and sodium selenite (30nM; Sigma-
Aldrich). Every subsequent third day, a 2/3 media change with N2 media was 
repeated. 
When the cells have reached confluency and OPCs can be observed propagating 
on top of the astrocyte monolayer at a reasonably high concentration (fig. 2.1), 
usually D8-10, pure OPCs were isolated and cultured. Mixed glial cultures were 
fastened securely to an orbital shaker at 37°C, 5% CO2 and shaken at 160rpm for 30 
minutes. This first shake is to remove weakly adhered microglia from the cultures. A 
full media change was performed to remove the floating microglia. For primary 
microglial cultures, this media can be centrifuged at 300xg, 10°C for 5 minutes and 
reseeded with DMEM containing FBS (10%). For primary OPC cultures, following the 
full media change, the mixed glial cultures were attached to the orbital shaker at 
37°C, 5% CO2 and shaken at 200rpm for 16 hours. 
Following shaking, media was removed carefully to prevent dislodging of 
astrocytes. The media was then seeded in to 10cm tissue culture dish, 2 flasks worth 
of media per dish, and incubated at 37°C, 5% CO2 for 30 minutes. This step was to 
remove any loose astrocytes/microglia that would have become dissociated in to the 




Figure 2.1: An example of the mixed glial cultures. The small circular cells with dual 
processes are OPCs, indicated by the arrows. A monolayer of large flat astrocytes 
can be seen coating the surface of the flasks which the OPCs are proliferating on top 
of. Scale bar represents 200μm.
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than OPC, they will bind to the surface of the dish more readily than OPC so will not 
remain in solution. Every 10 minutes, the dishes were gently shaken to prevent the 
adhering of OPC to the base of the dish. 
The media was then removed and centrifuged at 300xg, 10°C for 5 minutes. 
Supernatant was removed and cells were resuspended in 500μl of media. For OPC 
cultures, cells were resuspended in SATO media, consisting of DMEM supplemented 
with apo-transferrin (10µg/ml), insulin (10µg/ml; Sigma-Aldrich), putrescine (100µM), 
tri-iodo-L-thyronine (500nM; Sigma-Aldrich), sodium selenite (220nM), L-thyroxin 
(520nM; Sigma-Aldrich) and Horse serum (1%; Life Technologies), supplemented 
with bFGF (20ng/ml; Peprotech) and PDGF-AA (20ng/ml; Peprotech). OPCs were 
counted and seeded on Matrigel (Corning) coated surfaces and analysed following 
24 incubation at 37ºC, 5%CO2, as described per experiment. For mature OL, OPCs 
were suspended as for OPC cultures. After 24 hours incubation, media was replaced 
with SATO media, excluding the bFGF and PDGF-AA. Media was replaced on D3 
and samples were collected on D5. Unless otherwise stated, OPC were dissociated 
from Matrigel coated surfaces by scraping with either a cell scraper or a 1000μl 
pipette tip if the wells were too small for a scraper. Scraping was performed with 
500μl phosphate buffered saline (PBS) chilled to 4ºC. Following scraping, an extra 
rinse was performed with the PBS to ensure the maximum collection of cells 
possible. The solution was collected in a sterile Eppendorf tube which had been pre-
chilled to 4ºC. This solution was then used for further processing. 
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2.3 In vitro procedures 
2.3.1 Cell culturing 
2.3.1.1 Oli-neu 
Oli-neu cells are an immortalised murine cell line derived from primary mouse 
OPCs. They are immortalised through the incorporation of a t-neu oncogene, leading 
to the production of a constitutively active tyrosine kinase (Jung et al., 1995; Pereira 
et al., 2011). These cells have been shown to express the OPC marker, NG2 (Jung 
et al., 1995; Foale et al., 2014; Sakry et al., 2015). They also differentiate in to MAG 
positive (an OLG marker) cells when treated with cAMP. Oli-neu also maintain the 
ability to interact with axons both in vivo and in vitro (Jung et al., 1995). As such 
these cells appear to express an OPC phenotype and as such Oli-neu cell cultures 
are a useful tool for investigating OPCs. Despite this, Oli-neu do not appear to 
produce dense, compacted myelin, indicating that they are not a perfect model and 
that they lose some of their ability to fully differentiate in to mature OLs (Jung et al., 
1995). Finally as mouse EAE models were used in this investigation, mouse OPC 
lines were chosen over other species. This ensured that our in vitro cell studies were 
closely related to the in vivo experiments. 
2.3.1.1.1 Collection and maintenance of Oli-neu cells 
Oli-neu cells (originally provided by Prof Jacqueline Trotter, Johannes Gutenberg 
University of Mainz) were stored at -80°C, with 500,000 cells in 400μl of freezing 
media, which consisted of DMEM supplemented with FBS (20% v/v) and dimethyl 
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sulphoxide (DMSO) (10% v/v; Sigma-Aldrich). For experiments, Oli-neu cells were 
thawed at room temperature and suspended in SATO media. Following 
centrifugation at 150xg, 10°C for 5 minutes, the supernatant was removed and one 
sample of cells was seeded with 4.5ml of SATO in a T25 flask. The cells were then 
incubated at 37°C with 5% CO2. When confluent, the cells were trypsinised and 
reseeded in a T75 flask with 10ml SATO and incubated at 37°C and 5% CO2. When 
~80% confluency is met, the cells were trypsinised and split as previously described. 
2.3.2 Histology 
2.3.2.1 Principles of Histology 
2.3.2.1.1 Immunohistology 
Immunohistology is used to localise specific antigens in either tissue samples, 
IHC, or cell cultures, immunocytochemistry (ICC). The technique utilises antigen 
specific antibodies, to highlight the localisation of specific proteins on a sample. A 
blocking protein such as bovine serum albumin (BSA) or non-immune serum is 
applied to coat the sample in non-specifically bound proteins and therefore prevent 
non-specific binding of the antibodies. A non-specific antibody will have a similar 
strength interaction to general proteins as the BSA, and thus is unlikely to displace 
bind and give incorrect signalling. This helps to reduce background staining. When 
examining intracellular antigen, a detergent is also applied to permeabilise the cells 
and allow infiltration of the antibodies (Polak and Noorden, 2003). 
Following preparation of the samples, a primary antibody is applied which will only 
bind to the antigen of interest due to the blocking of non-specific interactions. This 
63 
 
primary antibody can contain a fluorescently probed tag or an enzyme, to produce 
signal directly. Alternatively, a fluorescently tagged secondary antibody targeted to 
the primary antibody, is used. The use of a  secondary antibody step allows signal 
amplification since multiple secondary antibodies can bind to a single primary 
antibody (fig. 2.2) (Polak and Noorden, 2003). 
Fluorophores will emit coloured light when excited by a specific wavelength of 
light. This can then be visualised and photographed for further analysis (fig. 2.2). An 
advantage of this system is that multiple antigens can be visualised independently on 
a single sample, providing that the fluorophores used are not excited by the same 
wavelengths of light. The antibodies used also have to be carefully chosen to ensure 
that they are not from the same/similar species and thus susceptible to crossover 
from the secondary antibodies (Polak and Noorden, 2003). 
For fluorescent imaging, we also used 4’, 6-diamidino-2-phenylindole (DAPI) as a 
counter stain. DAPI is a nucleic acid binding protein which greatly increases it 
fluorescent signal (at 461nm) when bound to regions of high adenosine-thymine 
interactions. As such, DAPI will only present signal when bound to DNA and thus 
highlights nuclei (Brisard and Rusling, 2007; Biancardi et al., 2013). As DAPI only 





Figure 2.2: principles of Immunohistology. The primary antibody (blue) binds to the 
antigen of interest on the cell/tissue. Secondary antibodies (green) with labelled 
fluorescent probes can then bind to the primary antibody. Multiple secondary 
antibodies are then able to bind to the primary antibody and amplify the signal.
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For enzymatic imaging, the secondary antibody contains a conjugated enzyme. 
When a certain compound is added, the enzyme will catalyse the conversion of said 
compound producing a colour change which can be visualised microscopically. In 
this study, diaminobenzidine (DAB) staining was used. The secondary antibody is 
biotinylated, meaning that when an avidin-biotin complex (ABC) is administered, the 
avidin will produce a strong interaction with the biotin. The ABC contains horseradish 
peroxidase which is able to oxidise DAB. When DAB is added to the ABC containing 
sample, the oxidation results in the generation of a brown colour which can be 
visualised under brightfield microscopy (Polak and Noorden, 2003). We used the 
nuclear staining compound, haematoxylin, in this study as a counterstain (Chan, 
2014). 
2.3.2.2 Processing of tissue for histology 
Following dissection of tissue samples, as specified per tissue type, the samples 
were incubated in paraformaldehyde (PFA; TAAB laboratories) at 4°C. Incubation 
times varied for tissue samples as specified. Samples were then washed three times 
in PBS for 30 minutes. Following washing, samples were submerged in PBS with 
increasing concentrations of sucrose (10/20/30%). Samples were incubated for 
between 8-12 hours for cryoprotection. Tissue samples were submerged in optimal 
cutting temperature media (OCT) (TAAB Laboratories) and orientated upright. The 
samples were then snap-frozen with dry ice and stored at -20°C until use. The 
resultant frozen tissue blocks were then sectioned to 15μm using a cryostat 
microtome (Brights Instruments) and adhered to charged glass slides and stored at -
20°C until required. 
66 
 
2.3.2.3 Processing of cell cultures for histology 
Unless specified, cells were grown in 8 well chamber slides (Corning Falcon). 
Following treatment, cells were fixed with 4% PFA for 20 minutes. Fixed cells were 
then washed three times in PBS. Samples were then either used immediately or 
stored at 4°C for a maximum of 4 days. 
2.3.2.4 Immunohistology Protocol 
All stains were accompanied with a negative control, with no primary antibodies. 
Additionally, when more than one primary antibody was used, tests containing 
individual primary antibodies with all secondary antibodies were conducted to check 
that non-specific antibody interactions did not occur. 
2.3.2.4.1. Immunofluorescence 
Immunohistology was performed as previously described unless stated otherwise 
(Ahmed et al., 2013). Slides were thawed for 30 minutes at room temperature before 
washing in PBS. After washing the sections were incubated in PBS-T (PBS 
containing 0.5% BSA and 0.5% Triton-X100) to permeabilise the tissue and block the 
sample from non-specific antibody binding. If all of the secondary antibodies used in 
the experiment were of the same species, 15% normal serum was also included, 
derived from the same species as the secondary antibodies (Burry, 2011). After 
incubation in a humidified chamber at room temperature for one hour, primary 
antibodies were applied at the stated concentrations in antibody diluting buffer (ADB). 
ADB consisted of PBS with 0.5% BSA (w/v) and 0.05% Tween 20 (v/v). Samples 
were incubated with 100μl of primary antibody/ADB solution for 14-16 hours at 4°C in 
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a humidified chamber. Following incubation, slides were washed in PBS. Secondary 
antibodies at the stated concentrations were applied in 100μl of ADB and samples 
were incubated in a humidified chamber at room temperature for 1 hour. Slides were 
washed in PBS and then a coverslip was mounted onto the slide using Vectashield 
mounting media (Vector laboratories). In some examples, this solution also contained 
DAPI. 
2.3.2.4.2. DAB/ABC 
For DAB/ABC staining, samples were prepared similarly to the protocol for 
immunofluorescence, however a biotinylated secondary antibody was incubated 
rather than the fluorescently labelled tag. This was performed in 100μl of ADB in the 
humidified chamber for 1 hour at room temperature. Following another PBS wash, 
samples were incubated for 30 minutes with ABC reagent (Vector Laboratories) and 
washed again in PBS. Sample were incubated with DAB solution (Vector 
Laboratories) for 5 minutes. A further wash in PBS was performed and then samples 
were incubated with Mayer’s Haematoxylin (Thermo Fisher Scientific) for 1 minute 
and washed in PBS. The samples were dehydrated for in successive ethanol 
treatments (70%, 90% and twice in 100%, v/v), each for 5 minutes before being 
incubated in histoclear (National Diagnostics). This was performed 3 times for 5 
minutes. Finally samples were mounted with Vectamount permanent mounting 
medium (Vector Laboratories). 
2.3.2.5 Antibodies 
The antibodies used in this study are listed below in table 2.2. 
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2.3.2.6 Imaging and analysis 
Following labelling, sections were visualised using either a Zeiss Axioplan 2 
epifluorescent microscope, equipped with an Axiocam HRc and imaged with the 
Axiovision software (all from Carl Zeiss Ltd), or a Zeiss Axiovert  microscope 
equipped a differential spinning disc module (Revolution DSD1,Andor Technology) 
and a CCD camera (Andor Technology). Images were then thresholded and 
standardised using ImageJ (U.S.A. National Department of Health) to remove 
background staining and ensure that images could be compared fairly. Images were 
then randomised and anonymised to eliminate bias during analysis. 
2.3.2.7 Semi-quantification of images 
For the most part, histology was analysed qualitatively for localisation and 
expression patterns. In some cases it was possible to gain some quantification to 
examine the changing levels of expression. Multiple methods were used for semi-




Table 2.2: antibodies used for immunohistology and their sources.
Primary Antibodies 
Target Source Supplier (code) 
AMIGO3 Rabbit polyclonal Novus Biotech (NBP1-
86405) 
CC1 Mouse monoclonal Calbiochem-Millipore 
(Cat. No. OP80) 
CD4 Rabbit polyclonal Novus Biotech (NBP1-
19371) 
CD8 Rabbit monoclonal Novus Biotech (NBP1-
79055) 
GFAP Rabbit polyclonal Abcam (ab7260) 
LINGO1 (C-15) Goat polyclonal Santa-Cruz (sc-48582) 
LINGO1 Rabbit polyclonal Abcam (ab23661) 
MBP Rat monoclonal Millipore (MAB386) 
Neurofilament-
200 (NF200) 
Mouse N52 clone, 
monoclonal 
Sigma-Aldrich (N0142) 
NG2 Rabbit polyclonal Millipore (AB5320) 
NG2 Mouse monoclonal Abcam (ab20156) 
NG2 Rat polyclonal R&D (MAB6689) 
NgR1 Rabbit polyclonal Millipore (AB15138) 
O1 Mouse polyclonal Privately sourced 
O4 Mouse monoclonal R&D (Mab1326) 
Olig2 Rabbit polyclonal Millipore (AB9610) 
OX42 Mouse monoclonal Santa-Cruz (sc-53086) 
Secondary Antibodies 
Target Source Supplier (code) 
α-Goat Alexa 
Fluor (AF)488 
Donkey Molecular Probes 
(A11055) 
α-Goat AF594 Donkey Invitrogen [Molecular 
Probes ] (A11058) 
α-Mouse AF594 Donkey Invitrogen (A21203) 
α-Mouse AF594 Goat Molecular Probes 
(A11032) 
α-Mouse AF350 Donkey Invitrogen (A10035) 
α-Rabbit AF488 Donkey Invitrogen [molecular 
Probes] (A21206) 
α-Rabbit AF488 Goat Molecular Probes 
(A11034) 
α-Rat AF594 Donkey Invitrogen (A21209) 




2.3.3 Total pixel counts 
Total pixel counts were used to examine the total distribution of a protein in a set 
area. Images were converted to display individual channels. A set sized region of 
interest (ROI) was applied to each image within a set anatomical region. This region 
was selected using the DAPI channel to prevent bias during ROI selection. Images 
to be quantified were then converted to binary images to only display only positive 
pixels over the threshold value. The total number of positive pixels within the ROI 
was then calculated and a percentage positive pixel count was analysed for 
quantification. 
2.3.3.1 Pixel intensity 
ROI were collected from samples as for pixel counts, however after thresholding, 
the average pixel intensity of positive pixels was measured. 
2.3.3.2 Cell counts 
ROIs and binary processing were applied as described above. Cells were then 
counted based on the number of areas with positive signal on the image. Automated 
counting was used attempt to minimise human error in the counting procedure. This 
was performed using the ‘Particle Analysis/ITCN’ plugin. This was predominantly 
used with DAPI, taking advantage of its nuclear expression. 
2.3.3.3 Cell co-expression 
Images and ROIs were generated as described above. The ‘Colocalization’ plugin 
on ImageJ was used to generate an image in which only pixels that were positive for 
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both proteins was displayed. The ‘Particle Analysis/ITCN’ plugin on ImageJ was then 
used to count the number of colocalised pixels. 
2.3.4 Western Blot 
2.3.4.1 Principles of Western Blot 
Western blotting is a renowned technique for separating and visualising specific 
proteins from a mixture of proteins taken from a tissue or cell sample. In brief, a 
protein lysate solution is collected and heated with mercaptoethanol and sodium 
dodecyl sulphate (SDS). Heating causes denaturation of the proteins and disrupts 
the quaternary and tertiary structures, linearising the proteins. Mercaptoethanol 
breaks disulphide bonds between proteins, and SDS coats proteins in a negative 
charge. This results in unfolded proteins which have a net negative charge 
proportional to their size. The protein solution is inserted into a polyacrylamide gel, 
containing narrow pores which obscure the passage of proteins based on their size. 
As a result, when an electrical charge is supplied across the gel, short proteins 
migrate rapidly to the anode whereas large proteins migrate slower (Mahmood and 
Yang, 2012). 
The proteins can then be transferred from the gel on to a membrane and 
visualised. Antibodies are used, similarly to that of Immunohistology, with a primary 
antibody against the protein of interest, and a secondary antibody to amplify the 
signal. Similarly to Immunohistology, immunofluorescence can be used, however in 
this study we used electrochemiluminescence (ECL). The secondary antibodies are 
conjugated with horse radish peroxidase (HRP), an enzyme which converts ECL 
agents to their luminescent form. This luminescence can then be recorded and 
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imaged, creating bands dependent on the quantity of the protein. Semi-quantification 
can be then performed on these bands (Mruk and Cheng, 2011). 
2.3.4.2 Processing of samples for Western Blots 
2.3.4.2.1 Cells 
A protein lysis buffer (PLB) was used to disrupt the samples to obtain valid protein 
solutions. The protein lysis buffer was comprised of Tris-HCl (20nM; Sigma-Aldrich), 
NaCl (150mM; Sigma-Aldrich), ethylenediaminetetraacetic acid (EDTA) (1mM; 
Sigma-Aldrich), egtazic acid (EGTA) (0.5mM; Sigma-Aldrich), NP-40 (1% v/v; 
Thermo Fisher Scientific) and Protease inhibitor solution tablets (1 tablet per 10mls 
solution; Thermo Fisher Scientific). Two protocols were used, one for primary cells 
and one for immortalised cell lines. 
Cell cultures were trypsinised and pelleted by centrifuging at 150xg, 10°C for 5 
minutes. 50-100μl of ice cold PLB was added per sample. Primary cells had 50-
100μl ice cold PLB added directly to the cell culture. The cells were then scraped 
and the resulting cell solution was triturated gently through a 27-gauge needle to 
disrupt the cell structure. 
Following collection of the PLB-cell lysate solution for both primary and 
immortalised cell lines, the cell lysate solutions were vortexed at 1000rpm. The 
samples were then put on ice for 45 minutes and vortexed at 1000rpm every 10 
minutes. After 45 minutes on ice, the samples were centrifuged at 8000xg, 4°C for 4 
minutes. The supernatant was removed and the samples were stored at -20°C. 
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2.3.4.2.2 Tissue samples 
Following dissection, samples were split in to roughly 25mg chunks and added to 
500μl PLB. Samples were then homogenised with a mechanical homogeniser. 
Following homogenisation, the samples were vortexed at 1000rpm and put on ice for 
45 minutes, being vortexed at 1000rpm every ten minutes. Samples were then 
centrifuged at 16000xg, 4°C for 20 minutes. The supernatant was removed and the 
samples were stored at -20°C. 
2.3.4.3 Western Blot protocol 
Gels were prepared with a resolving gel and a loading gel above which contained 
the loading wells. The resolving gel consisted of 2.75ml Protogel (Geneflow), 1.65ml 
Tris-HCl (1.5M, pH8.8), 2.2ml water, 66μl SDS (10% v/v;Sigma-Aldrich), 23.1μl 
ammonium persulphate (APS) (10% v/v; Sigma-Aldrich) and 9.9μl 
tetramethylethylenediamine (TEMED) (Sigma-Aldrich). The solution was then 
pipetted in to a 1mm cassette and ethanol was pipetted on top to prevent the 
formation of bubbles. This was then given 20 minutes to set at room temperature. 
The loading gel consisted of 0.4ml Protogel, 1.85ml Tris-HCL (0.5M, pH6.8), 0.75ml 
water, 30μl SDS (10% v/v), 15μl APS (10% v/v) and 7.5μl TEMED. This solution was 
similarly pipetted on top of the set resolving gel and given 30 minutes to set at room 
temperature. 
A gel tank was filled with running buffer, which consisted of 3.03mg/ml Tris base 
(Sigma-Aldrich), 14.4mg/ml glycine as well as 5ml of 20% SDS/l of running buffer. 
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The western blot gel was submerged in running buffer in the chamber and connected 
to a power supply. 
Cell/tissue lysis solutions were thawed on ice. Protein concentrations were then 
measured using the DC protein assay following the manufacturer’s instructions (Bio-
rad Laboratories), following the manufacturer’s instructions. 5-30μg of total protein 
was mixed with a minimum of 5μl of lamelli blue buffer (Sigma-Aldrich) to make a 
total volume of 25μl. This solution was heated to 90°C for 4 minutes. Once heated, 
the samples were centrifuged at 8000xg for 5s. 
Each protein lysis solution was then loaded into a well on the western blot gel, 
along with a protein ladder, and the samples were run at 150V, 45mA at room 
temperature for 110 minutes or until the proteins at the area of interest had 
separated sufficiently. Samples were run in running buffer, consisting of Tris Base 
(3.03g/L), glycine (14.4g/L; Geneflow) and SDS (0.01% v/v). Following 
electrophoresis, the bands were electrotransferred on to a methanol activated 
hydrophobic polyvinylidene difluoride (PVDF) membrane at 35V, 170mA for 110 
minutes in transfer buffer, consisting of Tris Base (3.03g/L), glycine (14.4g/L), 
methanol (20% v/v) and SDS (0.01% v/v) 
Following blotting, the membrane was removed, rinsed in TTBS solution for 
5mintues at room temperature. TTBS consisted of Tris base (14g/L), Tris HCl 
(60g/L), NaCl (87.5g/L) and Tween 20 (500μl/L), pH 7.3. The membrane was then 
incubated with Marvel solution, consisting of TTBS with Marvel dried milk (5% w/v), 
for 1 hour at room temperature. The primary antibody was then applied to the 
membrane in Marvel solution overnight at 4°C. 
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Following incubation with the primary antibody, membranes were washed in TTBS 
before incubating with the secondary antibody in Marvel solution for 1 hour at room 
temperature. Finally the membranes were washed in TTBS before imaging. 
Membranes were imaged using ECL Western blotting reagents (GE Healthcare) 
following the manufacturer’s instructions. Briefly, the ECL solution is applied evenly 
across the membrane and incubated in darkness for up to 1 minute. The membrane 
is dried, sealed inside a transparent plastic bag and then exposed to 
autoradiography film in darkness for the appropriate development time. 
2.3.4.4 Antibodies 
The primary antibodies used were the same antibodies for the Immunohistology 
studies. Housekeeper primary antibodies and secondary antibodies used for western 





Table 2.3: antibodies used for western blots and their sources 
Gene Forward primer Reverse primer 
α-tubulin AAGCAGCAACCATGCGTGA CCTCCCCCAATGGTCTTGTC 





LINGO1 CAAGAGAGACATGCGATTGG TGGTTGAGTGTCTTGATGCG 
Table 2.4: List of primers used in this study.
Primary Antibodies 
Target Source Supplier (code) 
Alpha-tubulin Rabbit polyclonal New England 
Biotechnologies (2144S) 
HPRT1 Rabbit polyclonal Enogene (E19-7463) 
Secondary Antibodies 
Target Source Supplier (code) 
α-Rabbit HRP Goat PI-1000 
α-Rat HRP Goat PI-9400 
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2.3.4.5 Semi-quantification of western blots 
ImageJ was used to quantify the protein levels from the intensity and size of bands 
produced from the western blots. Briefly, imaged autoradiography film was scanned 
and images were imported to ImageJ. Integrated densities were measured for each 
band using the built-in gel plotting macros in ImageJ. Integrated densities from test 
samples were then normalised to the level of so-called ‘house keeper’ proteins 
chosen for their stable levels of expression (alpha-tubulin or β-actin). 
2.3.5 PCR 
2.3.5.1 Principles of PCR 
The polymerase chain reaction (PCR) is an efficient technique for amplifying and 
measuring the concentration of DNA samples. In this study, only mRNA 
concentrations were measured, and thus needed to be converted to complementary 
DNA (cDNA) prior to PCR amplification. Reverse transcriptases are used to convert 
the mRNA samples to cDNA. 
Thermosensitive synthetic oligonucleotides, DNA polymerase (Taq polymerase) 
and deoxynucleotide triphosphate bases are then combined with the cDNA sample in 
a thermal cycler to amplify the samples. The mixture is heated to 95°C, causing the 
cDNA strands to separate. The sample is then cooled to 50°C, allowing the primers 
to anneal before raising the temperature to 72°C, where Taq polymerase is activated 
and new DNA strands are replicated. This cycle can then be repeated to rapidly 
amplify the DNA samples (Eisenstein, 1990; Kramer and Coen, 2001). 
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For this study, we used SYBR green to quantify cDNA samples. SYBR green is 
able to bind to the minor groove within double stranded DNA (dsDNA), but is not able 
to bind to single stranded DNA. When bound to dsDNA, the dye emits a thousand 
fold greater fluorescence compared to when in solution (Tajadini et al., 2014). 
Therefore, as the reaction progresses and produces greater quantities of dsDNA, the 
greater the intensity of fluorescence from the sample. The number of cycles that are 
required to reach a set level of fluorescence, the threshold cycle (Ct), is inversely 
correlated to the concentration of original DNA. 
2.3.5.2 Processing of samples for qPCR 
RNA was collected from both cells and tissue for PCR analysis. For cell lines, the 
cell line was pelleted by centrifugation as per cell line. Supernatant was removed and 
the centrifugation was repeated twice with PBS to wash the cells. Following washing, 
RNA was collected from the samples using the RNeasy mini kit and Qiashredder kits 
(Qiagen) as directed on by the supplier. 
For tissue samples, samples were cut in to 50mg chunks. These chunks were then 
loaded in to a cryotube with 500μl of Trizol and homogenised using a mechanical 
homogeniser for 1 minute, whilst incrementally increasing the speed of 
homogenisation. Samples were then incubated at room temperature for 5 minutes 
before adding 200μl chloroform and incubating for 5 minutes at room temperature. 
Samples were centrifuged at 10,000xg, 4°C for 15 minutes. The top layer of the 
subsequent solution (roughly 200μl) was removed and added to 700μl of 100% 
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ethanol. Samples were then briefly vortexed. These samples were then treated with 
the RNeasy mini kit (Qiagen) as directed by the supplier to collect pure RNA 
samples. 
Concentrations of RNA samples from tissue and cells were measured using a 
Nanodrop spectrophotometer. Purity from contaminants was measured by examining 
the ratio of absorbance at 260/280nm. Readings of 1.8-2.1 were considered 
acceptable for use. 
2.3.5.3 cDNA production 
RNA was converted to cDNA using the SensiFAST cDNA synthesis kit (BIOline) 
as described by the supplier. Briefly, the RNA sample was added to 4μl of 5x 
Transamp buffer and 1μl reverse transcriptase as provided in the SensiFAST kit. 
DNase/RNase free water was added to the solution to make a final volume of 20μl. 
The samples were heated at 25°C for 10 minutes, 42°C for 15 minutes, 48°C for 15 
minutes, 85°C for 5 minutes and finally held at 4°C for 5 minutes. Resultant cDNA 
samples were stored at -20°C until use. 
2.3.5.4 qPCR protocol 
Samples were amplified and analysed using SYBR green PCR master mix and 
IQ5 Optical System Software (BioRad Laboratories). A master mix solution was 
produced, containing 10μl SYBR green and forward/reverse primers at the optimised 
concentration per well used. cDNA was added at an equilibrated concentration and 
master mix/cDNA solution, topped up with RNAse free water to 20μl, was added in to 
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a 96 well plate on ice. The 96 well plate was centrifuged at 2000xg, 4°C for 5s. 
Following centrifugation, the 96 well plate was loaded in to the Biorad MyiQ PCR 
thermal cycler. 
2.3.5.5 qPCR quantification 
ΔCT values were calculated from SYBR green fluorescence by the BioRad IQ5 
software. These values were then normalised against housekeeper genes and ΔΔCT 
were calculated and converted to expression-fold changes. 
2.3.5.6 Primers 
Primers used for this study are listed in table 2.4. 
2.4 Statistics 
As all statistics were used between ordinal and continuous data, student t-tests, 
one way ANOVAs, Kruskal-Wallis tests or Mann Whitney U tests were used to 
analyse our samples. Prior to tests, samples were checked for both normal 
distributions and homogeneity of variances. If these assumptions were not met, 
samples were tested using the non-parametric, Kruskal-Wallis or Mann Whitney U 
tests. For ANOVAs, post-hoc Tukey tests were performed and for Kruskal Wallis 
tests, post hoc Bonferroni tests were performed. Significance was deemed when 
p<0.05. All values are included with ± one standard error of the mean (SEM). All 
















As our preliminary data suggested that AMIGO3 is expressed in OLG, it was 
decided to examine whether AMIGO3 plays a role in OLG during development as 
well as if its expression has any relationship with the onset of myelination in 
postnatal mice. 
3.1.1 Myelination during development 
It was decided in this study to examine myelination in the corpus callosum (CC) 
since it provides a white matter region which is easily identified in multiple sections, 
and at multiple stages of development. It is therefore an ideal structure in which to 
visualise and analyse the development of myelin in the mouse CNS. The optic nerve 
is also a viable region for measuring the development of myelin during the same 
period, however it was considered less preferable to the CC since it is more difficult 
to extract at earlier developmental stages due to its size and its transparent 
appearance prior to myelination. 
 Myelination in the murine models appears to begin around P8-14, commencing 
laterally and progressing medially (Hamano et al., 1996; Shen et al., 2005; 
Calabrese and Johnson, 2013). Compact myelin is first observed around P17, with a 
rapid period of myelination between P14 and P21. By P21, the vast majority of 
myelination has occurred. The majority of the myelination of the corpus callosum can 
be seen from P35-40, although there is remodelling throughout life (Bjartmar et al., 
1994; Hamano et al., 1996; Lodygensky et al., 2012). MRI images of whole murine 
and human brains show similar distributions, with myelination beginning after birth 
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and developing rostrally, with the frontal cortex receiving the last wave of myelination 
at around 18months (van Tilborg et al., 2018). 
3.1.2 LINGO1 during myelination stages 
LINGO1 expression appears very low during postnatal development. Its levels in 
the CNS rapidly increase around P4 and appear to decrease again during the main 
stages of myelination in mice. This led to the hypothesis that LINGO1 could be 
inhibiting myelination, and that its downregulation may enable myelination during 
development (Mi et al., 2004). Following this hypothesis, it would be valuable to 
examine whether AMIGO3 displays a similar pattern of expression as this would 
support a potential role in the mechanisms that suppress and promote OLG 
differentiation and myelination during postnatal myelination. 
3.2 Aims 
In this study we aim to examine the expression profile of AMIGO3 during 
development stages of myelination. Ideally we would like to examine the expression 
profiles in OLG to gain an insight in to the role of the LRRs during the early 
myelination stages. We also aim to determine the best antigens for analysing the 
changes in OPC maturation in the murine CC. 
3.2.1 Hypothesis 
We hypothesise that AMIGO3 expression will be high at the early stages of 
postnatal development however there will be a negative correlation between 
AMIGO3 expression and myelination. This would indicate that AMIGO3 will be 
reducing its inhibitory role on OPCs to allow OPC maturation and myelin production. 
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3.3 Experimental design and methods 
3.3.1 Optimisation of IHC studies 
Prior to embarking on the development study, antibodies were optimised on 
positive control tissue samples. Appropriate tissues were chosen based on a 
literature search. All mice used for the optimisation study were 6 weeks old as this 
meant that the animals had reached sexual maturity and were therefore likely to 
have reached full development, removing any variation based on age differences 
(Medina and Shepherd, 1981; The Jackson Laboratory, 2007; Yu et al., 2012). 
3.3.2 Developmental studies 
Coronal sections of mouse brains were collected which contained the CC as well 
as the lateral ventricles but did not include the hippocampi. This was to allow for a 
sufficient number of sections for all tests, but to limit any variation introduced by 
varying section position in the rostral-caudal axis. To determine the extent of 
myelination, the medial CC, immediately inferior to the cingulum, was chosen to be 
imaged. The medial CC rather than the lateral CC was chosen due to its more 
homogenous features in varying depths through the brain as well as the longer 
period for myelination to become completed, therefore a more gradual change in 
protein expression is likely to be observed (fig 3.1). 
Incremental age groups were used for the development investigations. Mice were 
collected at P0, P7, P14, P21 and P28. This range was chosen to include the full 
range of myelination stages, P0 where myelination had not begun and (P8-14) with 
the initiation of myelination. It is not entirely clear when novel myelination finishes in 
85 
 
mice, considering that in a ‘healthy’ state, there is a constant turnover of mature OL 
from local OPC, therefore P28 was chosen as a terminal group when the majority of 
myelination and compaction has completed (Sturrock, 1980; Berger et al., 1991; 
Lodygensky et al., 2012; Chan et al., 2013; Yuen et al., 2014; Dai et al., 2015). For 
all developmental studies, n=4. 
3.3.2.1 Immunohistochemistry 
Due to the variation in volume and therefore time required to penetrate as well as 
saturate the tissue, the samples were left in 4% (v/v) PFA for varying times as shown 
in table 3.1. The choice of markers, and combinations to be used, in the main 
developmental study were dependent on the results obtained from these 
optimisation experiments. Total pixel counts observed in a uniform sized region of 
the medial CC (fig 3.1) were normalised against thresholds and quantified as 
previously discussed. 
3.3.2.2 Western blots 
Neocortices from neonate pups were isolated and dissected into 25mg chunks. 
Protein lysates were collected as previously described. Concentrations of primary 
antibody were as previously listed unless otherwise stated. Bands were visualised 
and analysed semi-quantitatively as previously discussed. 
3.3.2.3 Experimental plan 
A summary of the plan for the investigation, findings and experiments used is 




Figure 3.1: A coronal section of a mouse brain labelled with haematoxylin (blue) 
and Oil-Red-O (red). Images were taken at the medial and lateral corpus callosum 
as highlighted. Arrows indicate sites of imaging, where (a) is the medial CC and (b) 
is the lateral CC. Scale bar represents 1mm. 
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Figure 3.2: Flow chart demonstrating the plans and summarising the findings 





3.4.1 Optimisation of immunohistochemistry 
Immunohistochemistry for AMIGO3, CC1, LINGO1, MBP, NG2, NgR1 and Olig2 
was performed using antibody dilutions previously used within this laboratory and as 
stated previously. Control tissues used for testing antibodies are listed in table 3.2. 
Where possible, samples for controls were collected using the same strains and 
dissection/preparation procedures as for the main studies. 
Despite some signal being observed for AMIGO3, CC1, LINGO1 and NG2 (fig. 
3.3A-D) the signal was weak and therefore it is likely that variation would be difficult 
to detect in the main developmental study. Signal was not observed in all tests, 
specifically NgR1 showed no signal (fig 3.3E). Furthermore, the minimal CC1 
staining, as well as the LINGO1 staining, did not match previous studies, suggesting 
the staining observed may only be background (fig 3.3B & C). As a result, further 
optimisation was performed to improve the quality of the staining. OLIG2 and MBP 
antibodies however were observed to demonstrate reasonably strong signal (fig 3.3F 
&G) 
3.4.1.1 Initial antibody concentration trials 
Firstly, concentrations of antibodies used were tested to examine whether the lack 
of signal was simply due to a lack of available antibodies. Varying concentrations of 
CC1 antibodies were employed to test this whether the antibody was being used at 




Figure 3.3: Representative positive control staining for (A) AMIGO3 in DRGs, (B) 
CC1 in the lateral CC, (C) LINGO1 in the cerebellum, (D) NG2 in the lateral CC, (E) 
NgR1 in the lateral CC, (F) Olig2 in the lateral CC and (G) MBP in the lateral CC. All 
sections were obtained from adult BALB/C mice. Blue shows DAPI staining and 
red/green shows the stated protein. Strong signal was observed with MBP, however 
all other markers showed limited signal. Scale bars represent 50µm, insets show 





Figure 3.4: Representative staining for CC1 concentration trials. Images were 
taken of sections treated with anti-CC1 (red) antibodies at (A) 200ng/ml, (B) 
500ng/ml and (C) 1µg/ml in the lateral CC. Blue shows DAPI staining. All image 
groups had a similar minimal intensity but maximum intensities were modified 
independently to produce the greatest qualitative signal. Scale bars represent 50µm, 




minor improvement over the lowest concentration. However, overall fewer CC1+ cells 
were observed than expected for the CC which should contain a relatively high 
number of mature OLG. Due to the negligible improvements provided at higher 
concentrations of the antibody further optimisation was attempted. 
3.4.1.2 Permeabilisation trials 
We have previously found that a stronger permeabilisation treatment (2% (v/v)) 
Triton X-100 rather than 0.2%) is able to improve immunofluorescence signals in this 
system (Ahmed et al., personal communication). To assess whether the tissue 
samples were sufficiently permeabilised, samples were tested with a published 
technique previously used to stain thicker (300 µm) acute brain slices which involved 
a longer permeabilisation step (Fulton D et al., 2010). This method involved a single 
4 hour block/permeabilisation step following the first wash. The 
blocking/permeabilisation solution consisted of 0.5% BSA (w/v), 0.1% or 2% (v/v) 
Triton X-100 and 15% normal serum (v/v). All subsequent steps followed the original 
protocol as previously described. 
For this test, Olig2 was used due to the greater signal observed in the previous 
trials. It is apparent that there is a clear increase in the intensity of the Olig2 staining 
when treated with 2% (v/v) Triton X-100 (fig 3.5A-D). Furthermore, the extended 
blocking and permeabilisation treatment also permitted greater signal intensity (fig 
3.5C-D & G-H). Although extended treatment with 0.1% Triton did improve the signal 




Figure 3.5: Representative 1/200 Olig2 staining (green) CC sections treated with 
the varying permeabilisation protocols. (A-D) Treatment with 2% (v/v) Triton following 
(A-B) the original protocol and (C-D) the new protocol. (E-H) Treatment with 0.1% 
(v/v) Triton following (E-F) the original protocol and (G-H) the new protocol. Images 
were either taken in the medial CC (A, C, E, G) or the lateral CC (B, D, F, H). Blue 
shows DAPI staining. For all images, varying minimal/maximal signal intensity 
adjustments were applied to produce the greatest qualitative signal. Increasing 
concentrations of Triton and treatment times appear to increase signal for Olig2 IHC. 




incubation as well. As such it was decided that subsequent staining in this project 
would use a protocol involving permeabilisation in 2% (v/v) Triton X-100 for 4 hours. 
To further optimise the staining, we tested whether further permeabilisation of the 
tissue would improve the signal. NG2 labelled sections were treated with the newly 
developed method of 2% (v/v) Triton X-100 for 4 hours to permeabilise the cells, or 
with 2% (v/v) Triton X-100 also in the ADB replacing Tween-20 as well as the 
permeabilisation step. Greater signal intensity was observed with the modified 
antibody incubation procedure, with Triton X-100 in the ADB (fig 3.6). Subsequent 
stains for all antibodies were therefore performed with 2% (v/v) Triton-X-100 in both 
the blocking/permeabilisation buffer as well as in the ADB. 
3.4.1.3 Further antibody concentration trials 
To further optimise the staining, concentration trials were performed. 
3.4.1.3.1 AMIGO3 
Due to the lack of signal, the anti-AMIGO3 antibody was trialled at a higher 
concentration. The antibody was tested at 1/100 (2µg/ml) and 1/50 (4µg/ml) (fig 3.7). 
In this study AMIGO3 was co-stained against anti-NF200 for reference. Interestingly, 
a degree of signal could be observed in all treatment groups, contradicting previous 










A fairly widespread distribution with high 
levels observed in the DRG of mice (Ahmed 
et al., 2013) and preliminary data from our 
lab 
CC1 Lateral CC 
A monoclonal IgG recognising 
adenomatous polyposis coli protein in the 
cytoplasm of OLG. CC1 binding in the CNS 
are considered to be a specific marker for all 
differentiated OLs. The CC contains 
relatively high staining in mouse brains (Lin 
et al., 2006; Shen et al., 2008) 
LINGO1 Cerebellum 
Purely within the CNS, with high levels 
observed in the cerebellum (Llorens et al., 
2008; Kuo et al., 2013) 
MBP Lateral CC 
MBP is widespread within the brain, 
predominantly in the white matter. The CC 
contains relatively high levels (Mi et al., 
2009; Guglielmetti et al., 2014; McQueen et 
al., 2014) 
NG2 Lateral CC 
NG2 positive cells are observed through 
the developing and adult brain, primarily in 
the CNS. The CC has relatively high levels 
(Clarke et al., 2012; Sullivan et al., 2013) 
NgR1 Lateral CC 
Present on most neurons, with levels 
being identifiable within the CC (Wang et al., 
2006) 
O1 CC 
Presents clear staining within the CC of 
adult mice. O1 is expressed in the later 
stages of OPC differentiation, prior to full 
maturation (Sommer and Schachner, 1981; 
Liu et al., 2011) 
O4 CC 
Presents clear staining within the CC of 
adult mice. O4 appears to be a sign of OLG 
which have begun to differentiate, reaching 
a pro-OL stage (Gard and Pfeiffer, 1989; 
Sow et al., 2006) 
Olig2 Lateral CC 
Transcription factor present in all stages 
of OLG including OPC and differentiated 
OLG. Clear staining is observed in the white 
matter, including the CC of mouse brains 
(Cai et al., 2007; Maglione et al., 2010) 
Table 3.2: Immunohistochemical markers used for examining OLG development 




Figure 3.6: Representative NG2 staining (green) with DAPI (blue) of lateral CC 
sections. The ADB used for incubation of the sections either had the (A) described 
solution or (B) 2% (v/v) Triton X-100 replacing the Tween-20. Scale bars represent 
50µm. For all images, varying minimal/maximal signal intensity adjustments were 
applied to produce the greatest qualitative signal. Insets show negative controls. 2 





Figure 3.7: Representative staining for the AMIGO3 concentration trials. Images 
were taken of sections treated with anti-AMIGO3 antibodies at (A) 4µg/ml, and (B) 
2µg/ml in the lateral CC. Blue shows DAPI and red shows NF200. Scale bars 
represent 50µm. For all images, varying minimal/maximal signal intensity 
adjustments were applied to produce the greatest qualitative signal. Insets show 





To improve the signal to noise ratio of the CC1 immunostaining, multiple 
concentrations of the primary antibody were tested with the new staining protocol. 
Anti-CC1 was tested at the original concentration as previously used in our lab 
(Fannon J et al., 2015), 1/500 (200ng/ml) as a control, as well as 1/200 (500ng/ml 
and 1/100 (1µg/ml) (fig 3.8). Interestingly high signal could be observed in all 
treatment groups. As signal was observed in all treatment groups, 1/200 (500ng/ml) 
anti-CC1 was selected for use in all subsequent experiments to ensure that sufficient 
signal could be observed, even if there is minimal expression. 
3.4.1.3.3 LINGO1 
  The anti-LINGO1 antibody (Santa-Cruz Biotechnology, Wembley, UK) was tested 
at multiple concentrations in an attempt to improve the signal. Concentrations tested 
were 1/100 (2µg/ml), 1/50 (4µg/ml) and 1/25 (8µg/ml) (fig 3.9). Interestingly there was 
a lack of LINGO1 signal even with the highest concentration of the anti-LINGO1 Fc. 
Considering that even the highest concentration of this antibody failed to produce a 
positive signal, it was decided that a new anti-LINGO1 Fc would be tested. The 
alternative chosen was a rabbit anti-LINGO1 Fc (Abcam, Cambridge, UK). A 
subsequent titration was performed for optimisation. The anti-LINGO1 Fc was trialled 
at 1/100 (10µg/ml), 1/200 (5µg/ml), 1/400 (2.5µg/ml) and 1/500 (2µg/ml) (fig.3.10). 
We observed clear staining throughout the study, however the distribution did not 
follow previously observed patterns unless used at 10µg/ml (Llorens et al., 2008; Kuo 




Figure 3.8: Representative staining for the CC1 concentration trials Images were 
taken of sections treated with anti-CC1 antibodies at (A) 1µg/ml, (B) 500ng/ml and 
(C) 200ng/ml in the lateral CC. Scale bars represent 50µm. For all images, varying 
minimal/maximal signal intensity adjustments were applied to produce the greatest 
qualitative signal. Insets show negative controls. 2 sections, with 2 images per 






Figure 3.9: Representative staining for the Santa Cruz LINGO1 concentration 
trials. Images were taken of sections treated with anti-LINGO1 antibodies at its 
highest concentration, (A) 8µg/ml and (B) 4µg/ml in the cerebellum. Blue shows 
DAPI. Scale bars represent 50µm. For all images, varying minimal/maximal signal 
intensity adjustments were applied to produce the greatest qualitative signal. Insets 






Figure 3.10: Representative staining for the Abcam LINGO1 concentration trials. 
Images were taken of sections treated with anti-LINGO1 antibodies at (A) 10µg/ml, 
(B) 5µg/ml, (C) 2.5µg/ml and (D) 1.25µg/ml in the lateral CC. Blue shows DAPI. 
Scale bars represent 50µm. For all images, varying minimal/maximal signal intensity 
adjustments were applied to produce the greatest qualitative signal. Insets show 
negative controls. 2 sections, with 2 images per section used per treatment group.
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2013). It was therefore decided that the anti-LINGO1 Fc would be used at a dilution 
of 1/100 for subsequent studies. 
3.4.1.3.4 MBP 
MBP staining was repeated using the new protocol (2% v/v Triton, 4 hour 
permeabilisation, 2% v/v Triton in ADB). The concentration of antibodies was 
unaltered due to the successful staining using the original procedure. MBP staining 
with the optimised staining procedure showed a clear signal following the expected 
expression patterns in the CC (fig 3.11). Subsequent immunolabelling was therefore 
performed using anti-MBP at 1/200 (100µg/ml). 
3.4.1.3.5 NG2 
Although the conditions for the anti-NG2 antibody examined in section 3.3.1.1.2 
(Fig. 3.6) appeared successful from the previous trials, the rabbit anti-NG2 Abcam 
was no longer useful as it was derived from the same source (rabbit) as the new 
LINGO1 antibody. Further trials were therefore performed with multiple 
concentrations using a mouse derived antibody (Millipore, Nottingham, UK). The 
mouse anti-NG2 was trialled at 1/800 (1.375µg/ml), 1/400 (2.75µg/ml) and 1/200 
(5.5µg/ml) (fig 3.12). None of the samples showed any staining over background. It 
should be noted that there was excessive background staining in most cases when 
mouse antibodies were used, although this was acceptable when exceptionally 





Figure 3.11: Representative staining for the anti-MBP trial. Blue shows DAPI. 
Scale bars represent 50µm. The image was adjusted through minimal/maximal signal 
intensity adjustments to produce the greatest qualitative signal. Insert shows a 






Figure 3.12: Representative staining for the mouse anti-NG2 Fc concentration 
trials. (A-B) Only the highest concentration is shown, 1/200 (5.5µg/ml) from two 
different samples within the study. Blue shows DAPI. Scale bars represent 50µm. 
Images were adjusted through minimal/maximal signal intensity adjustments to 
produce the greatest qualitative signal. 2 sections, with 2 images per section used 
per treatment group. Note the signal observed with anti-NG2 is equivalent with that in 
the negative controls (insets).
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As no positive signal above the background staining was observed with the mouse 
anti-NG2, even at the highest used concentration, it was decided that a new antibody 
should be used. The replacement antibody was a rat anti-NG2 Fc (R&D, Abingdon, 
UK). Ultimately time constraints prevented the use of this antibody. However, if time 
had permitted, concentration titrations would have been performed using dilutions of 
1/20, 1/50, 100, 1/200 and 1/500 based on the supplier’s specifications.  
3.4.1.3.6 NgR1 
NgR1 antibodies were tested in the CC as previously discussed. The anti-NgR1 Fc 
was trialled at 1/200 (5µg/ml), 1/100 (10µg/ml) and 1/50 (20µg/ml) (fig 3.13). No 
signal was observed with 5µg/ml of anti-NgR1 Fc. Signal however became apparent 
when using a concentration of antibody of at least 10µg/ml, with increasing signal 
observed at the highest concentration tested. Subsequent studies would use 20µg/ml 
of NgR1 Fc. 
3.4.1.3.7 O1 
The mouse monoclonal O1 antibody, which recognises OLG specific glycolipid 
GalC is used as a marker of post-mitotic OL lineage cells (Gard & Pffeifer 1989) so 
was considered as a potential marker for colocalisation with anti-AMIGO and anti-
LINGO1 IgG. O1 antibodies were trialled for its potential use in this investigation. The 
O1 antibody was obtained from the laboratory of Anthony Campagnoni (University of 
California, Los Angeles, USA). The concentration of anti-O1 Fc within our sample is 




Figure 3.13: Representative staining for the mouse anti-NgR1 Fc concentration 
trials. Images were taken of sections treated with anti-NgR1 Fc at (A) 20µg/ml, (B) 
10µg/ml, (C) 5µg/ml. Blue shows DAPI. Scale bars represent 50µm. Images were 
adjusted through minimal/maximal signal intensity adjustments to produce the 
greatest qualitative signal. Insets show negative controls 2 sections, with 2 images 
per section used per treatment group.
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1/50, and 1/100 (fig 3.14). A clear signal could be observed with all treatment groups, 
although it appears excessive in the, ‘neat’, antibody treatment group, possibly 
indicating background staining due to a high concentration. Despite the abundant 
staining, the expression appears vesicular, in small patches, rather than labelling the 
whole cell. This is similar to previously observed, low powered images (Liu et al., 
2011), therefore it was decided that O1 would be an inappropriate marker for this 
investigation. 
3.4.1.3.8 O4 
The glycoprotein O4, a surface antigen, is considered to be a marker of late OPCs 
(Back et al., 2001), so could potentially be a useful marker for undifferentiated 
oligodendroglia. A concentration trial was tested using 1/100 (5µg/ml), 1/200 
(2.5µg/ml), 1/400 (1.25µg/ml) and 1/500 (1µg/ml) (fig 3.15). A reasonable signal was 
observed with all treatment concentrations, however the intensity was low even at 
5µg/ml. Additionally, and similar to O1, a vesicular expression pattern was observed, 
with signal being localised to small patches, rather than across the entire cell. Based 
on the limited signal with this antibody it was decided that O4 would not be used in 
this investigation. 
3.4.1.3.9 Olig2 
Despite the satisfactory staining that we previously observed for the Olig2 (fig. 
3.5), a concentration trial was conducted to try to optimise its staining. The antibody 




Figure 3.14: Representative staining for the O1 concentration trials. Images were 
taken of sections treated with anti-O4 antibodies at (A) undiluted, (B) 1/25, (C) 1/50 
and (D) 1/100 in the lateral CC. Blue shows DAPI. Scale bars represent 50µm. For all 
images, varying minimal/maximal signal intensity adjustments were applied to 
produce the greatest qualitative signal. Insets show negative controls. 2 sections, 




Figure 3.15: Representative staining for the O4 concentration trials. Images were 
taken of sections treated with anti-O4 antibodies at (A) 5µg/ml, (B) 2.5µg/ml, (C) 
1.25µg/ml and (D) 1µg/ml in the lateral CC. Blue shows DAPI. Scale bars represent 
50µm. For all images, varying minimal/maximal signal intensity adjustments were 
applied to produce the greatest qualitative signal. Insets show negative controls. 2 




Figure 3.16: Representative staining for the Olig2 concentration trials. Images 
were taken of sections treated with anti-Olig2 antibodies at dilutions of (A) 1/200 and 
(B) 1/500. Blue shows DAPI. Scale bars represent 50µm. For all images, varying 
minimal/maximal signal intensity adjustments were applied to produce the greatest 
qualitative signal. Insets show negative controls. 2 sections, with 2 images per 
section used per treatment group.
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was clear that greater levels were observed in the higher antibody (1/200) trial. The 
anti-Olig2 Fc was therefore used at a 1/200 dilution for subsequent studies.     
3.4.1.3.10 Mature OL staining 
CC1 is cytoplasmic so does not provide a signal which covers the entire OL. It was 
decided that a triple stain with CC1, MBP and the test marker (e.g. AMIGO3) would 
be useful for a comprehensive OL localisation study. To achieve effective spectral 
separation of the secondary antibody fluorophores in this triple stain, CC1 antibodies 
were tested with an AF 350 (blue) secondary antibody that could be used with the 
AF488 and AF593 labels (fig 3.17A-B). The spinning disc confocal system used for 
imaging in this study lacks a filter set compatible with the AF350 dye, thus it was not 
possible to perform confocal imaging on triple labelled sections. However, the 
staining was successful as shown by imaging of the AF350 signal on a wide-field 
fluorescent microscope (Axioplan-2, Carl Zeiss Ltd, Herefordshire, UK) (fig 3.17C-D). 
Since the available confocal system could not detect the AF350 signal, and because 
confocal imaging was desirable, it was decided that a double stain involving CC1 or 
MBP would be used for future localisation studies on mature OL.  
3.4.1.4 Conclusions of optimisation studies 
The preceding stages of this chapter focussed on optimising the IHC protocol so 
that a reliable analysis of the degree of myelination and AMIGO3/LINGO1 expression 
can be obtained during the early stages of development. We first observed that for 




Figure 3.17: Representative staining for the mature OL test. (A) A triple stain for 
AMIGO3 (green), MBP (red) and CC1 (blue). (B) A single stain for CC1 alone (blue). 
No modifications were made to the CC1 signal. (C-D) Wide-field imaging of singe 
stained CC1 staining with AF350 secondary antibodies. Images were modified, with 
minimal/maximal signal intensity adjustments to produce the greatest qualitative 
signal. The same adjustments were applied to image pairs (A-B) for MBP and 
AMIGO3 and (C-D) for CC1. Scale bars represent 50µm. Insets show negative 
controls. 2 sections, with 2 images per section used per treatment group.
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the tissue. Following a more extensive permeabilisation treatment protocol with 
higher concentrations of Triton X-100, as well as extended incubation with the 
detergent, and its inclusion in the ABD we observed improved staining. A limitation 
with this method is that Triton X-100 is a non-selective detergent, with overuse 
potentially resulting in removal of proteins (Goldenthal K et al., 1985; Jamur M and 
Oliver C, 2010). Our data, when using high concentrations of Triton X-100, showed 
improved signal, although it is possible that some protein has been lost during the 
preparation. 
The subsequent aims of the immunohistochemistry experiments were to examine 
the expression of AMIGO3, LINGO1 and NGR1 proteins in oligodendroglia at various 
developmental stages. As AMIGO3, LINGO1 and NgR1 are all membrane bound 
proteins, it was decided that membrane proteins for the varying stages of OLG 
differentiation would provide the best target for colocalisation with the proteins of 
interest. A number of markers were considered for use in the identification of 
oligodendroglia at distinct points in their development. NG2 is a marker of 
undifferentiated OPC (Clarke et al., 2012). Other markers of OPC include platelet 
PDGFαR and anti-O4 (Fancy et al., 2004), although anti-O4 binding is retained in 
OLs thus this marker requires the use of a second OLG marker, such as anti-MBP to 
distinguish OPC from differentiating OLG.  
Both PDGFαR and NG2 have been widely used as a reliable marker of OPCs. 
Previous success with anti-NG2 labelling of OPC in our lab influenced our decision to 
use NG2 as a marker of OPC in the present work (Fannon J et al., 2015). Anti-O4 Fc 
has similarly been observed to label both OPC processes and soma (Baccarini M et 
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al., 2008; Buzby J et al., 2010). Conversely, after our trials, we observed O4 staining 
in small nodules, possibly following a vesicular expression profile. Previous studies 
have used O4 antibodies in immunocytochemistry, rather than IHC (Baccarini M et 
al., 2008; Buzby J et al., 2010). It is possible that in our investigation the signal from 
the anti-O4 Fc was not clear enough over the background signal observed in vivo, 
despite being used at a high concentration. Additionally, O4 is not expressed during 
the early stages of OPC development, but rather expression begins when the cells 
begin to differentiate (Baumann N and Pham-Dinh D, 2001; Neman J and de Vellis J, 
2008). Based on these observations and our data, O4 would not be appropriate for 
our investigation. Furthermore, NG2 staining provided positive results, displaying an 
expression pattern which appears to mark the entire OPC. 
To examine the mature development stages, we examined the expression 
patterns of mature OL markers using IHC, including CC1 and O1. O1 staining has 
previously been observed in a nodular arrangement within the CC of wild-type mice, 
however these conclusions were obtained from low power images and thus may not 
be representative of the true staining pattern (Liu et al., 2011). We observed a similar 
staining pattern, indicating that the O1 is unlikely to be a useful marker for these 
studies, as there will likely be a significant portion of the cell which is not labelled. 
CC1 can be seen to be a reliable marker of mature OLs from our data, however 
the antigen is cytoplasmic and so only the soma of the cell is labelled. To overcome 
this, we considered that co-staining with MBP to capture staining across the soma 
and processes. MBP is expressed on the processes of mature OLs, and within the 
myelin sheath where it plays an important structural role (Kotter M et al., 2005; 
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Quarles R et al., 2006). This method however required the use of a third fluorescent 
label (AF350) with adequate spectral separation from AF488 and AF594. Our data 
showed signal from this combination when imaged on a wide-field system, but due to 
technical limitations described above (section 3.3.1.3.10) it was not possible to 
acquire confocal images from sections with this triple label. Since confocal imaging 
was preferable for detecting colocalisation it was decided that a double stain 
involving CC1 or MBP would be used for the studies on mature OLs.  
Based on the data obtained, we have determined the antibodies and their 
concentrations that will be used in subsequent studies (table 3.3). The subsequent 
studies will also look at combinations of the test markers (AMIGO3 and LINGO1) with 
the developmental markers. We intend to analyse whether there is a correlation 
between the intensity of test marker staining with the various development markers 
as well as to examine if this correlates with the extent of myelination, as determined 
from MBP staining, and differentiation, as indicated by the ratio of CC1+ mature OLs 
within the total Olig2+ oligodendroglia population (including OPCs and OLs) (Fannon 
J et al., 2015). 
3.4.2 IHC analysis of AMIGO3 and myelination during development 
Our first studies examined the frequency of AMIGO3 staining in relation to the 
CC1/Olig2+ ratios, with a high ratio representing a high proportion of total 
oligodendroglia (Olig2+) having matured to OL (CC1+), and MBP pixel proportion, 
representing the degree of myelination. Qualitatively, both MBP and CC1 are not 
present, or are expressed at very low levels at P0 (fig 3.18F & K). It does not appear 


































































Table 3.3: List of the antibodies to be used in subsequent experiments for the IHC 




decrease in total OLG. A much greater CC1+ staining can be seen as early as P7 
(fig3.18K-O). MBP also appears to increase with strong signal being observed 
throughout the CC as of P21 (fig 3.18F-J). Qualitative analysis of the AMIGO3 IHC is 
more difficult to interpret, there are only low levels observed throughout the 
observation period within the medial CC. Although there is some evidence to a 
change in the levels at P14 with IHC appearing more frequent, the observation was 
not consistent between all samples. Generally, AMIGO3 appears in a globular 
formation without any clear distribution within the CC. 
Following qualitative analysis, pixel counts above the normalised threshold was 
used to semi-quantify the extent of myelination and AMIGO3 and MBP expression. 
Ratios of CC1+/OLIG2+ cells were also calculated (fig 3.18P). Again, it is clear that 
both the mature OLG percentage and the extent of MBP expression start at 
negligible levels at P0 (1.7%±0.5% and 1.4x10-3±1.2x10-3 respectively) and rise 
during the observed periods of postnatal development. 
MBP expression appears to reach a peak at P14 of 96.3±1.4, and plateau for the 
rest of the examined period. As all samples were normally distributed, an ANOVA 
was used to determine if the level of anti-MBP signal increased significantly over the 
time-points.  One-way ANOVA detected a significant source of variation between the 
5 ages that were examined (ANOVA, F(4,10)= 533.458, P<0.05). Post-hoc 
comparisons revealed significant differences between MBP signals (P<0.05) between 
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Figure 3.18: Representative staining for the development study for AMIGO3 (A-E, 
MBP (F-J) and Olig2//CC1 (K-O). AMIGO3 and MBP were counterstained with DAPI 
in blue. Olig2 is shown in green and CC1 in red. Scale bars represent 50μm. Insets 
show negative controls. Quantitation shown graphically (P), with AMIGO3 percentage 
positive pixels (green), MBP percentage positive (red) and the percentage of Olig2+ 




found between P14, P21 and P27.  CC1+/OLIG2+ ratios also increased from 
negligible levels at P0 however the rise is steadier and does not surpass ~60% even 
at P28 which reaches 56.4%±2.5%. As all samples were found to be normally 
distributed, ANOVAs were used to test the significance in the changing levels, with 
significance found within the groups (ANOVA, F(4,10)=37.259, P<0.05). P0 levels 
were found to be significantly different from all other samples following post-hoc tests 
(P<0.05). All subsequent groups did not show significance from their immediate 
neighbour (specifically P7 to P14, P21 to P14 and P28), however significance was 
found between every other group. This demonstrates that there was a significant 
increase over time in the CC1+/Olig2+ ratios, demonstrating a rise in the proportion of 
mature OLG. 
AMIGO3 data was difficult to interpret. Despite starting at negligible levels 
(1.1±0.4) there appeared to be a small increase in the AMIGO3 positive pixel 
percentage. A peak was observed at P14 (29.2±15.6) before dropping but still being 
raised compared to original levels (8.5±3.4) at P21 and 15.2±13.3 at P28). Despite 
these observations, there was a high variability beyond P7 therefore it is unlikely that 
any definitive observations can be made from this analysis. Kruskal-Wallis analysis of 
the data failed to find significance between the groups (P>0.05). 
3.4.3 Western Blot analysis of AMIGO3 expression in developing 
mouse neocortices 
Following on from IHC analysis, Western blots were performed to test the 
expression of AMIGO3/LINGO1 and OLG proteins in whole neonatal pup 
neocortices. Due to the variability observed with the AMIGO3 IHC, we checked a 
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number of different AMIGO3 antibodies for western blot analysis. The Santa-Cruz, 
anti-AMIGO3 Ab was checked with Oli-neu cells, as well as cerebellum samples from 
BALB/c mice (fig 3.19). Clear bands were observed at 55kDa, indicating that 
AMIGO3 is present in CNS samples as expected, as well as within OPC derived cell 
lines. 
Following optimisation, AMIGO3, LINGO1 and MBP were examined by western 
blot in the developing mouse neocortex. Two bands were observed for AMIGO3, one 
at 55kDa and one at 45kDa (fig 3.20). The integrated density level for the 55kDa 
band, the expected species for AMIGO3, started relatively low at P0 (0.26±0.02) 
before rising to its peak at P7 (1.91±0.13). An immediate drop is observed 
(0.46±0.11) by P14 which remains level at P21 (0.80±0.11) before dropping to 
negligible levels by P28 (0.06±0.01). The 45kDa band stays relatively constant 
throughout the development period (0.19±0.03, 0.45±0.06, 0.28±0.07 and 0.36±0.04 
for P0, P7, P14 and P28 respectively), however there is a sharp rise at P21 
(1.12±0.04) which immediately drops by P28. Only the 55kDa band was analysed 
statistically as this is the expected sized band for the functional protein (Ahmed et al., 
2013). Not all of the samples were normally distributed so a Kruskal-Wallis test was 
used to test for statistically significant sources of variation, with significance found 
within the data (P<0.05). Following post-hoc tests, a significant difference (P<0.01) 
was found between P7 and P28, although there was a trend towards significance 





Figure 3.19: Representative Western blot bands observed with the Santa-Cruz 
anti-AMIGO3 Ab. Both Oli-neu samples as well as whole cerebellum samples 
demonstrated positive staining for AMIGO3 at 55kDa.
 
Figure 3.20: Quantification of AMIGO3 bands, normalised against α-tubulin, from 
whole neocortices of BALB/c mice during postnatal stages. Two bands were 
observed, one at 45kDa (white) and one at 55kDa (as expected, black). The largest 
and expected band showed an initial increase before dropping down to negligible 
levels by P28. Error bars represent one SEM, n=4. 
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A number of bands were observed for LINGO1 expression within the neocortex. 
Bands were observed at 87kDa (expected), 45kDa, 28kDa, 23kDa and 17kDa (fig 
3.21). All of the bands start at relatively low integrated density levels at P0, 
0.43±0.06, 0.32±0.07, 0.27±0.07, 0.25±0.07 and 0.37±0.05 respectively. For both the 
18kDa and the expected 87kDa bands showed an immediate increase in integrated 
density to 2.89±0.06 and 2.28±0.05 respectively. Both samples showed a brief 
decline in expression at P14, 1.26±0.10 and 1.24±0.10 respectively, before 
increasing at P21, 3.13±0.39 and 2.62±0.17 respectively. A final decline was 
observed at P28 for both bands as well, although integrated density levels were 
maintained at greater levels than at P0, at 1.57±0.10 and 0.97±0.07 respectively. A 
similar pattern was observed for the 45kDa band, as it increased at P7 to 1.80±0.05 
before decreasing at P14 to 0.57±0.06. Following this stage though, a steady 
increase in integrated density levels was observed for the remaining treatment 
period, 0.80±0.05 at P21 and 0.95±0.08 at P28. The 28kDa band showed an 
increase from P0, peaking at P14 0.94±0.07 before a steady decrease to P28 
0.20±0.03. Finally, the 23kDa band showed an initial increase at P7, reaching 
1.55±0.16. Subsequent levels were undetectable at P14 and P21 but a final modest 
increase was observed at P28, 0.79±0.07. 
Only the 87kDa band was analysed statistically as this is the expected sized band 
for the functional protein (Jepson et al., 2012). As not all of the samples were 
normally distributed, a Kruskal-Wallis test was used to detect any variation. Following 
post-hoc tests, a significant difference was only found between P0 and P21 (P<0.01). 




Figure 3.21: Quantification of LINGO1 bands observed from whole neocortices of 
BALB/c mice during postnatal stages. Five bands were observed, 87kDa (red), 
45kDa (green), 28kDa (blue), 23kDa (orange) and 17kDa (black). The largest and 
expected band (red) demonstrated two peaks at P7and P21 before dropping but 
maintaining relatively high levels at P28. Error bars represent one SEM, n=4.
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significance was observed between P0 & P7 (P=0.075) and PP21 & P28 (P=0.083) 
when looking at the adjusted significance values. 
One band was observed for MBP at 18kDa. No signal was observed from P0-P14, 
0.02±0.002 at P0, 0.03±0.003 at P7 and 0.02±0.002. A minor rise was observed at 
P21, 0.12±0.03 before a subsequent rise at the end of the observed period, reaching 
1.21±0.10 (fig 3.22). 
Figure 3.23 demonstrates the proportion of maximum integrated density signal for 
AMIGO3, LINGO1 and MBP, during the observed developmental stages so that 
comparison can be made between expression profiles. When compared against the 
signal for MBP in the neocortex, total levels of AMIGO3 appear to drop prior to the 
appearance of significant MBP expression. MBP expression rose to significant levels 
at P28 when AMIGO3 levels dropped to negligible levels. Similarly, LINGO1 levels 
were generally high when MBP levels were negligible, although the rise of MBP 





Figure 3.22: Quantification of the MBP band observed from whole neocortices of 
BALB/c mice during postnatal stages. One band was observed at 18kDa. Low levels 
of MBP were observed throughout the development stages until a sharp rise at P28. 




Figure 3.23: (A) representative western blots for AMIGO3 (green, LINGO1 (black) 
and MBP (red). (B) Proportion of the maximum normalised integrated density 
recorded for the various markers to highlight proportional changes and relationships. 
Both AMIGO3 (green) and LINGO1 (black) increase substantially at P7. Both 
demonstrate a rapid drop at P14, with LINGO1 increasing again at P21. A rise is also 
observed with AMIGO3 although levels stay relatively similar before both proteins 
demonstrate a final drop at P28, although LINGO1 levels remain raised. MBP (red) 
stays reduced until the end of the development period, coinciding with the final drops 




3.5.1 Analysis of myelination during postnatal development 
From our data it is clear that substantial myelination occurs in the CNS during P0-
P28. This conclusion is supported by observations from both IHC of the CC and from 
western blot of whole mouse neocortices. Our IHC data matches with previous data 
from mouse models where the majority of myelination within the CC occurs between 
P8-P30 (Lodygensky et al., 2012; Chan et al., 2013; Dai et al., 2015). Interestingly 
there appears to be a variation between IHC and western blot data. As our dissection 
procedure included all structures above the lateral ventricles, the corpus callosum 
should have been included within the neocortex. As such, it would be expected that 
MBP should rise in the neocortex as detected by western blot at the same time as it 
does within the CC as detected by IHC. It should be highlighted that this variation 
may simply be a result of the variation in the techniques used. It is possible that the 
dissection and lysis procedure used in the western blot preparation resulted in 
damage or loss of the corpus callosum or myelin proteins therefore removing some of 
the signal. It is more likely however that the western blot protocol is simply less 
sensitive than IHC. Considering that IHC will be able to detect signal in individual 
cells rather than in whole tissue samples, it would be expected to have a higher 
sensitivity and therefore be able to detect smaller changes than western blot is able 
to. It has been reported previously that MBP levels in the telencephalon/forebrain of 
embryonic and postnatal OF1 mice become significant by P15, with some detectable 
levels by P10 (Gil et al., 2010). Our data show a later expression of MBP, whereas 
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the data from Gil et al 2010 more closely matches our IHC data, albeit, with a 
potential lag behind the CC. These data show that myelination in the CC precedes 
the rest of the neocortex although it is not clear why this would be the case. There 
may be variation between our western blot data and that of Gil et al 2010 simply due 
to sensitivity of the antibodies or due to variations in MBP expression between the 
strains of mice. As the murine neocortex is predominantly grey matter (Zhang and 
Sejnowski, 2000), it is likely that myelin will not be as prevalent proportionally when 
compared to the CC alone. Although myelination levels out from P21 in mouse 
forebrains (Gil et al., 2010), it would have been interesting to examine whether there 
would have been any further changes beyond P28 for the BALB/c mice. 
Interestingly, when looking at OLG maturation in the CC, there appears to be a 
steadier rate of increase than the rate of myelination. The percentage of mature OL 
to total OLG (CC1+ and Olig2+ against all Olig2+ cells) increased from negligible 
levels at P0 to almost 40% by P7 however this increase slows to almost 60% by P28 
although our data do not show a levelling off suggesting that OPC maturation 
continues beyond this stage. Previous studies have also shown an increase in total 
CC1+ cells as well as a greater proportion of Olig2+ cells that are also CC1+ in other 
murine CNS/white matter samples, albeit only at the early stages P7-P12 . 
Expectedly, this shows that maturation of OPC precedes the onset of myelination. 
3.5.2 AMIGO3 in the murine CC during postnatal development 
The levels of AMIGO3 during development are more difficult to interpret from our 
IHC data. Firstly, AMIGO3 in the CC appears to be largely variable when semi-
quantified through IHC. A non-significant increase in AMIGO3 signal was observed at 
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P14 despite a considerable degree of variability in this data and a relatively low 
sample size (n=4). It is likely that due to our low sample size, anomalous data has led 
to unrepresentative increases. Additional replicates would be desirable to provide 
further confidence in this finding. Similarly, AMIGO3 co-localisation with CC1 (data 
not shown) did not produce any meaningful and reproducible data due to the 
variability in the AMIGO3 signal. If the results are correct however, the IHC data 
suggests that AMIGO3 levels rise when myelination reaches its peak and just after 
the main onset of OPC maturation, coinciding with a slowing of the rate of 
maturation. This could suggest that AMIGO3 plays a role in the postnatal inhibition of 
OPC maturation and myelination, helping to slow the rate of OPC maturation and 
myelination when sufficient levels have been reached, potentially to prevent an 
excess of myelin being produced, and also to maintain an OPC population in the 
CNS. It should be highlighted that these data do not show AMIGO3 expression 
exclusively in OLG. 
 The distribution of AMIGO3, as viewed qualitatively, shows a light distribution 
across the CC with small clusters. Although there is very limited previous examples 
of AMIGO3 IHC in OLG, AMIGO3 has been found localised to the somas of retinal 
ganglion cells (RGCs) as well as the somas of Oli-neu cells (Ahmed et al., 2013; 
Foale et al., 2014). AMIGO3, being a homodimer, could make small clusters on the 
membranes of cells within the CC (Kuja-Panula et al., 2003). However, it is very 
possible that the extended blocking and permeabilisation steps that were required to 
get sufficient staining in the positive controls, may have removed too much of the 
membrane and therefore removed a lot of the protein as well.  It would have been 
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interesting to compare the expression of AMIGO3 in both OPCs and OLs in 
developing brains. Our original plan was to use IHC double staining with AMIGO3 
and CC1 or NG2 similarly to the CC1/Olig2 study. Due to the variability observed with 
AMIGO3 IHC it was deemed that this would not valuable. One method that could 
have been used would have been to isolate and separate OLG from developing mice 
using fluorescence-activated cell sorting (FACS) based on makers of differentiation 
and maturation and make an analysis of the AMIGO3 levels in the separated 
populations (Robinson et al., 2014a). This would allow detailed analysis of the 
expression of AMIGO3 in the OLG subpopulations at various stages of development, 
although large numbers of samples would be required for this study. Unfortunately, 
resource and time constraints meant that this was not possible. 
3.5.3 AMIGO3 and LINGO1 in the murine neocortex during postnatal 
development 
As previously discussed, to overcome the limitations with the AMIGO3 IHC, 
western blots were performed. Following our preliminary studies, it was clear that our 
antibodies were sufficient at detecting AMIGO3 in CNS samples. Similar results have 
already been shown in our group with the Abcam LINGO1 antibody (Ahmed et al., 
2013). 
From our data both AMIGO3 and LINGO1 protein expression in the mouse 
neocortex is high prior to the onset of myelination but decreases as myelination 
progresses. Interestingly the onset of myelination appears immediately following the 
reduction in AMIGO3 with the highest levels of myelin observed when AMIGO3 has 
reached negligible levels. Interestingly LINGO1 protein levels appear to drop and rise 
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again as myelination begins. If LINGO1 is the predominant inhibitor of developmental 
myelination, then its raised expression at P21 poses a dilemma. It is possible that 
AMIGO3 has a more crucial role during the developmental stages and that its 
expression is reduced earlier to ensure that AMIGO3 does not provide its inhibition to 
OPC development and myelination. 
Considering that AMIGO3 has shown to be able to interact with the same 
receptors as LINGO1 (Ahmed et al., 2013), it is possible that the drop in expression 
of both AMIGO3 and LINGO1 is not sufficient as both proteins are still expressed at 
relatively high levels. I conclude that both proteins may be able to inhibit myelination 
through the same pathway. It is not until both LINGO1 levels have dropped and 
AMIGO3 has become absent that myelin increases by any significant amount, 
indicating that until low levels of both AMIGO3 and LINGO1 are present, myelination 
is still inhibited. As such it would be interesting to observe whether levels of 
LINGO1/AMIGO3 rise again as the rate of myelination decreases. Furthermore it 
should be noted that a number of other pathways have been indicated in the 
regulation of myelination such as the mTOR pathway, Wnt pathway and ERK 
pathway (Gaesser and Fyffe-Maricich, 2016), therefore it is likely that even though 
both LINGO1 and AMIGO3 levels are being altered, further changes from other 
pathways are required to properly regulate the state of myelination and OPC 
development. 
One interesting point is that both AMIGO3 and LINGO1 are not expressed at high 
levels a P0. This shows that neither of the proteins are involved with any inhibition 
prior to birth in murine models. There are a number of pathways that are involved 
132 
 
with regulating the maturation of OPCs, therefore it is likely that other pathways are 
involved in the early stages of development. Recent data shows LINGO1 mRNA is 
expressed in embryonic day dpf13-17 mouse brains, specifically in the hippocampus 
and cortical plate and thalamus when labelled with digoxigenin-labelled antisense 
probes. AMIGO3 however only showed very faint levels in the ventricular zone and 
subventricular zone (Chauhan and Egea, 2014). Considering that our data shows low 
LINGO1 protein expression at P0, this suggests that, or the gene is expressed but 
there is a blockade on translation until early postnatal days. This could be examined 
by assaying total mRNA levels by PCR for LINGO1 during this period. Such an 
approach would help to determine if the levels of LINGO1 mRNA drop at P0 before a 
rise for P7, or whether there is a further blockade of translation. 
 The data from Chauhan and Egea (2014) and our study show that AMIGO3 is not 
being produced at the protein or mRNA level until P7. This could suggest that 
AMIGO3 is not involved with regulating OPC maturation process. If AMIGO3 is 
involved with limiting the maturation of OPCs, then there must be an alternative 
method being used in the prenatal stages of development. Alternatively, these data 
indicate that AMIGO3 may be more relevant in the myelination blockade, therefore 
AMIGO3 is not translated until mature OLs are present. 
3.5.4 Limitations 
There are a number of limitations associated with this study that need to be taken 
in to account for the analysis. As previously discussed, in both the IHC and western 
blot studies, it was not possible to analyse the expression of AMIGO3 or LINGO1 in 
exclusively OLG. Both AMIGO3 and LINGO1 have been indicated in the inhibition of 
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axonal growth, as well as being expressed in astrocytes and in the case of LINGO1 
immune cells (Mi et al., 2004; Satoh et al., 2007; Ahmed et al., 2013). Therefore, it is 
possible that changes in expression could be related to the role of these proteins in 
the various cell types. This could be an area of further interest regarding OLG 
behaviour. AMIGO3 is both a heterodimer and homodimer and expressed on the 
external membrane, therefore it is possible that AMIGO3 signals between neurons, 
astrocyte and OLG as also proposed for LINGO1 (Kuja-Panula et al., 2003; Kajander 
et al., 2011; Jepson et al., 2012; Ahmed et al., 2013). This idea is also supported by 
the observations that neuronal signalling is essential for proper myelination, therefore 
there must be a method for neurons to interact with local OPCs to stimulate or inhibit 
their maturation and ensheathment (Bradl and Lassmann, 2010). This is not 
surprising as regulation of myelination is important to ensure proper timing of the 
onset of ensheathment, as well as to determine sheath length so that the neuronal 
circuits can function appropriately (Klingseisen and Lyons, 2018). This would mean 
that AMIGO3 expression on neuronal and astrocytic external membranes during 
development could signal to neighbouring OLG. If our hypothesis for the role of 
AMIGO3 is correct, this intercellular signalling could in turn have an impact on OLG 
maturation and myelination. Notably though, it is possible that these major changes 
in expression at P14 may represent changes in expression of the proteins in cells 
other than OLG or in specific grey matter regions where OLG are limited or absent.   
It should also be pointed out that due to the time and financial constraints 
associated with this project, a limited sample size had to be used. With a larger 
sample size, it is likely that a normal distribution would have bene identified for the 
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studies and ANOVAs would have been appropriate to examine and significant 
differences in the data.  Additionally, a number of the groups showed trends towards 
significance when analysed with the Kruskal-Wallis test. It is likely that a larger 
sample size would have reduced the SEM, helping to further identify minor variations, 
and allowing greater confidence in the results. Performing a power calculation would 
be beneficial to determine the number of animals that would be required. A similar 
study with LINGO1 was performed and could have been used as a basis for power 
calculations. However this study is not a direct preliminary study and therefore could 
have only been a guide rather than direct indication of the numbers required (Mi et 
al., 2004). 
Another potential limitation with our work is the antibodies that were used. Multiple 
bands were observed for both AMIGO3 and LINGO1. For AMIGO3, bands were 
observed at 55kDa and 45kDa. The 45kDa likely represents a breakdown product of 
the original protein. Multiple bands were observed from the LINGO1 western blot. 
Again, all of the extra bands were at a reduced band size compared to the expected 
band therefore are likely breakdown products but again this does raise a limitation in 
that there is a small chance of non-specific binding. It also raises the possibility that 
there has been some degradation of the samples which may lead to unrepresentative 
results. Non-specific binding with antibodies could also lead to incorrect expression in 
our IHC providing false positives, however our controls should minimise this risk. 
3.5.5 Future studies 
A number of further questions have been posed by these data. Firstly, as 
previously discussed, it would be interesting to analyse the expression profile of 
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these proteins at both the protein and mRNA level in individual cell types. This would 
provide a better analysis of the role that AMIGO3 and LINGO1 have specifically in 
OLG. Although this would be difficult for mRNA analysis due to degradation during 
the fixation process, microarray following FACS has been performed and could 
provide an interesting further analysis (Iglesias-Ussel et al., 2013). Alternatively, a co-
staining process could be developed for mRNA as well as OLG proteins markers to 
provide qualitative analysis. 
It would also be very interesting to examine whether AMIGO3 is in fact able to 
interact between cells or even in solution. Although unlikely, it would be interesting to 
examine whether AMIGO3 is expressed in solution and in sufficient levels in the 
interstitial fluid, and whether altering levels would affect cultured OLG populations in 
vitro or even in vivo. Cellular interactions could also be investigated through co-
cultures of neuronal/astrocytic populations with OLG. Increasing or decreasing 
expression of AMIGO3 through transfections in the neurons/astrocytes would then 
allow any changes in OLG behaviour to be attributed to intercellular interactions from 
neighbouring neurons/astrocytes. 
Another avenue of investigation would be to investigate whether OLG exhibit an 
underlying expression of AMIGO3 both when reaching maturity and during their 
lifespan. It is known that both local OL and media from cultured OL inhibit the 
maturation of OPC therefore it would be interesting to observe whether AMIGO3 is 
potentially involved in this process (Miller, 2002). Finally, it still remains to be 
answered whether AMIGO3 is able to interact in OLG. Although we have data 
showing trends of AMIGO3 expression inversely correlating with myelination, as well 
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as data showing AMIGO3 expression in OLG (unpublished), there is yet to be any 
evidence examining molecular interactions or changes in cell behaviour after altering 
















4.1.1 MS and OLG trauma 
For the context of this study, I hereby shall be using the term ‘trauma’ in reference 
to all forms of injury including, but not limited to; inflammatory insults, excitotoxicity 
and hypoxia, rather than only physical injury. 
MS shares a number of characteristics with simple CNS trauma, in that OLG are 
lost, albeit due to differing mechanisms, with an autoimmune response being the 
most likely cause in MS compared to mechanical injury in CNS trauma. Furthermore, 
CNS axons following both chronic and traumatic injury and MS demonstrate the 
ability for remyelination, however this becomes impaired due to environmental factors 
(Patani et al., 2007; Alizadeh et al., 2015). As such, the molecular mechanisms 
involved in OLG trauma are of value to remyelination therapies and should be 
relatable to MS. 
As previously discussed, a number of OPCs survive even in developed MS 
plaques, and it is thought that these cells lose their innate ability to differentiate or 
their differentiation is inhibited, which results in the inefficient remyelination following 
demyelination (Patani et al., 2007). With this in mind, it would be valuable to develop 
an in vitro model to replicate the trauma that OPC receive during a bout of 
demyelination. Both LINGO1 and AMIGO3 are upregulated following CNS trauma 
and both molecules have been shown to some degree to be present in OLG. Based 
on this we wanted to investigate how conditions in the diseased CNS, such as in MS, 
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may affect the expression of AMIGO3 in OPC (Mi et al., 2004; Mi et al., 2005; Mi et 
al., 2007; Ahmed et al., 2013). 
There are a number of potential processes that could be involved in the blockade 
of remyelination in MS. The simplest hypothesis is that due to repeated bouts of OL 
trauma, the amount of myelination-inhibiting, myelin-derived products increases, 
thereby inhibiting the maturation and myelin production capability of OPCs (Kotter et 
al., 2006; Zhao et al., 2006). A number of other inhibitory pathways have been 
suggested including the Notch-jagged signalling pathway (John et al., 2002), 
hyaluronan-TLR2 signalling (Sloane et al., 2010) and type IV collagen signalling with 
OPCs (You and Gupta, 2018), as well as the proper release of pro-regenerative 
factors from the immune system, such as TGF-β, Activin-A and IGF-1 as well as 
others. 
Overall, it is believed that inhibition to OPC differentiation or OLG myelination is 
increased in MS plaques, therefore it is important to examine the inhibition process 
so that effective therapies can be developed to promote remyelination. As LINGO1 
and AMIGO3 have been identified as potential inhibitors of remyelination, we decided 
to investigate whether there is a change in their expression following trauma to OLG. 
4.1.2 Models of demyelination and OLG trauma 
A number of models have been developed to investigate OLG trauma and 
demyelination. Most of these models have been used in vivo, namely cuprizone, 
ethidium bromide and LPC and the inflammatory based models of EAE (Merrill, 2009; 
Miron et al., 2011). Cuprizone is a copper chelator which is administered orally 
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preferentially affecting oligodendrocytes and leading to mitochondrial dysfunction and 
OLG death. LPC is an effective focal demyelination agent, which when used at the 
correct concentration (usually 1% v/v), results in localised demyelination followed by 
complete remyelination within four weeks (Jeffery and Blakemore, 1995; Lu et al., 
2018). Ethidium bromide is similarly used as a focal demyelinating agent, which 
leads to more extensive and rapid demyelination than LPC (Squire, 2009). Ethidium 
bromide is a DNA intercalating agent which leads to the death of local astrocytes and 
OLG, requiring action of the immune system to clear debris before proper 
remyelination can occur (Merrill, 2009; Squire, 2009; Miron et al., 2011). 
Although these models are useful techniques for examining demyelination in the 
whole system, we decided that an in vitro homogenous cell culture model would be 
beneficial as a way to quickly and reliably get an idea of AMIGO3 OLG responses 
independently that can then be related to a larger system. This also avoids the time 
constraints and expense associated with using animal models. We decided to 
examine two models for our in vitro OLG injury investigation. An excitotoxic model of 
OPC injury involving application of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) with cyclothiazide (CTZ) (Begum et al., 2018), and LPC induced OPC 
injury. Due to the expense and time-constraints involved in generating large numbers 
of primary OPC, the Oli-neu cell line was used for our models. As previously 
discussed, and shown by ourselves and others, Oli-neu cells are Olig2 and NG2 
expressing and demonstrate a number of characteristics of OPC, having been 
immortalised from murine OPC (Jung et al., 1995; Pereira et al., 2011; Foale et al., 




CTZ is a positive allosteric modulator of AMPA receptors. After binding with AMPA 
receptors, CTZ increases the receptor sensitivity to AMPA and blocks 
desensitisation. This results in the channel opening more readily and increases the 
length of time that the channel is open for, causing a much greater influx of ions 
(Fucile et al., 2006). This has then been correlated to an influx in Ca2+, an increase in 
Ca2+ levels in mitochondria and subsequent mitochondrial damage, ultimately leading 
to cell death in a method that mimics excitotoxicity (Chen et al., 2007). Glutamate 
excitotoxicity has been presented to be a mechanism of lesion progression in MS. 
Inhibiting AMPA receptors with AMPA antagonists, as well as inhibiting other 
glutamate receptors, in EAE models reduces the clinical score (Werner et al., 2000; 
Gentile et al., 2018). This demonstrates that using AMPA receptor-induced 
excitotoxicity mimics some of the features observed in the cell degradation in MS. 
Furthermore, OLG have been identified to be extremely vulnerable to AMPA 
mediated excitotoxicity (McDonald et al., 1998) and the AMPA-CTZ model has been 
established in our lab (Begum et al., 2018). As such, it is highly likely that the excess 
release of glutamate into the extracellular space in MS lesions will cause over-
activation of receptors on OPC, resulting in trauma to the cells (Kostic et al., 2013). 
As such, we believe that treating OPC with AMPA-CTZ will be an effective model for 
investigating some of the traumatic events observed in MS. 
4.1.4 LPC 
As already mentioned, LPC traditionally has been used to induce demyelination in 
vivo or ex vivo, and is believed to predominantly affect OLs, rather than OPCs 
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(Fressinaud et al., 1996; Zhang et al., 2011). However, examples exist of LPC being 
used to induce OL and OPC trauma in vitro, where the count of viable cells reduces 
following incubation (Ou et al., 2016). LPC is believed to function as a detergent, 
which leads to the disruption of the myelin membrane by inducing blebbing and 
disruption of the membrane (Seyedsadr and Ineichen, 2017). Recent work has 
demonstrated that LPC treatment leads to a detrimental over-activation of Olig2 in 
mature OL which leads to demyelination and appears to inhibit the OL survival 
mechanisms in a Gpr17 regulated manner. This is contrast to Olig2’s role in OPCs 
where it promotes their differentiation (Ou et al., 2016; Lu et al., 2018). Although the 
exact mechanism that LPC functions through to induce damage to OPC is unclear, 
LPC has shown to be an effective agent for inducing damage to OLG (Jeffery and 
Blakemore, 1995; Keough et al., 2015; Ou et al., 2016; Lu et al., 2018). It was 
decided that this model would be interesting to examine the effects of trauma on 
OPCs. 
4.1.5 AMIGO3 in CNS trauma 
As previously discussed, AMIGO3 has been shown to be upregulated more rapidly 
than LINGO1 in SCI trauma (Ahmed et al., 2013). Furthermore, as LINGO1 
experiences a lag before its protein expression is raised in EAE, it appears likely that 
LINGO1 does not have a role in acute diseases. AMIGO3 on the other hand has been 
shown to be upregulated, at least at the transcript level, immediately after trauma in 
murine SCI (Ahmed et al., 2013). As such, it is likely that AMIGO3 is also raised acutely 





Specifically, we wanted to examine whether we could develop effective models of 
CNS trauma and whether these models could be used to demonstrate changes in 
LRR protein expression. This could be used as evidence to back up a role for LRR 
proteins in the pathogenic blockade of remyelination in demyelinating diseases. 
4.2.1 Hypothesis 
We hypothesise that: 
- AMIGO3 is upregulated following trauma to Oli-neu cells. 
- AMIGO3 is upregulated to a higher degree than LINGO1 in the acute stage 
following trauma to Oli-neu cells, indicating its role in acute demyelination. 
4.3 Experimental design and methods 
4.3.1 AMPA-CTZ induced Oli-neu trauma 
The AMPA-CTZ model has previously been tested and optimised within our group 
(Begum et al., 2018). Cell viability dropped to between 75-40% when treated with 
concentrations of AMPA ranging from 1-1000μM AMPA (with CTZ fixed at 100µm), 
demonstrating effective cell trauma. Previously our group used 100μM AMPA with 
100μM CTZ as this demonstrated reliable and sufficient cell trauma to Oli-neu cells to 
measure responses to excitotoxicity. 
500,000 Cells were seeded in a 6 well plate and cultured for 24 hours in SATO 
media at 37ºC with 5% CO2, to allow them to adhere. After 24 hours, media was fully 
144 
 
replaced with SATO media containing 100μM AMPA and 100μM CTZ. Control 
groups were also prepared with either SATO containing 100μM CTZ as well as 
SATO alone shams. The samples were then incubated for 5 hours. Following 
incubation, samples were collected and processed as previously described, to detect 
AMIGO3 and LINGO1 protein and mRNA by western blot and RT-qPCR. 
4.3.2 Optimisation of LPC induced Oli-neu trauma 
To enable comparison with the AMPA-CTZ studies, incubations in LPC were 
designed initially planned as 5 hour treatments. However, since previous experience 
of the effects of LPC on Oli-neu was not available optimisation of the concentration of 
LPC was necessary. For this work 500,000 Cells were seeded into the wells of a 6 
well plate and cultured for 24 hours in SATO media at 37ºC with 5% CO2, to allow 
them to adhere. After 24 hours, LPC was applied at varying concentrations. Cell 
cultures were then analysed in a number of ways: 
- Qualitative analysis was performed by imaging the cells directly. 
- Brightfield images were taken and cells were analysed for morphological and 
density changes to determine whether trauma had been induced. 
- Cell counts and viability assays through trypan blue analysis. 
Cells were trypsinised and centrifuged as described (see section 2.3.1). Samples 
were then resuspended in equal volumes of SATO and 0.04% trypan blue. Samples 
were counted for total cells and viable cells in a haemocytometer. 
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4.3.3 LPC induced Oli-neu trauma 
Once an appropriate concentration and time period of LPC incubation was 
decided, analysis of AMIGO3 and LINGO1 expression was performed in this model. 
500,000 Cells were seeded in a 6 well plate and cultured for 24 hours to allow them 
to adhere. After 24 hours, LPC was applied in SATO media and incubated. Two tests 
were performed; firstly, samples were collected immediately after incubation. 
Secondly samples had media replaced with SATO media and left for a total period of 
24 hours. After either the 5 hours or 24 hours, samples were collected and processed 
for AMIGO3 and LINGO1 expression by western blot. 
4.3.4 Experimental plan 
A summary of the plan for the investigation, findings and experiments used is 
demonstrated in figure 4.1. 
4.4 Results 
4.4.1 AMIGO3 and LINGO1 expression in Oli-neu cells following 
incubation with AMPA-CTZ 
Our first model of Oli-neu cell trauma was the AMPA-CTZ model. AMIGO3 protein 
expression, normalised to α-tubulin, increased almost twofold following incubation 
with AMPA-CTZ compared to both CTZ alone and sham treated cells, reaching 
0.92±0.07 compared to 0.52±0.09 and 0.59±0.02 respectively (fig 4.2). Significance 
(ANOVA, F(2,8)=9.577, P<0.01 ) was found within the samples, therefore variation in 
the mean AMIGO3 protein level existed. The increase in AMIGO3 expression in 




Figure 4.1: Flow chart demonstrating the plans and summarising the findings from 





Figure 4.2: (A) AMIGO3 protein expression in Oli-neu cells treated with 100μg/ml 
AMPA and 100μg/ml CTZ, 100μg/ml CTZ or sham for 5 hours. (B) Representative 
Western blots for the treatments. AMIGO3 levels were found to rise, only when 
treated with both AMPA and CTZ, indicating that levels of AMIGO3 have risen 
following the induction of trauma in this model. Error bars represent one SEM, n=4 




alone and sham treated cells (p<0.01 and p<0.05 respectively). No significant 
variation was detected between the sham and CTZ alone treated samples. 
 Interestingly our first studies showed an inverse reaction to the LINGO1 protein 
levels. Integrated density readings of LINGO1 protein levels were relatively high in 
both the sham treated and CTZ treated (1.13±0.14 and 1.07±0.06 respectively). 
ANOVA analysis showed significance between the mean LINGO1 expression in the 
groups (ANOVA, F(2,9)=8.195, P<0.01). No significance was detected between 
sham and CTZ alone treated groups (P>0.05). However the levels of LINGO1 protein 
dropped reaching 0.62±0.08 following incubation with AMPA-CTZ (fig 4.3), showing a 
significant decrease compared to both of the control groups (P<0.05). 
RT-qPCR was subsequently used to analyse the expression of AMGO3 and 
LINGO1 mRNA following incubation with AMPA-CTZ. Changes in expression were 
normalised against the expression of the proteins in sham samples. Both AMIGO3 
and LINGO1 mRNA levels showed a modest relative increase in expression levels 
compared to untreated samples, with relative changes of 1.32±0.09 and 1.28±0.30. 
These were compared against the relative fold changes for the CTZ alone treated 
groups and both groups did not display a significant increase in the relative fold 






Figure 4.3: (A) LINGO1 protein expression in Oli-neu cells treated with 100μg/ml 
AMPA and 100μg/ml CTZ, 100μg/ml CTZ or sham for 5 hours. (B) Representative 
Western blots for the treatments) LINGO1 levels were found to decrease when 
treated with both AMPA and CTZ. This indicates a reduction in LINGO1 expression 







Figure 4.4: RT-qPCR analysis of AMIGO3 and LINGO1 mRNA expression 
in Oli-neu cells treated with 100μg/ml AMPA and 100μg/ml CTZ or 100μg/ml 
CTZ alone. Data is displayed as fold-changes compared against untreated 
controls. Although a rise in the mRNA levels of AMIGO3 and LINGO1 is 
observed, it is not significant when compared to the relative change in mRNA 






4.4.2 Optimisation of LPC induced Oli-neu cell trauma 
Various concentrations of LPC were tested in Oli-neu cell incubations to determine 
an optimal concentration and treatment period for inducing cell trauma. Cells were 
then visualised at the varying time points to get a qualitative analysis of the effects on 
cell viability. Treatment with concentrations of LPC ranging from 0.5-2.5mg/ml 
induced rapid and comprehensive cell death in Oli-neu cell cultures. Some residual 
cells were still present in the group receiving 0.5mg/ml when incubated for 40 
minutes, however the cells were shrunken and spherical, having lost their 
characteristic bipolar phenotype (fig 4.5). It is clear from this data that the 0.5mg/ml 
treatment was too severe. 
Due to the severe level of cell death observed with concentrations of LPC from 
0.5mg/ml and above, levels of LPC were reduced to 0-50μg/ml and treatment periods 
examined between 5 minutes and 5 hours. Treatment with 5 and 10μg/ml LPC did 
not induce any clear phenotypical alterations in the Oli-neu cells morphology or 
density for up to 5 hours (fig 4.6). However, increases in LPC concentration above 
this level induced drastic results. A modest reduction in the density of Oli-neu cells 
was observed following addition of 25μg/ml LPC to the media following 5 minutes 
incubation. By 30 minutes incubation, most of the cells had retracted their processes 
and the density of the cells was drastically reduced. Following 5 hours, few cells 
remained and all cells were spherical with no processes visible. Treatment with 
50μg/ml LPC showed more drastic changes, with a drastic reduction in cell density 




Figure 4.5: Representative images of Oli-neu cells treated with varying 
concentrations of LPC. Concentrations tested vary from 0.5-2.5mg/ml. LPC at this 
concentration appears to cause marked cell death even at the lowest time point and 




Figure 4.6: Representative images of Oli-neu cells treated with varying 
concentrations of LPC. Concentrations tested vary from 0-50μg/ml. very little 
phenotypical changes can be observed qualitatively with up to 10μg/ml LPC with any 
time point, however further increases lead to a marked reduction in cell density, with 




this time point. Further incubation showed a greater reduction in the cell density as 
well as a loss of all visible processes, with barely any cells present following 5 hours 
incubation (fig. 4.6). 
 Further tests were performed on Oli-neu in the range of 10-15μg/ml, where cells 
were still observed to survive following treatment for 5 hours. Total cell counts and 
the proportion of cells that take up the trypan blue (cell viability) were used to 
examine the extent of trauma to cells with LPC at this range. Counts of the total cell 
numbers following treatment with LPC showed no reduction after 5 hours with all 
concentrations (fig 4.7A). Interestingly, significance was found in the mean 
population of cells (ANOVA, F(3,8)=7.833, P<0.01). Post-hoc tests revealed that 
there was a significant increase (p<0.05) in the total cell population in cells which had 
been treated with 15μg/ ml (1.31x106±9.4x104 cells) when compared to Sato treated 
sham controls (9.2x105±2.4x104 cells), 10μg/ml (8.8x105±6.7x10 cells) and 12.5μg/ml 
(9.5x105±7.5x104) (fig 4.7A). 
Proportions of cells that took up trypan blue were also measured. The control 
group did not show a normal distribution, therefore a Kruskal-Wallis and subsequent 
Dunn-Bonferroni post-hoc tests were used to analyse the proportion of Oli-neu which 
incorporated trypan blue following incubation with LPC. Qualitatively, it can be 
observed that the proportion of trypan blue positive cells does not increase until at 
least 12.5μg/ml, where a minor increase from 0.076±0.007 and 0.070±0.001 in sham 
controls and 10μg/ml respectively, to 0.131±0.006 was observed. A more substantial 




Figure 4.7: Optimisation of LPC induced Oli-neu cell trauma. Cells were treated 
with varying concentrations of LPC for 5 hours. (A) Total cell counts. Cell numbers 
increased at the highest levels of LPC, suggesting that cells were replicating. No 
other groups showed any significant change in cell population after treatment with 
LPC. (B) Proportion of trypan blue positive cells. There was an increase in the 
number of cells taking up trypan blue in the higher concentrations of LPC treated 
cells, although only significant at 15μg/ml. This indicates that a number of the cells 




only found (p<0.05) between the mean proportions of trypan blue incorporated cells 
treated with 15μg/ml and 10μg/ml, although a trend towards significance was 
observed between control and 15μg/ml LPC treated groups (p=0.105) (fig 4.7B). 
4.4.3 AMIGO3 and LINGO1 expression in Oli-neu cells following 
incubation with LPC 
An initial preliminary study looked in to the levels of AMIGO3 following treatment 
with LPC between 10-15μg/ml for 5 hours. A modest increase in expression was 
observed at both 10μg/ml and 15μg/ml LPC samples, reaching 0.50±0.08 and 
0.51±0.13 respectively from 0.38±0.13 in controls. However, this trend did not reach 
statistical significance, and indeed ANOVA did not detect a significant source of 
variation within the groups’ means (ANOVA, F(3,8)=1.409, P>0.05). Interestingly a 
small drop in AMIGO3 expression was observed in the 12.5 μg/ml LPC group, to 
0.24±0.05, although again significance was not found between this sample and any 
of the other samples (fig 4.8). 
LINGO1 protein levels were analysed for cells treated with 10μg/ml LPC (fig 4.9). 
LINGO1 protein expression levels were normally distributed and had equal variance 
following incubation with 10μg/ml LPC for 5 hours, therefore a t-test was used to 
analyse variation in the mean compared to control samples. Similar to AMIGO3, a 
small and minor increase in LINGO1 expression was observed following incubation 
with 10μg/ml, raising LINGO1 integrated density levels from 0.26±0.05 in controls, to 




Figure 4.8: AMIGO3 protein expression in Oli-neu cells following treatment with 
LPC for 5 hours. Although significance was not observed, levels of AMIGO3 appear 
to rise following treatment with LPC, except in the 12.5μg/ml group, where a 




Figure 4.9: LINGO1 protein expression in Oli-neu cells following treatment with 
LPC for 5 hours. A minor and non-significant increase in LINGO1 protein levels was 
observed after treatment with 10μg/ml LPC for 5 hours. Error bars represent one 
SEM, n=4 for LPC treated, n=3 for controls.
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4.4.3.1 AMIGO3 protein expression following 5 hour and 24 hour LPC 
A further repeat with a larger size (n=12) was performed with cells exposed to 
15μg/ml LPC for 5 hours. In this experiment protein samples were taken either 
immediately (5 hours), or 19 hours later (24 hours since incubation began). Both LPC 
treated and controls were found to be normally distributed with equal variance 
therefore samples were analysed using a t-test. A large variation in integrated density 
levels were observed for AMIGO3 levels in the LPC treated group, ranging from 0.7 
to 1.3, with a mean normalised integrated density of 0.96±0.04. This was found to be 
an increase compared to untreated control samples which had a mean normalised 
integrated density of 0.83±0.08, however significance was not observed between the 
means of the groups (p=0.175, therefore p>0.05) (fig 4.10). 
The 24 hour treatment data (5 hours LPC, 19 hours recovery) were analysed to 
examine AMIGO3 protein levels at a later time after trauma. Both LPC treated and 
controls were found to be normally distributed with equal variance therefore samples 
were analysed using a t-test. Again a large variation in normalised integrated density 
levels was observed in both the LPC treated and control groups, ranging from 0.64-
1.70 and 0.50-1.45 respectively (fig 4.11). Similarly, no significance was observed 
between the means of the two groups (p=0.662, therefore p>0.05) and qualitatively, it 
appears that the mean normalised integrated density levels are equal, 1.07±0.10 for 





Figure 4.10: AMIGO3 protein expression in Oli-neu cells following treatment with 
15μg/ml LPC for 5 hours. A larger repeat trial observed a large variation in levels of 
AMIGO3 following treatment with LPC. A minor although not significant increase in 
protein expression was observed. Error bars represent one SEM, n=12 for LPC 




Figure 4.11: AMIGO3 protein expression in Oli-neu cells following treatment with 
15μg/ml LPC for 5 hours, followed by 19 hours in normal growth media. AMIGO3 
levels show high variation in both treated and controls with no clear change in the 





4.5.1 AMIGO3 and LINGO1 expression in OLG trauma: AMPA-CTZ 
From the results of CTZ, it is useful to note that the levels of AMIGO3 and LINGO1 
do not alter when treated with CTZ alone. This is expected as CTZ is not able to 
activate AMPA receptors in its own right. However, as levels of both AMIGO3 and 
LINGO1 are not altered between sham controls and CTZ alone incubation, this helps 
to validate our model. Interestingly in the acute stages of excitotoxic trauma, our 
model indicates that AMIGO3 is significantly upregulated within 5 hours of trauma, 
raising to over 80% in its protein expression. This matches our hypothesis and 
indicates that AMIGO3 is having a role in the acute stages of trauma. However, it is 
not clear exactly what role AMIGO3 is playing in this stage as, in contrast to the 
literature (Jung et al., 1995), our preliminary data was unable to elicit Oli-neu 
differentiation in response to cAMP treatment,  thus we were unable to test the 
effects of differentiation on AMIGO3 expression. AMIGO3 mRNA levels are also 
observed to increase, albeit only qualitatively, after 5 hours of AMPA-CTZ induced 
excitotoxicity to Oli-neu cells. This agrees with our results from the western blot 
analysis, however it is unclear why significance was not observed. The most likely 
reason for this is the large degree of variation we observed in the data, hence a 
larger sample size is probably needed to detect the minor changes in the AMIGO3 
mRNA expression. 
Interestingly in this acute model of OPC trauma, LINGO1 levels are actually seen 
to decrease, reducing by around 30%. This appears to go against the in vivo trauma 
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data for LINGO1, where in demyelination and spinal cord injury, LINGO1 is observed 
to increase in protein expression (Ahmed et al., 2013; Wang et al., 2014; Theotokis 
et al., 2016), however it should be noted that these are all viewing LINGO1 levels 
after a longer time delay. It is interesting to note that the LINGO1 mRNA appears to 
increase during the 5 hour treatment period with AMPA-CTZ, opposing the protein 
levels, however this was not found to be significant. This actually matches data 
obtained in vivo, where multiple regions of the brain demonstrate increases in 
LINGO1 mRNA following kainic acid induced excitotoxicity (Karlsson et al., 2017). 
Similarly though, most anatomical regions analysed did not show a significant 
increase in expression until after 4 hours (Karlsson et al., 2017). This suggests that 
LINGO1 protein is being broken down at a rapid rate during the acute stages of 
trauma. It is possible that LINGO1 is simply broken down due to the trauma itself or it 
is being used up rapidly during this acute stage. 
From this data however, it appears that AMIGO3 is upregulated more rapidly than 
LINGO1 following excitotoxic trauma. We propose that this indicates that just as with 
neurons in spinal cord injury (Ahmed et al., 2013), OPCs also upregulate AMIGO3 
preferentially to LINGO1 during the early stages of disease. If both of these proteins 
are involved in the pathogenic inhibition of remyelination in MS and other 
demyelinating diseases, then our results suggest that AMIGO3 would be a more 
beneficial therapeutic target than LINGO1 as remyelination would be encouraged at 
an earlier stage of the disease. Earlier repair of myelin would allow neurons to be 
protected at an earlier stage so that less long-term damage would develop. 
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 Interestingly, the excitotoxic model of trauma seems especially relevant as NgRs 
have been shown to play a role in protecting hippocampal neurons from excitotoxic 
damage (Lopez et al., 2011). This suggests that a signalling pathway that both 
AMIGO3 and LINGO1 are associated with, could be involved with mediating the 
effects of excitotoxic damage in OLG as well as limiting maturation and myelin 
production. As AMIGO3 is upregulated, whereas LINGO1 is downregulated following 
excitotoxicity in our model, it demonstrates that any NgR1 signalling that occurs in 
the OPCs must be utilising AMIGO3 preferentially over LINGO1 in the acute stages 
of trauma. Admittedly, the present data only investigates a single cell line so it 
possible that the OPCs and other OLG cell lines have variations in the downstream 
effects of NgR1 signalling. Furthermore, as already discussed, there is speculation to 
the presence and role of NgR1 on OLG (Bourikas et al., 2010; Mei et al., 2013). 
However if NgR1 is present and providing a protective role in excitotoxicity then 
further questions are raised as to why this signalling would also lead to an inhibition 
of OPC maturation and OL myelin production, assuming this hypothesis is correct. 
4.5.2 AMIGO3 expression in OLG trauma: LPC 
4.5.2.1 Optimisation 
From our results, it is clear that relatively high concentrations of LPC (>25μg/ml) 
induced rapid and extensive cell death. When levels of LPC were at least 50μg/ml, 
none of the cultured cells maintained a bipolar morphology when viewed after 5 
minutes of incubation. This indicates that the treatment was too severe and was 
inducing cell death. Although some cell survival was observed after incubation with 
25μg/ml LPC for 30 minutes, the number of cells had appeared to reduce drastically 
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when viewed qualitatively. This means that it would be difficult to collect enough 
samples for protein analysis and that the treatment is likely causing such a severe 
reaction that it would not be relatable to disease. The range of treatments below 
25μg/ml in the imaging studies showed relatively minimal variation. There appeared 
to be a minor reduction in cell density after 5 minutes with both 5μg/ml and 10μg/ml 
which appeared to recover following 5 hours treatment. Despite signs of initial cell 
death, the cells appear to maintain their bipolar expression throughout. 
Further optimisation of the model focussed on concentrations of LPC ranging 
between 10-15μg/ml. We used trypan blue to provide cell counts and cell viability to 
get an insight in to the level of trauma that the cells were receiving. Interestingly, 
there was no sign of a reduction in the total number of cells at any of the time points, 
indicating that, although there was likely to be some degree of trauma, the cells were 
capable of surviving the treatment. Interestingly there was a significant increase in 
the total cell number when the cells were treated with 15μg/ml LPC for 5 hours. Why 
this would occur is not clear, but it could suggest that the treatment of LPC at this 
level actually encourages some cell division. The 15μg/ml LPC treatment was also 
the only time group where the proportion of cells positive for trypan blue, increased. 
Intriguingly, although at this level of LPC cells are starting to lose their viability, they 
seem to be replaced with new cells. It is likely that as the cells lose viability, their 
volume would decrease as their processes retract. Theoretically if the cells hadn’t 
died fully and were not releasing products which encouraged apoptosis or death of 
neighbouring cells, then they will provide more space for new cells to colonise and 
thereby allow the cell numbers to increase. This however also suggests that there is 
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heterogeneity in the cells, as some are losing their viability and being replaced with 
cells that are less susceptible to LPC. 
 It is interesting to note that previous models of LPC in OLG have used much 
higher concentrations to induce a reduction in cell viability (Ou et al., 2016). 
Previously LPC has been used at between 400-600 times more concentrated than in 
our studies, well into the levels that induced full cell death. This could possibly 
indicate that the Oli-neu cells are far more susceptible to LPC treatment than primary 
rat OPCs. It is not clear why this would be the case but it does raise questions as to 
the why there is variation and could potentially suggest some variation in phenotypes 
between the primary cells and the Oli-neu cell line. 
To confirm these findings, it would be useful to repeat with another analysis 
method. Another method that could have been used to investigate the cell 
death/degradation would have been to examine levels of lactate dehydrogenase 
(Merrill, 2009). Despite the potential concerns in the model due to the cell number 
changes, it was decided that further studies would use 10μg/ml LPC, as well as 
higher concentrations where time permitted. 
4.5.2.2 AMIGO3 and LINGO1 following LPC incubation in Oli-neu cells 
Following treatment with LPC at 10 and 15μg/ml, there appears to be a small 
increase in the levels of AMIGO3, albeit not significant. This suggests that AMIGO3 
may be raised following treatment with LPC, although only at a low level. The means 
were only observed to increase by ~25-30% therefore it is not clear whether this 
would lead to a substantial change in activity even if the results are accurate. 
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Furthermore, there appears to be a small reduction in AMIGO3 expression at 
12.5μg/ml, again not significant, therefore it is possible that AMIGO3 levels do not 
actually change following treatment with LPC between 10-15μg/ml for 5 hours. It is 
likely that more confidence could be obtained for the results if a higher sample size 
was used. A large variation was observed within the data for all groups which could 
have prevented our ability to detect significance between the means of the AMIGO3 
levels. Western blots are only semi-quantitative, thus it is likely that a larger sample 
size is required to provide sufficient data to examine the means of AMIGO3 
expression in Oli-neu cells following treatment with LPC. 
To test this possibility we repeated the LPC treatment study with a larger sample 
size and only using LPC at a concentration (15μg/ml )where significant reductions in 
cell viability had been observed. Despite using a larger sample size, we again found 
that although a qualitative increase in the mean AMIGO3 protein expression was 
observed after the 5 hour LPC incubation, this was not found to be significant. 
Furthermore, repeating the tests and allowing the cells a further 19 hours following 
LPC incubation for further AMIGO3 translation, resulted in a similar minor increase in 
the mean that was not significant. Interestingly, the variation in AMIGO3 expression 
in both control and treated groups increased considerably in the 24 hour extracted 
samples when compared to the samples collected after 5 hours. 
 From these data it would appear that AMIGO3, and LINGO1, do not increase their 
protein expression significantly following LPC induced trauma. Even after 24 hours, 
AMIGO3 levels stilled remained relatively low indicating that this form of trauma did 
not induce the expression of either LRR proteins.  
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4.5.3 Comparison of OLG trauma models 
The variations between the models of cell trauma may explain the variation that 
was observed. Depending on the method of trauma, different mechanisms will be 
activated and therefore the cells will react in a different manner (Kroemer et al., 
2009). As LPC has been shown to promote Olig2 in mature OLs, it is possible that 
Olig2 is similarly promoted in OPC following LPC induced trauma. Olig2 expression 
has been demonstrated to encourage OPC maturation (Ou et al., 2016; Lu et al., 
2018). Furthermore, it is also clear that LPC treatment results in efficient and 
complete remyelination in a relatively short period (Vereyken et al., 2009). As such, 
this model may not provide a true comparison to MS and demyelinating systems as it 
may directly encourage the maturation of OPC unlike the human diseases. If 
AMIGO3 is involved in inhibiting OPC maturation, then it would be expected to be 
downregulated when remyelination is occurring. Therefore, it is possible that LPC 
treatment may actually prevent an increase in AMIGO3 protein expression, whether 
directly or indirectly, through its potential stimulation of Olig2, and OPC maturation. 
It could also be argued that excitotoxicity is more likely to have a more controlled 
destruction of OPC than LPC treatment due to the build up of calcium in the cells that 
is expected with this treatment (Chen et al., 2007). The LPC model however appears 
to produce a more direct and rapid break down of cell structures, therefore necrosis 
may occur rather than the more regulated apoptosis pathway. Indeed, it may be 
considered that LPC damages the cells from the outside in, while excitotoxicity is 
likely to induce injuries that proceed from inside to out (e.g. Ca2+ induced apoptosis). 
This variation of course raises questions to the validity of the models as they will only 
169 
 
be investigating one aspect of the OPC trauma response that would be observed in 
vivo. These models do however provide an invaluable insight which can help explain 
the responses in the animal models. 
4.5.4 Limitations 
There are a number of limitations associated with this study. Firstly, 
experimentally, our sample sizes were not always large enough to detect significance 
between variations in data. Furthermore, on the experimental procedures, further 
repeats of the data would have been beneficial to confirm our findings. 
Our models, although able to address specific types of trauma to OPCs also 
contain limitations. Firstly, when comparing to MS or other demyelinating diseases, 
our models are limited in that they only examine one specific form of OPC trauma. 
MS is a multi-faceted disease and the environment within the lesion can become 
detrimental to OPC survival and maturation for a number of reasons. As the exact 
cause of MS is unknown, it is not clear if there is another unknown contributor which 
inhibits OPC development which we are not able to model. Furthermore, the models 
also are only able to examine OPCs in isolation. Although this is an advantage to 
examine the responses in the cell line alone, it does not represent the true 
environment where multiple cell types are present and may react to the disease 
conditions. However, as our experiments are simply looking at a potential mechanism 
for OPC inhibition, they remain relevant despite these limitations. Another limitation 
to these experiments is the narrow range with which we were able to use LPC. Minor 
increases in the LPC concentration caused dramatic changes in the proportion of Oli-
neu which were no longer viable. This is likely to introduced variability to the data. 
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Finally, it is also possible that the reactions that we observed may be a specific 
behaviour of the Oli-neu cell line. It would have been beneficial to use a number of 
cell lines, for example the MO3.13 (McLaurin et al., 1995) or N19 (Paez et al., 2007) 
OLG lines, or preferably primary cells, to ensure that the behaviours are 
representative of OPCs. It also is possible that there could be variation between 
murine cell lines and human cell lines. Unfortunately, due to the cost of other primary 
cell lines and the difficulties associated in setting up primary cultures, we were not 
able to perform these experiments in this study. 
4.5.5 Future studies 
Following on from our data, there are a number of studies which could provide 
fascinating insights in to the role of AMIGO3 in OPC differentiation and myelination. It 
would be very interesting to repeat these studies with cells that have been 
encouraged to mature. This would provide an idea of whether changes in AMIGO3 
expression following trauma correlate with its predicted inhibitory effects on OPC 
maturation. Furthermore, co-culture studies would provide a useful method to 
examine whether cultured OPCs or OPC cell lines, would be able to engage in some 
level of neuronal ensheathing. Co-culturing systems could also be examined through 
electron microscopy to get detailed images of the ensheathment of neurons, thereby 
giving a greater idea of the effects on the OLG development in correlation with 
AMIGO3 expression (Mi et al., 2005; Pang et al., 2012; Shao et al., 2017). An 
alternative would be using ex vivo cultured brain slices (Goebels, 2007). Our lab, as 
well as others, have previously modelled anti-MOG and complement induced 
demyelination in these ex vivo slice cultures (Fulton et al., unpublished; Goebels, 
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2007; Berg et al., 2017). These experiments would be invaluable to provide a more 
translatable view of the effects of inflammation induced demyelination in a whole 
system. 
It should be noted that there are a number of potential methods of CNS trauma 
associated with MS and as such it would be valuable to repeat these experiments 
using a number of various models. It would be useful to repeat the trauma 
experiments with a different injury model, for example, a complement mediated 
(Alberdi et al., 2006), or free radical induced injury (Whittemore et al., 1995), or 
simply another excitotoxic model to confirm our findings (Karlsson et al., 2017). 
Repetitions in numerous models may help to identify where variations exist and 
potentially give an insight as to why recovery occurs in some cases but not in all, 
such as long term plaque development in MS compared to early stages of the 
disease (Patani et al., 2007). Furthermore, although we examined a small range for 
the LPC treatments, it would be interesting to examine the changes of AMIGO3 in 
our AMPA-CTZ model both over a varying time course and after varying degrees of 
trauma. This could help to get a better understanding of when and why AMIGO3 is 
expressed in traumatic injury to OPCs. 
Another area of interest is that following LPC induced OPC trauma with 15μg/ml 
LPC, we observed an increase in the total number of cells. It would be interesting to 
note if there has been an increase in the cell proliferation following the trauma. This 
could be easily measured through BrdU counts, or flow cytometric cell cycle analysis, 
following LPC incubation (Chen et al., 2014). Furthermore, it would be interesting to 
note if there is any correlation between AMIGO3 expression and rate of proliferation. 
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It is possible that differentiation of OPC is initially inhibited following demyelination as 
a way to ensure sufficient OPC are present for full myelination, although it is known 
that this is not the limiting step in remyelination (Nakahara et al., 2009). It should be 
noted here that different degrees of demyelination may require different responses. 
For example, if there is only a small traumatic event, which has predominantly 
affected OLs, while high numbers of OPC are still present, then active remyelination 
would be the first process required. Although it would still need to be determined to 
what degree of OL/OPC loss is required for OPC proliferation to be more important 
than OPC differentiation, it would be interesting to determine whether AMIGO3 is 
linked to the control of these processes. 
Another area of interest would be to examine the exact pathways that AMIGO3 is 
signalling through. It is possible that although AMIGO3 levels are changing, they may 
not be having any more of an effect. AMIGO3 cellular localisation may be the 
important factor, and therefore higher levels of AMIGO3 may not correlate with 
increased signalling following trauma if AMIGO3 is not present with its signalling 
partners. Based on this hypothesis, it would be interesting to examine the cellular 
distribution of AMIGO3 following trauma to OLG. Furthermore, as a pathway has not 
been elicited for AMIGO3 in OLG, it would be very interesting to observe if AMIGO3 
interactions with itself or other proteins vary following OLG trauma. This could be 
easily investigated with ICC at a high power of magnification. Unfortunately, as we 
observed variability in AMIGO3 expression when visualising in IHC, it is unlikely that 
this approach would provide valuable data at this time. Such studies must wait until 
an efficient antibody and imaging system has been developed for visualising 
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AMIGO3. Alternatively, in terms of protein interactions, co-immunoprecipitation or 
Forester resonance energy transfer (FRET) analysis would be a useful tool to 
investigate the interactions of AMIGO3 at various stages in OLG lifecycles and in 
traumatic conditions. This however was not possible due to time constraints, but 
would be interesting for further research. 
4.5.6 Conclusions 
In conclusion, we have demonstrated that under an excitotoxic condition, both the 
mRNA levels and the protein levels of AMIGO3 rise in OPC cell lines in the first 5 
hours following trauma. Further repeats both in Oli-neu cells, and in other cell lines, 
or primary cells, would be valuable to back up our in vitro data. This raise in AMIGO3 
protein levels does not replicate in LPC induced OPC trauma, presumably due to the 
more direct cell destruction, or due to potential activation of Olig2 induced maturation 
pathways in the OPC. This demonstrates that AMIGO3 is likely to be raised following 
trauma to OPC in traumatic demyelination. It is still unclear what role AMIGO3 is 
having in this state, however it is possible that this represents a mechanism for 

















Current research for LRRs in demyelinating disease has focussed squarely on the 
role of LINGO1 in inhibiting the development of mature OPCs (Foale et al., 2017). As 
previously discussed LINGO1 has been identified in models of demyelination (section 
1.4.2.2), as well as in MS lesions (Mi et al., 2013), and its inhibition has led to in vivo 
remyelination. However, as already highlighted in (section 1.4.2.2.2) there are 
concerns with LINGO1 as a target for the development for treatments for MS, in that 
recent clinical trials did not demonstrate positive outcomes when optic neuritis 
patients were treated with opicinumab, an anti-LINGO1 antibody, compared to 
placebos (Cadavid et al., 2017). Visual evoked potentials appeared to improve 
slightly however there was no significance found when analysed. Furthermore, there 
was no evidence for any change in the thickness of RGC layers in the retina between 
treatment groups. The authors argue that these results are indicative of longer 
studies being required, or that an earlier imminent administration of opicinumab is 
warranted. Alternatively, these observations may indicate that, while LINGO1 plays a 
minor role in encouraging remyelination, these actions may be eclipsed by 
compensatory inhibition by AMIGO3. As a result, OPC maturation and remyelination 
may still be inhibited despite therapeutic blockade of LINGO1. A lack of improvement 
would then be observed in patients given anti-LINGO1 therapies to encourage 
remyelination, at least in the acute stages following demyelination. 
We have demonstrated that AMIGO3 is present during postnatal development, and 
that its protein concentration alters substantially during the main stages of postnatal 
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myelination. In addition we have shown that trauma to OPC alters the levels of 
AMIGO3. Based on these findings we decided to examine the expression profile of 
AMIGO3 during inflammatory demyelination in the brains of animal models and in 
human MS. Although minor preliminary evidence exists demonstrating expression of 
AMIGO3 in MS lesions and in OPC (Ahmed et al., personal communication), no data 
exists correlating any changes in expression, therefore this data will be invaluable in 
examining the role of AMIGO3 in demyelinating disorders. 
5.1.1 EAE as a model of MS 
EAE is the primary model used for examining immune related demyelination and is 
the most commonly used animal model for examining MS (Kipp et al., 2012). A 
number of varieties of EAE have been developed which can provide insight to 
various stage of inflammatory related demyelination (Baker et al., 2011; 
Constantinescu et al., 2011). EAE has been induced in multiple species, including 
primates, highlighting the translatability of the model, however the majority of studies 
have investigated it in mouse models (Kap et al., 2010; Robinson et al., 2014b). 
Similarly most LINGO-1 based studies have used mouse models, therefore for direct 
translatability we chose to use mouse models as well (Sun et al., 2015; Zhang et al., 
2015a; Foale et al., 2017). 
A number of variants of the EAE model have been developed allowing models to 
be chosen depending on the aspect of the disease under investigation 
(Constantinescu et al., 2011). As AMIGO3 mRNA expression rises at a faster rate 
compared to LINGO1 in  spinal cord following trauma (Ahmed et al., 2013), and 
because we observed a rise in AMIGO3, but not LINGO1, protein expression in our 
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acute excitotoxic model (section 4.4.1), we predict that AMIGO3 expression will be 
higher compared to LINGO1 in the acute stages of EAE induced demyelination. As 
such we decided to examine AMIGO3 in an acute EAE/optic neuritis model (section 
2.1.2.3),  as well as in a more developed relapsing-remitting model which better 
represents the most common form of  MS disease progression (Al-Izki et al., 2012). 
5.1.1.1 EAE progression 
As EAE is an ascending disease, progression begins in the inferior spinal cord 
with inflammation occurring in the lumbar region and progressively ascending 
through the spinal cord (Miller and Karpus, 2007). As a result, EAE begins with 
paralysis of the hind limbs, correlating with demyelination in the lumbar spinal cord. 
Therefore the loss of myelin proteins such as MBP, as well as an infiltration of CD4+ 
T helper cells would commence in the lumbar region of the spinal cord (Miller and 
Karpus, 2007). CD4+ cells appear to then have an integral role in the ensuing 
pathogenic demyelination through inducing CNS inflammation as well as priming of 
phagocytes for myelin derived proteins. This is further demonstrated by the fact that 
EAE can be induced in healthy naïve mice by transfer of CD4 cells primed for myelin 
derived proteins from myelin immunised mice (Elyaman et al., 2008; Constantinescu 
et al., 2011; McGinley et al., 2018). Although MS and EAE are thought to be 
predominantly a CD4+ T-helper cell mediated disease, there is also evidence that 
cytotoxic T-cells, or CD8+ cells, play an important role in progression of the disease 
(Robinson et al., 2014b). In fact, CD8+ cells are the predominant T cell in developed 
MS lesions (Rangachari and Kuchroo, 2013; Steckner et al., 2016). As a result, CD8+ 
cells are a prime target for indicating inflammation in the spinal cord in EAE. 
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There are a number of other signs that describe the progression of EAE. OX42 
(CD11b or α-integrin M) is a marker of microglia, with some small levels of 
expression reported on macrophages as well. During acute stages of EAE, whilst 
inflammatory related demyelination is occurring, an increase in the number of 
CD11b+ is observed indicating the increased role of local inflammatory cells in 
phagocytosing cellular debris (Crocker et al., 2006; Alrehaili et al., 2018). 
Furthermore, as the disease progresses and increased neurodegeneration occurs, 
an increase in the levels of GFAP is observed. GFAP is expressed normally at low 
levels in astrocytes, but then marked increases are observed following CNS trauma 
due to the resultant reactive gliosis and scar formation (Paintlia et al., 2008; Kundi et 
al., 2013). We intend to use these markers to determine the progression of disease in 
our models to correlate the expression of AMIGO3 with levels of the disease 
5.2 Aims 
The aim of this study is to examine the expression profile of AMIGO3 during the 
stages of demyelination. We wanted to characterise the extent and level of 
demyelination in our models to choose an effective stage to evaluate the expression 
of AMIGO3. These models will be used to evaluate the levels of AMIGO3 following 
demyelination. The aim of this investigation is therefore to gain a better 
understanding of the expression of AMIGO3 following demyelination, and to 




We hypothesise that AMIGO3 levels will be raised in the acute stages of 
demyelination. This will amount to higher AMIGO3 protein levels in EAE induced 
animals compared to controls. 
5.3 Experimental design and methods 
5.3.1 Demyelinating models 
As AMIGO3 is believed to be the more significant LRR molecule in the acute 
stages of demyelination, we decided to examine early stage models of 
demyelination. As such we used our acute EAE model which has a minimal 
demyelination so that we can examine the first stages of the disease, as well as a 
relapsing-remitting model where further progression will have occurred. 
5.3.2 Optic neuritis 
Optic neuritis was induced as previously described (section 2.1.2.3). For optic 
neuritis, optic nerves were dissected at D10 following disease induction. IHC was 
then use to analyse MBP and AMIGO3 expression profiles compared between optic 
neuritis induced and untreated controls. Expression levels of AMIGO3 were analysed 






5.3.3.1 Acute EAE 
Acute EAE was induced using the same protocol as optic neuritis, however mice 
were allowed to progress until D14 and D19 so that further disease progression could 
be observed. Clinical scores and IHC were used to analyse the model before further 
tests. For IHC, transverse lumbar sections were prepared as described (section 
2.3.2.2). Sections were then labelled with markers of myelin (MBP), inflammation 
(OX42, CD4 and CD8) and reactive gliosis (GFAP), to determine the extent of 
disease progression. DAPI counts were also performed on the sections to analyse 
whether cell numbers had changed during disease progression. Samples were 
compared against untreated healthy controls. Unless stated otherwise, images from 
transverse lumber sections were taken at the posterior fasciculus to analyse changes 
in the white matter (fig 5.1). Lumbar sections were used as EAE is an ascending 
disease, which begins with infiltration of immune cells at the lumbar region of the 
spinal cord (Miller and Karpus, 2007). Furthermore, MBP has been shown to be 
expressed highly in the lateral spinal cord within the white matter tracts, with high 
levels seen in the posterior fasciculus (Mei et al., 2012). Due to the high levels of 
MBP in the posterior fasciculus as well as lumbar segments being affected foremost 
in EAE, there should be a greater development of the disease in the lumbar region of 





Figure 5.1: Diagram of the spinal cord and regions used for IHC. Images were 
obtained predominantly, and unless otherwise stated, alongside the dorsal horn on 
the lateral edge of the spinal cord. Specifically, in the white matter of the posterior 
fasciculus (A). For CD4 and CD8 analysis, some images were obtained in grey 




5.3.3.2 Relapsing-remitting EAE 
Relapsing-remitting EAE was induced as previously described (section 2.1.2.3). 
As samples were collected once a clinical score of 4 had been reached, monitoring of 
clinical score disease progression over time was not performed. Transverse lumbar 
spinal cord sections were prepared for IHC analysis of the samples. Due to issues 
with immunofluorescence on samples that had been stored for an extended period of 
time, samples were only analysed for MBP expression through DAB staining. 
5.3.3.3 AMIGO3 protein analysis 
For analysis of AMIGO3 expression, protein lysates were collected from superior 
lumbar spinal cords from EAE and untreated control samples. Samples were then 
analysed by western blot to semi-quantitatively assess levels of AMIGO3. 
5.3.4 Multiple sclerosis 
White matter brain samples of chronic lesions from MS patients (MS white matter, 
MSWM), normal appearing white matter (NAWM) and healthy controls were gratefully 
obtained from the Multiple Sclerosis and Parkinson’s Tissue Bank, UK. Samples 
were flash frozen prior to collection. Protein lysates were obtained from the samples 
for semi-quantitative western blot analysis of AMIGO3 and LINGO1 protein levels in 
the chronic human disease. 
5.3.5 Experimental plan 
A summary of the plan for the investigation, findings and experiments used is 




Figure 5.2: Flow chart demonstrating the plans and summarising the findings from 




5.4.1 Optic Neuritis 
Following the induction of optic neuritis in C57BL/6 mice, samples were obtained 
of optic nerves to examine the extent of demyelination and AMIGO3 expression (fig 
5.3 & 4). Firstly, examining AMIGO3 staining, there is no qualitative evidence of any 
increase or decrease in AMIGO3 levels (fig 5.3). Interestingly though, the distribution 
of AMIGO3 in optic nerves from optic neuritis induced samples displayed a tendency 
to redistribute more to the external surface of the nerve. Our images also suggest 
that AMIGO3 appears to arrange in long strips running along the nerve, potentially 
redistributing along axons. This is opposed to a more globular arrangement which is 
more prevalent in the control samples. 
MBP distribution was also analysed qualitatively in the optic neuritis samples. As 
with AMIGOs, there is no major variation that can be observed qualitatively between 
the sham control and optic neuritis samples and it is not clear if there is a change in 
total MBP levels. Both controls and optic neuritis samples show a relatively even 
distribution across the optic nerve (fig 5.4). 
The intensity and percentage of positive pixels were analysed following IHC for 
AMIGO3 in the optic neuritis samples to determine semi-quantitatively if there was 
any change in AMIGO3 expression in this model of demyelination (fig 5.5). Firstly, the 
average pixel intensity was measured for AMIGO3 positive IHC. Although a larger 




Figure 5.3: Representative AMIGO3 staining in C57BL/6 mice optic nerves for the 
optic neuritis study. (A-B) optic neuritis and (C-D) normal controls. No major variation 
can be seen between treated and sham samples although a small retribution of 
AMIGO3 to the external membrane of the nerve as well as to axons is seen in optic 




Figure 5.4: Representative MBP staining in C57BL/6 mice optic nerves for the 
optic neuritis study. In both (A-B) optic neuritis and (C-D) normal controls. MBP 
distribution and staining intensity stays relatively constant between the groups. Scale 
bars represent 100μm, n=3. Insets show negative controls.
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Figure 5.5: Semi-quantitative AMIGO3 pixel analysis from optic neuritis samples. (A) 
The average pixel intensity was analysed and (B) the percentage of pixels positive 
above threshold for AMIGO3. No clear difference can be seen in the pixel intensity 
after IHC against AMIGO3, however a decrease in the total percentage of positive 




samples showed a relatively equal mean pixel intensity, 45.4±8.9 and 47.8±3.3 
respectively. Both samples were normally distributed and had an equal variance, 
therefore a t-test was used to analyse any variation in the mean pixel intensities. As 
expected from the qualitative results, no significant variation was observed (p>0.05). 
The percentage of positive pixels over the threshold value was then tested to 
observe if any variation existed based on areas of positive signal. Again the data for 
both groups was found to be normally distributed and have equal variance. T-tests 
did not find significance, although there was a potential trend towards significance 
(p=0.06) between the positive pixel percentages within optic nerves for AMIGO3. 
Interestingly, the sham group showed a higher mean level, with a mean positive pixel 
percentage of 9.16±0.60 compared to 5.90±1.11 in the optic neuritis samples, 
indicating a potential reduction in AMIGO3 following induction of optic neuritis. 
5.4.2 Evaluation of EAE models 
We evaluated two models of EAE to determine AMIGO3 expression, our D14 and 
D19 acute stage EAE and the relapsing-remitting model. 
5.4.2.1 Day 14 and Day 19 Acute models of EAE 
Clinical scores were measured during the study for the animals from D14 onwards 
(fig 5.6). D14 collected animals showed very limited disease progression with two 
animals reaching a score of 0.5, however the majority did not demonstrate signs of 
disease (fig 5.6A). Allowing the animals to progress further to D19 lead to animals 




Figure 5.6: EAE scores for the D14 and D19 acute EAE studies. (A) EAE scores 
on D14 for the animals collected on D14. Minimal signs of EAE induction were 
observed by this time. (B) EAE scores from D14-D19 for animals collected on D19. 
Scores can be seen to increase during the period up to collection on D19. (C) Mean 





a steady increase in the average clinical score was observed from 0.00±0.00 at D14 
for the D19 collected animals, to 1.20±0.12 by D19 (fig 5.6C). A maximum score of 
1.5 was observed in this model and timeframe. 
Lumbar sections were analysed for signs of demyelination and inflammation, 
matching with the progression of EAE. MBP IHC was used to assess the extent of 
demyelination in the acute model. Interestingly, qualitatively a marked reduction in 
MBP positive staining was observed compared to untreated controls in D14 collected 
samples, indicating demyelination (fig 5.7). It should be noted however that some of 
the samples displayed greater levels of MBP (not shown) therefore there was a 
degree of variability within the EAE groups. A reduction in the MBP levels is also 
observed in the D19 samples (fig 5.8), however it did not appear to be as great as in 
the D14 samples. Despite the modest reduction in MBP levels at D19, the staining 
appeared more dispersed than untreated controls suggesting a loss of the myelin 
sheath architecture. 
Both D14 and D19 samples were analysed for the expression of OX42. The 
majority of samples demonstrated very minimal numbers of OX42+ cells both in the 
untreated controls and the acute EAE (figs 5.9 & 10). Similar results were observed 
both in the white matter at the posterior fasciculus as well as the grey matter 
surrounding the central canal in the anterior commissure. Interestingly, there was one 
sample in the D14 acute EAE samples that responded at substantial levels with 
multiple OX42+ cells around the central canal. Despite being a clear development of 




Figure 5.7: Representative MBP (green) IHC in D14 acute EAE samples. 2 images 
are shown, from different animals in the same group of the study. Samples were 
counterstained with DAPI (blue). MBP levels appear to drop substantially between 
the untreated controls and EAE induced groups, demonstrating that demyelination 
has occurred. Scale bars represent 100μm, n=5 for treated, n=3 for untreated 




Figure 5.8: Representative MBP (green) IHC in D19 acute EAE samples. 2 images 
are shown, from different animals in the same group of the study. Samples were 
counterstained with DAPI (blue). A reduction in the intensity of the signal can be 
observed between untreated controls and EAE samples, however MBP can still be 
seen in a similar distribution throughout the white matter. Scale bars represent 




Figure 5.9: Representative OX42 (green) IHC in D14 acute EAE samples. 2 
images are shown, from different animals in the same group of the study. Samples 
were counterstained with DAPI (blue). Minimal staining was observed for both EAE 
and untreated controls following 14 days after EAE induction, both by the central 
canal and at the posterior fasciculus of lumbar sections. One animal did show 
positive staining around the central canal but this was not representative of the 




Figure 5.10: Representative OX42 (green) IHC in D19 acute EAE samples. 2 
images are shown, from different animals in the same group of the study Samples 
were counterstained with DAPI (blue). Minimal staining was observed for both EAE 
and shams following 19 days after EAE induction, by the central canal and at the 
posterior fasciculus of lumbar sections. Minor staining was observed in some 
untreated control samples and EAE samples however most samples showed minimal 
or no staining. Scale bars represent 100μm, n=5 for treated, 3 for untreated controls.
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GFAP was analysed to indicate signs of reactive gliosis in the lumbar spinal cords 
of D14 and D19 animals (figs 5.11 & 12). No GFAP+ staining was observed in any of 
the groups, both untreated and acute EAE in D14 and D19 analyses. CD4 and CD8 
IHC were only analysed in the D19 samples, where CD4+ IHC was similarly not 
observed (fig 5.13). CD8 positive staining was observed but only at very low levels 
and it was not seen in every sample either. 
DAPI counts were performed in white matter of acute EAE and untreated control 
samples to provide an additional means to suggest inflammation (fig 5.14). A slight 
reduction in the DAPI counts was observed in both the D14 and D19 EAE samples, 
however neither of these were found to be significant (ANOVA, F(3,11)= 1.061, P > 
0.05). Similarly, there was no significance in the DAPI counts between D14 and D19 
EAE samples either. 
5.4.2.2 Relapsing-remitting EAE 
All animals in the relapsing-remitting EAE were allowed to progress to a clinical 
score of 4, therefore significant signs of disease progression had occurred with 
hindlimb paralysis. Due to difficulties examining the samples by immunofluorescence, 
DAB staining was utilised. We stained for MBP to probe for clear sign of 
demyelination. Qualitatively, although both EAE and untreated controls showed 
MBP+ staining, it appeared that MBP levels reduced in the white matter of lumbar 





Figure 5.11: Representative GFAP (green) IHC in D14 acute EAE samples. 2 
images are shown, from different animals in the same group of the study. Samples 
were counterstained with DAPI (blue). Minimal GFAP staining was observed in both 





Figure 5.12: Representative GFAP (green) IHC in D19 acute EAE samples. 2 
images are shown, from different animals in the same group of the study. Samples 
were counterstained with DAPI (blue). Minimal GFAP staining was observed in both 





Figure 5.13: Representative CD4 and CD8 (green) IHC in D19 acute EAE 
samples. 2 images are shown, from different animals in the same group of the study. 
Samples were counterstained with DAPI (blue). No CD4 staining was observed in 
both untreated controls and EAE groups. Although minor, some EAE samples 
showed CD8 positive staining, however this was minimal and did not demonstrate a 





Figure 5.14: DAPI counts from lumbar posterior fasciculus of acute EAE mice and 
untreated controls at D14 and D19. A minor reduction in the DAPI counts was 
observed following EAE induction, compared to untreated control samples. This was 
however not found to be significant. Error bars represent one SEM, n=5 for D19 EAE, 




Figure 5.15: Representative IHC for MBP in relapsing-remitting EAE samples. 2 
images are shown, from different animals in the same group of the study. The 
intensity of the DAB staining reduces in EAE samples, indicating that there has been 
a decrease in the level of MBP, therefore demyelination is likely to have occurred. 
Scale bars represent 100μm, n=6 for EAE samples, 4 for untreated controls.
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5.4.3 Discussion of EAE models 
Our D14 and D19 models of EAE showed low levels of disease progression as 
expected for this acute model of inflammatory disease. MBP levels appeared to 
reduce slightly in both D14 and D19 models, suggesting a very mild response. The 
low levels of EAE induction could also explain the variability as one minor change in 
one animal would appear significant compared to the remaining samples. 
Interestingly, a number of markers of inflammation and lesion development were 
unchanged with variable levels within the groups, raising questions to the level of 
inflammation achieved. In contrast, the relapsing-remitting model has been 
demonstrated previously to induce comparative and reproducible signs of 
demyelination combined with the secondary signs of neurodegeneration (Al-Izki et 
al., 2012). In agreement with this we observed a reduction in the MBP staining 
indicating that the model had induced demyelination. Due to the lack of signs of 
inflammation and the low signs of disease progression, as well as the high variability 
in MBP levels and signs of inflammation within groups in the acute models of EAE, 
we decided to focus on the relapsing-remitting model of EAE for the Western blot 
analysis of AMIGO3 and LINGO1. 
5.4.4 AMIGO3 in relapsing-remitting EAE 
We observed a 30% increase in the expression of AMIGO3 protein in protein 
lysate collected from the lumbar spinal cord samples of relapsing remitting EAE 
compared to healthy controls (fig 5.16). The integrated density rose from 0.97±0.06 in 




Fig 5.16: AMIGO3 expression in relapsing-remitting EAE samples. AMIGO3 
expression can be seen to be significantly raised following induction of EAE in EAE 
spinal cord protein lysates. Error bars represent one SEM, n=4 for untreated controls, 




significant (P<0.05) when analysed via t-test. DAB staining for AMIGO3 showed 
minimal clear staining, with no major observable difference between EAE and 
controls (fig 5.17) 
5.4.5 AMIGO3 in MS 
Interestingly AMIGO3 showed a reduction in their proteins levels analysed from 
MS samples, both in the lesion sites and in the normal appearing white matter, 
compared to that of healthy tissue (fig 5.18). AMIGO3 protein normalised integrated 
density readings dropped from 0.64±0.17 to 0.44±0.08 in MS lesions as well as a 
decrease to 0.44±0.07 in NAWM samples from MS patients. None of these changes 
were found to be significant however (ANOVA, F(2,12)=1.149, P>0.05). 
5.5 Discussion 
5.5.1 Optic Neuritis 
We first modelled an acute model of induced demyelination with our previously 
developed optic neuritis model. Interestingly, there was no clear reduction in 
AMIGO3 expression, except that the strongest staining appeared to redistribute to 
some degree to appear in a linear distribution, presumably along axons, although it 
should be noted that was a degree of variability between samples with some samples 
not showing any change in the distribution. Furthermore, when pixel analysis was 
performed, there was no clear sign of any increase in AMIGO3, however there was a 
potential decrease at this stage, although this was minor and not found to be 




Fig 5.17: Representative DAB IHC for AMIGO3 in relapsing-remitting EAE samples. 
Samples were counterstained with eosin. The intensity of the DAB staining remains 
relatively low and constant in both EAE and untreated groups. Samples were 
counterstained with haematoxylin. Scale bars represent 100μm, n=6 for EAE 




Figure 5.18: AMIGO3 protein expression in MS samples. AMIGO3 expression 
appears to reduce slightly in both tissue samples from MS patients, both in lesions 
and NAWM, although no significance was found between any of the groups. Error 




quantitative nature of our analysis methods that we were unable to identify these 
changes. Furthermore, when MBP was also analysed to examine the extent of 
demyelination, we did not observe any changes between the optic neuritis group and 
untreated controls. Although we were aiming to examine AMIGO3 in the acute stages 
of disease, prior to extensive demyelination, it appears that the model may have 
been insufficient to induce a significant disease state. It should also be noted that 
due to the low time course allowed for disease progression, it was not possible to 
examine how far the disease had progressed prior to sample collection. As such it is 
very possible that animals may have experienced variable disease progression which 
may not have been significant enough to induce a noticeable disease state. To 
further examine the expression profile of AMIGO3 in demyelinating disease, more 
progressed EAE models were examined. 
5.5.2 Evaluation of EAE models 
Due to the low level of demyelination observed in our optic neuritis model, we 
decided that it was prudent to examine AMIGO3 expression in a more developed 
model of EAE. Firstly we tested our acute model following a longer treatment period, 
specifically 14 and 19 days, which has previously been shown to develop low scores 
in EAE in our group (Ahmed et al., personal communication. As briefly discussed 
previously (section 3.4.3), we observed that there was a steady increase in the 
clinical score from a mean average score of treated animals of 0 at D14 to 1.2 at 
D19. At this stage flaccid tails were observed indicative of early EAE progression (Al-
Izki et al., 2012). It should be highlighted however that scoring is subjective, therefore 
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although we did see a clear increase in the scores there is a risk of researcher bias in 
the scoring system. 
It is interesting to note that there was a variation between the level of 
demyelination observed in the white matter of lumbar sections, between the D14 and 
D19 samples. At D14, there appeared to be relatively low levels of MBP in the EAE 
induced animals compared to the untreated controls. This reduction in MBP staining 
was much less marked in D19 samples. It is not clear why this would have been the 
case, however one explanation is that the model exhibited some recovery within the 
timeframe. The model was a mild form of acute inflammatory induced demyelination, 
thus it is possible that the demyelination may have stopped by D19. It is also possible 
that we observed some early stages of remyelination by D19, hence the increased 
MBP signal. 
 We further tried to examine other signs of EAE progression to determine whether 
the model demonstrated signs of disease progression. As discussed, EAE 
progression is demonstrated by an increase in the numbers of local microglia (OX42+ 
cells) as well as an increase in the numbers of invading T-helper cells (CD4+). 
Although not considered the initiator, cytotoxic T-cells (CD8+) are also present to 
some degree as the disease progresses. Additionally, as axons are lost, there is an 
increase in reactive gliosis as astrocytes fill in the damaged area, creating glial 
filaments and leading to the production of a glial scar (Correale and Farez, 2015). 
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We generally observed very minimal positive IHC signal for all of these markers, 
although some variability was observed. One sample did show strong staining for 
OX42 surrounding the central canal at D14 indicating that some of the animals did 
experience a degree of inflammation through activation and recruitment of microglia. 
This observation however was only detected in one of the groups, therefore it 
highlights that there is significant variation between groups. Furthermore, as only one 
sample in the earliest collection time point demonstrated this inflammatory marker, it 
supports the view that the model may be observing the remyelination period rather 
than the active demyelination period. 
Again, as with OX42, CD4+ and CD8+ staining was not detected to any relevant 
degree, indicating a lack of T-cell recruitment to the spinal cord. These data indicate 
that there had been a minimal inflammatory response, or if it was present, that it was 
regressing by the time of collection. It is likely due to the increasing signs of MBP and 
the limited sign of inflammatory cells and reactive gliosis, that by the time of tissue 
collection, the samples had already experienced demyelination, and remyelination 
was occurring. Alternatively, the models had simply not experienced sufficient 
disease induction. 
 The lack of development may be a result of the variation in our procedure 
compared to similar studies. Pertussis toxin is traditionally injected subcutaneously 
with the Mog-35-55 to further elicit the immune response (Zeinali et al., 2018). We 
decided against this protocol based on our previous investigations as without the 
pertussis toxin our model should have lead to a less developed form of 
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demyelination. Although our scoring does appear reduced compared to the traditional 
method, the disease induction may have been too light to provide a sufficient 
response for examining the expression of AMIGO3 during demyelination. Due to the 
lack of clear and consistent signs of demyelination as well as the minimal signs of 
disease progression within the groups in both D14 and D19 samples, it was decided 
that we would employ another model of EAE to examine a more progressed form of 
the disease. 
We decided to examine the relapsing-remitting model of EAE, with samples 
gratefully received from Professor David Baker and Dr Gareth Pryce (Blizzard 
Institute, Barts and London Medical School). Due to the samples being fixed with 
formal saline (containing 4% formaldehyde and 8.5g/L sodium chloride) for multiple 
days before processing, it was not possible to perform immunofluorescent IHC due to 
the high amount of background signal created by the fixation process. As a result, 
myelination was analysed by examine MBP+ signal through DAB staining. A clear 
reduction in the MBP levels was observed between the relapsing-remitting EAE 
induced samples when compared to the untreated controls.  
It should be noted however that EAE, and MS, do not demonstrate even 
demyelination across the spinal cord, instead having focal regions of demyelination 
(Barnett and Prineas, 2004; Linker and Lee, 2009; Boyd et al., 2013). This might 
explain why different degrees of demyelination were observed in the relapsing-
remitting model of EAE. Time constraints meant that it was not possible to examine 
the entirety of the spinal cord. It is very possible that despite our efforts to select 
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sections where demyelination appeared, that we may have chosen sections where 
lesions were not developing. As such it was decided to analyse AMIGO3 expression 
via western blots, so that an average of the expression in the lumbar section of the 
spinal cord, both in MSWM and NAWM could be analysed compared to healthy 
levels. This approach should have helped to remove some of the variability between 
samples.  
5.5.3 AMIGO3 in EAE 
We observed in our relapsing-remitting model of EAE, that AMIGO3 levels were 
significantly raised compared to healthy controls. These data indicate that AMIGO3 is 
likely to be playing a role in the development of disease in this model of EAE. As the 
model is relapsing remitting, it is likely that animals at a score of 4 are experiencing a 
degree of acute inflammation in the spinal cord. As such, we can conclude that 
AMIGO3 levels are raised in lumbar spinal cords during bouts of inflammation 
induced demyelination. 
Although not completed in this study, it would have been valuable to investigate 
whether LINGO1 levels were raised at a similar time point to AMIGO3, or if AMIGO3 
increased expression precedes LINGO1 as it does in spinal cord injury (Ahmed et al., 
2013). A recent study has analysed the levels of LINGO1 mRNA in acute and chronic 
forms of MOG35-55 induced EAE (Theotokis et al., 2016). They found that although a 
minor increase in LINGO1 was observed in spinal cords at the acute stage, this was 
not significant. It was not until the disease was deemed chronic, that a significant 
upregulation of LINGO1 mRNA was observed in the spinal cord samples. As this 
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form of EAE is a chronic progressive model, with a low clinical score, it is unlikely to 
experience major stages of inflammation. As such, our relapsing-remitting model, 
developed a score 4 after the second relapse (Al-Izki et al., 2012) and therefore 
sample collection is likely to have followed a large inflammatory response. Although 
this raises difficulties in directly comparing the results, it could be argued that the 
relapsing-remitting model would demonstrate a more severe acute response, 
therefore the rise in AMIGO3 expression is likely to correlate with the acute damage 
to the CNS, rather than a chronic build up. As such these data suggest that AMIGO3 
is raised at an earlier stage than LINGO1. It should be stated again however that the 
different models and analysis techniques raise questions to this conclusion and it is 
essential to evaluate the levels of AMIGO3 and LINGO1 in our EAE model so that a 
direct comparison can be procured. 
We were unable to confirm the localisation of AMIGO3 to a certain cell type, due to 
the variability in previous AMIGO3 immunofluorescence experiments and the lack of 
clear AMIGO3+ staining with our DAB staining protocol. It is likely that our anti-
AMIGO3 antibodies were lacked the specificity to identify AMIGO3 levels through 
IHC as previously observed (chapter 3). As such, it still remains to be answered 
whether AMIGO3 expression is changed in specific cell types in demyelinating 
disease. It should be noted however that changes in expression in non-OLG cells 
could also lead to changes in activity in OLG due to potential homotypic interactions 
of AMIGO3, and its potential to signal intercellularly in a similar manner to LINGO1 
(Kuja-Panula et al., 2003; Jepson et al., 2012). 
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5.5.4 AMIGO3 in MS lesions 
From our investigation, we observed a non-significant decrease in AMIGO3 in both 
the MSWM and NAWM compared to healthy control white matter. It should be noted 
that this study had only a small sample size, therefore it is possible that significance 
would have been detected had a greater number of replicates been possible. This 
would be an interesting finding if correct. This could indicate that in developed MS, 
AMIGO3 based therapies may not prove beneficial due to the lack of expression. 
This of course ignores the concept that the proteins may be relocated to areas of 
higher activity in OLG following trauma so the reduced levels may not be indicative of 
reduced activity. 
Interestingly, if the minor reductions in AMIGO3 in MS tissue that we observed are 
correct, then it is interesting to note that the reductions occur in both MSWM and 
NAWM. This is unexpected as ‘healthy’ white matter tissue in MS patients would not 
be expected to change levels as they have not received any direct trauma. 
Conversely however, axonal loss has been observed in NAWM suggesting that these 
expression changes may relate to the loss of axons (Constantinescu et al., 2011). As 
both LINGO1 and AMIGO3 are expressed within axons (Mi et al., 2004; Ahmed et al., 
2013), it is possible that potential increases in protein expression in OLG, as 
suggested from our and other EAE studies, may be counteracted by a reduction in 
axonal expression due to this loss of axons (Theotokis et al., 2016). An alternative 
interpretation of this MS data is that AMIGO3 does not play a significant role in the 
human demyelinating disease. However, as stated above the sample sizes used in 
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this study were low, thus additional replicates would be required to confirm this 
interpretation. 
5.5.5 AMIGO3 and LINGO1 in demyelinating diseases 
Based on our data, it appears that AMIGO3 is upregulated following significant 
inflammation and trauma to the mouse CNS. It is still yet to be determined whether 
this increase is seen earlier than LINGO1, however the delay in LINGO1 mRNA 
displayed in both spinal cord and chronic progressive EAE is likely indicative that 
AMIGO3 is upregulated preferentially in early stages of disease (Ahmed et al., 2013; 
Theotokis et al., 2016). 
 Furthermore, it would appear that AMIGO3 has a more active role in acute 
stages, and potentially is no longer relevant in chronic disease, due to the relatively 
reduced or similar expression levels between human healthy and MS lesions in brain 
white matter. Direct comparisons between our MS and EAE data should be taken 
with caution due to the differing white matter regions and models examined though. 
5.5.6 Limitations 
A number of limitations are present from this study. Firstly, relatively low sample 
sizes were used due to time and financial constraints. Further repeats would be 
valuable to confirm our findings. 
In the terms of our models, it has to be noted that although EAE is considered a 
valuable animal replication of MS, there have been a number of therapeutic 
approaches that have proven successful in EAE but have not translated into MS 
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therapies. This indicates that there must be a significant difference between the 
human disease and disease progression in the EAE models (Baker and Amor, 2015). 
Despite these issues, the results still provide an insight in to the potential role of 
AMIGO3 in demyelinating disorders. 
 Although in our MS study there was selection between lesion sites and NAWM, 
this was not possible in our EAE studies due to time constraints. As a result, we were 
unable to compare whether the increased expression of AMIGO3 that we observed in 
our EAE samples is specifically located within lesion site, within the unaffected white 
matter, or a general change across the whole matter. 
It is also pertinent to mention that our relapsing-remitting samples were not 
analysed in this study to determine the extent of inflammation. Previous studies have 
shown that inflammation is significant and that due to the development of the 
disease, that significant immune infiltration will have occurred, however it would be 
valuable to define this for our own study (Al-Izki et al., 2012). 
One major limitation is that our EAE studies used untreated controls rather than 
sham treated controls. It is possible, although unlikely, that some of the responses 
that we observed were due to treatment procedure alone, rather than the induction of 
EAE itself. This has been the traditional approach for EAE studies, however it would 
be valuable for repeats to re-examine the results with sham treated subjects to 
remove this variability. 
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5.5.7 Future studies 
Firstly, it would be interesting to repeat the experiments in a number of different 
EAE models to confirm whether our findings are indicative of a general change in 
demyelinating states or whether it is specific to the models that we used. 
Despite our progression in understanding the expression profile of AMIGO3 in 
demyelinating disease, we are still to determine the potential methods through which 
AMIGO3 could act in vivo and in MS. It would be very interesting to firstly repeat 
these experiments but analyse the level of expression with particular cell lines. This 
could be done through FACS to separate cell lines prior to analysing the levels of 
mRNA or protein, however it is possible that the FACS process could alter 
expression or limit the number of cells available for further analysis.  
Furthermore, a study altering the levels or action of AMIGO3 in vivo would be 
fascinating to gain an insight into potential roles for AMIGO3 in disease. This could 
be done through genetic modifications, through addition of active AMIGO3, or 
through inhibiting the action of AMIGO3 through antibody therapies. Despite being an 
important part of our experimental design, the cost of providing an effective inhibitor 
of AMIGO3 for the full period of an EAE study was not viable. Therefore it was not 
possible to investigate the effects of inhibiting AMIGO3 on a model of demyelination. 
This would be an invaluable piece of information as it would present whether 
AMIGO3 based therapies would have any direct impact on demyelination in vivo. 
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Interestingly, Theotokis et al (2016) noted that there was a shift between TROY 
and P75 mRNA expression between acute and chronic forms of EAE in C57BL/6 
mice. TROY was expressed at higher levels in the acute stages, with P75 levels 
increasing whereas TROY levels decrease in chronic form of the disease. It is 
possible that these change in co-receptor molecules could show preferential binding 
to either LINGO1/AMIGO3, thus potentially indicating a method for AMIGO3 to act 
with the NgR1 receptor complex over LINGO1 in different stages of EAE 
development. This raises an interesting further study to determine whether there is 
any competition between the proteins in OLG responses to demyelination. This 
hypothesis is reliant on NgR1 being expressed in OLG, therefore further work is 
required to confirm this concept.  
5.5.8 Conclusions 
We conclude from this study that AMIGO3 levels rise following inflammatory 
induced demyelination in murine EAE. A significant inflammatory response is 
required however before AMIGO3 expression is upregulated. It is likely that the 
elevated levels of AMIGO3 have an effect on OLG. However, it still remains to be 
answered exactly what impact AMIGO3 will have on the cells. Chronic MS lesions 
showed reduced AMIGO3 expression, potentially due to the loss of neural cells, 
predominantly neurons, but OLG as well. Further work is required to confirm whether 
this reduction is related to the differentiation potential or level of OPC in chronic 

















In this project so far, we have predominantly been investigating the expression 
profile of AMIGO3 during models of disease states, however there has yet to be any 
evidence published which analyses the potential pathways through which AMIGO3 
could function, the levels of AMIGO3 during myelination and the potential effects of 
altering AMIGO3. As we have discussed, AMIGO3 has been identified in OLG and 
we have identified that AMIGO3 is raised during excitotoxic trauma to the cells. 
AMIGO3 shares a number of attributes with LINGO1, and has been shown to be 
able to interact with the NgR1 receptor in both neurons and COS7 cells transfected 
to express both AMIGO3 and the NgR1 receptor complex proteins. Therefore it is 
likely that AMIGO3 shares a similar mechanism of action in OLG (Mi et al., 2004; 
Ahmed et al., 2013). There is some debate as to whether LINGO1 is able to function 
through the NgR1 receptor in OLG as traditionally, LINGO1 was shown to be able to 
function through the NgR1 receptor in both COS-7 cells and neurons leading to 
growth cone collapse in regenerating axons in a RhoA dependent manner. More 
recent evidence has been found suggesting that in OPC LINGO1 is able to function 
via interactions with a number of proteins, including ErbB2, gelsolin and PI3K (Foale 
et al., 2017). 
As previously discussed (section 1.4.2.2) there is some debate about whether 
NgR1 is present on OLG. Data supporting NgR1 expression on OLG tends to be 
generated from OPC cells derived from neural stem cell lines or entirely different cell 
lines altogether (Jepson et al., 2012; Mi et al., 2013; Kwon et al., 2014). Furthermore, 
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it has been reported that OL do not express NgR1, albeit without evidence (Mei et al., 
2013), and studies with a human hybrid oligodendrocyte hybrid cell line, MO3.13, 
demonstrate P75 expression, but a lack of NgR expression at both the transcript and 
protein level (Bourikas et al., 2010). The MO3.13 data demonstrates evidence of a 
lack of OLG expression of NgR1, however it should be highlighted that these cells 
are a hybrid line with human rhabdomyosarcoma cells, and have been shown to also 
express the astrocyte marker GFAP, therefore they do not exhibit a purely OLG 
phenotype (McLaurin et al., 1995). Despite this data there is no clear consensus as 
to whether the NgR1 receptor complex is expressed on OLG, therefore it is of value 
to examine the expression of the proteins in primary OLG cell lines. 
Furthermore, despite our repeated findings of changes in AMIGO3 levels in 
various models of myelination, there has yet to be a direct link to OLG maturation or 
myelin production. As such, it was deemed necessary to examine the expression 
profile of AMIGO3 in primary OPC cultures following and during the maturation 
process. 
6.2 Aims 
The aim of this study is to investigate whether any of the proteins of the NgR1 
complex are present in primary OLG to determine whether NgR1 signalling could be 
a mechanism through which AMIGO3, and LINGO1 could function. We also aim to 




We hypothesise that: 
- NgR1 receptor proteins will be expressed on OPCs to allow for AMIGO3 
signalling in the immature cells. 
- NgR1 will not be present on mature cells as its role in inhibiting maturation and 
myelin production will no longer be relevant. 
- AMIGO3 will also be downregulated following maturation. 
6.3 Experimental design 
6.3.1 NgR1 expression in OLG 
Primary OPC were collected and grown as previously described (section 2.2.1.1). 
These cells were used for ICC studies to examine for markers of OLG and to 
characterise the cells for NgR1 receptor complex proteins. 
6.3.1.1 IHC in OLG cultures 
For ICC imaging of OPC cultures, following collection and resuspension of OPCs 
as described (section 2.2.1.1), the cells were then seeded at 25,000 cells per well on 
Matrigel coated, 8 well chamber slides (Corning Falcon). Cells were incubated at 
37ºC, 5% CO2 for 24 hours. Following incubation, cells were fixed and IHC was 
performed as described (section 2.3.2.3). OPCs were labelled for the OLG marker 
Olig2 (Cai et al., 2007; Maglione et al., 2010), the OPC marker NG2 (Clarke et al., 
2012), the microglia marker OX42 (Alrehaili et al., 2018), the astrocyte marker GFAP 
(Kundi et al., 2013) and NgR1 and P75. 
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For mature OLs, OPCs were similarly seeded on 8 well chamber slides for 24 
hours. However maturation treatment was performed as described (section 2.2.1.1). 
On D5, cells were fixed and IHC was performed as described (section 2.3.2.3). OLG 
were then labelled for Olig2 & CC1 and NgR1. 
6.3.2 AMIGO3 expression during maturation 
AMIGO3 and PLP levels were analysed at the transcript level by qPCR to examine 
the expression of AMIGO3 during maturation. Following collection of primary OPCs, 
cells were seeded at 25,000 cells per well in a Matrigel coated 48 well plate as 
previously described (section 2.2.1.1). At D1 post-shaking, primary OPCs were 
collected with a cell scraper and mRNA/cDNA collected and generated as previously 
described. 
OPC were treated to induce maturation and mRNA/cDNA samples were similarly 
collected and generated on D5 post-shaking. For transfections, on D11 when 
maturation was encouraged, SATO media was supplemented with Opti-MEM (8% 
v/v) containing lipofectamine (8% v/v) and 40nM siRNA. Samples were incubated 
with the siRNA for 6 hours at 37ºC, 5% CO2 before a full media change with SATO. 
Normal maturation treatment was continued from this step and samples were 
collected on D5 post-shaking. 
6.3.3 Experimental plan 
A summary of the plan for the investigation, findings and experiments used is 





Figure 6.1: Flow chart demonstrating the plans and summarising the findings from 




6.4.1 NgR1 in OLG 
6.4.1.1 Characterising primary OPC 
We first attempted to characterise our primary OPC cultures to confirm their OLG 
identity. Olig2+ staining could be seen in the majority of cells, with DAPI+ and Olig2+ 
matching for the majority of cells in our samples (fig 6.2). We then attempted to 
characterise the maturity of the cells through NG2 and CC1 ICC (fig 6.3). Although 
not clear in all of the imaged cells, NG2+ was observed surrounding the majority of 
DAPI+ nuclei (fig 6.3A & B). In a number of cells, NG2+ staining demonstrated clear 
staining across the cell, with the soma and processes highlighted. Interestingly, 
multiple processes could be seen from these cells. CC1+ staining was also observed 
in some cells, but the signal was relatively weak and centred immediately around the 
nucleus in the soma (fig 6.3 C & D). Just under half of the cells appeared to present 
some CC1+ staining, however this was not quantified. 
Having confirmed the OLG identity of these cultures, OX42 and GFAP IHC was 
performed to identify if there was any contamination in our primary OPC cultures (fig 
6.4). OX42+ staining was not observed in any of our samples (fig 6.4A & B). GFAP 
did show small levels of positive staining above the threshold value, however this did 
not localise to cells or demonstrate the expected staining profile, therefore this likely 





Figure 6.2: Representative Olig2 ICC in cultured primary OPC. 2 images are 
shown, from different cultures within the same group of the study. (A & B) Samples 
were counterstained with DAPI (blue). Olig2 and DAPI are colocalised in the majority 
of cells. The majority of cells demonstrate Olig2+ staining in the nucleus. (C & D) the 
same images are shown however without DAPI signal was removed. Scale bars 




Figure 6.3: Representative NG2 (A & B) and CC1 ICC (C & D) in cultured primary 
OPC. 2 images are shown, from different cultures within the same group of the study. 
Samples were counterstained with DAPI (blue). (A & B) NG2+ (green) is seen in a 
number of the cells and appears to label the soma and processes of the cells, 
indicative of OPC. (C & D) CC1+ (red) is present, however only a few of the cells 
demonstrate positivity, indicating that some of the cells have, at the least, begun to 




Figure 6.4: Representative OX42 (A & B) and GFAP (C & D) ICC in cultured 
primary OPC. 2 images are shown, from different cultures within the same group of 
the study. Samples were counterstained with DAPI (blue). (A & B) OX42+ (green) 
was not observed in any of the samples. (C & D) GFAP (green) was seen at low 
levels, likely representing minor contamination of astrocytes. Scale bars represent 





GFAP+ cells. It is also possible that GFAP+ cells may have infiltrated the cultures but 
were not able to survive in the new media as well as the OLG. 
6.4.1.2 NgR1 in immature OPCs 
NgR1 and P75 expression was analysed in our OPC cultures (fig 6.5). We 
observed strong NgR1+ ICC signals localised in a bipolar distribution as well as within 
the soma (fig 6.5A & B). Almost all DAPI+ cells demonstrated NgR1+ staining 
surrounding the nucleus indicating that the majority of cells are positive for the NgR1. 
P75 ICC was also performed (fig 6.5C & D) which showed similar results. Almost all 
cells demonstrated positive staining around the DAPI+ nucleus suggesting a somal 
distribution. Interestingly, the signal was not as strong as NgR1 and images had to 
be enhanced to clearly identify positive staining over the thresholded value. 
6.4.1.3 AMIGO3 and LINGO1 in OPCs 
AMIGO3 expression was relatively limited within our OPC cultures (fig 6.6A & B). 
Not all of the DAPI+ cells showed co-staining with AMIGO3+ signal, however there 
does appear to be AMIGO3 staining within the soma of most cells to some degree. 
LINGO1+ staining was also analysed in the primary OPCs (fig 6.6C & D). Similarly, 
LINGO1 was not observed in all cells however the majority of DAPI+ nuclei also 
exhibited LINGO1+ staining. Interestingly, the LINGO1+ staining largely matched the 






Figure 6.5: Representative NgR1 (A & B) and P75 (C & D) ICC in cultured primary 
OPC. 2 images are shown, from different cultures within the same group of the study. 
Samples were counterstained with DAPI (blue). (A & B) Clear images could be taken 
of NgR1 staining (green) in primary OPC, appearing to be distributed throughout the 
soma of the cells and in the processes. (C & D) P75+ (green) was observed in the 
majority of cells as well. P75 demonstrated localised staining to and immediately 







Figure 6.6: Representative AMIGO3 (A & B) and LINGO1 (C & D) ICC in cultured 
primary OPC. 2 images are shown, from different cultures within the same group of 
the study. Samples were counterstained with DAPI (blue). (A & B) A large number of 
the DAPI+ cells demonstrated low levels of AMIGO3 in the SOMA of OPC. (C & D) 
Most cells demonstrated LINGO1+ staining which tended to correlate with DAPI+ 
nuclei, suggesting a lack of LINGO1 distribution across the soma and membrane of 
the cells. Scale bars represent 100μm, n=3. Insets show negative controls.
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6.4.1.4 NgR1 in mature OL 
Following incubation with maturation media to encourage maturation of the cells, 
we performed ICC for OLIG2 and CC1 (fig 6.7A & B) to confirm that the cells had an 
OL phenotype. Strong and extensive CC1+ ICC signals surrounded the majority of 
Olig2+ nuclei. Some cells expressed lower levels with minor signal, however 
generally the CC1 signal was more intensive and more extensively distributed than 
that observed in the untreated cultures (fig 6.3C & D). 
The maturation media incubated cells were also stained for NgR1 (fig 6.7C & D). 
Most of the DAPI+ regions demonstrated a region of NgR1+ IHC in the immediate 
vicinity. Although not comprehensive, it is possible to see that the NgR1+ staining 
appeared in small clumps, potentially a vesicular distribution, rather than the bipolar 
distribution observed in the primary OPC cultures (fig 6.5A). 
6.4.2 AMIGO3 and primary OPC maturation 
AMIGO3 mRNA expression was examined in primary OPC following incubation 
with maturation media (fig 6.8). Firstly, a large variation was observed with AMIGO3 
expression in these primary cells before treatment was administered. The relative 
levels of AMIGO3 mRNA normalised to the untreated controls was 1.48±0.67. No 
significant change was observed following induction of maturation (P>0.05) , with the 
mature cells having a relative level of AMIGO transcript of 1.43±0.45. We also 
analysed the levels of PLP transcript expression to determine the extent of myelin 




Figure 6.7: Representative CC1/Olig2 (A & B) and NgR1 (C & D) ICC in cultured 
primary OPC cultured in maturation media for 5 days prior to imaging. (A & B) CC1+ 
(red) was observed clearly surrounding the majority of Olig2+ (green) nuclei, 
demonstrating a high proportion of cells having matured. (C & D) samples were 
counterstained with DAPI (blue). NgR1+ (green) staining was observed in small 
clusters immediately surrounding DAPI stained nuclei. Scale bars represent 100μm, 




Figure 6.8: RT-qPCR analysis of AMIGO3 mRNA expression in primary OPCs in 
AMIGO3 maturation studies. Pure OPC cultures were examined for AMIGO3 
expression prior to treatment (represented as maturation media negative), and 
following treatment with maturation media alone. A high variation was observed in 
AMIGO3 transcript levels, which do not appear to alter between OPC and OL. Error 





Figure 6.9: RT-qPCR analysis of PLP mRNA expression in primary OPCs in 
AMIGO3 maturation studies. Pure OPC cultures were examined for PLP expression 
prior to treatment (represented as maturation media negative), and following 
treatment with maturation media alone. PLP mRNA is observed to increase following 




seen to significantly increase (P<0.01) over tenfold from 4.94±4.61 to 69.75±7.63 
after 5 days of incubation in the differentiation medium. 
6.5 Discussion 
6.5.1 Characterisation of primary OLGs 
Our data shows convincing evidence that the majority of our primary cells are in 
fact OPCs. The majority of cells imaged clearly have Olig2+ and NG2+ staining, 
indicating that they are of OLG descent and that they are immature in nature. 
Unsurprisingly, there were minimal signs of contamination similar to previous reports 
(O'Meara et al., 2011). We did not observe any OX42+ staining, demonstrating 
negligible infiltration of microglia, and we also did not observe any clear definitive 
GFAP+ staining. The minor GFAP+ staining that we did observe did not demonstrate 
its normal phenotype (Cho and Messing, 2009) and appeared in small clusters that 
did not associate with cells. This likely represents a small degree of infiltration, or it 
could even represent that the astrocytes were not able to survive in the SATO media, 
although as astrocytes are much more adept at surviving than OLG, this would 
appear unlikely (Burman et al., 2014). Due to the cells demonstrating clear OPC 
markers and there being minimal signs of infiltration of other glial cells, it is very likely 
that these primary cultures will be a strong model for looking at AMIGO3 and NgR1 
expression in OLG. Additionally, as they are primary cells, they are unlikely to 
express additional markers outside of the OLG lineage as can be the case with 
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immortalized cell lines, such as the MO3.13 cells expressing the astrocytic marker 
GFAP (McLaurin et al., 1995). 
Following characterisation of the OPCs, we encouraged primary OPCs to mature 
by removing bFGF and PDGF-AA from the media. Following maturation treatment we 
performed ICC analysis to determine the phenotype of the cells. Firstly we co-stained 
with Olig2 and CC1 to investigate the numbers of Olig2+ OLG that also expressed the 
mature OL marker CC1. The vast majority of the Olig2+ cells in the OPC that had 
received maturation treatment, demonstrated clear CC1+ staining, with a bright stain 
surrounding the Olig2+ nucleus, very similar to the staining observed in vivo in our 
previous studies (section 3.3.2). Significantly clearer staining was observed for CC1 
in the maturation treated cells compared to the primary OPC cultures. Furthermore 
the vast majority of OLIG2+ cells in the matured cultures demonstrated CC1+ ICC, 
indicating a high proportion of the cells had successfully matured or were maturing. 
These observations provide strong evidence that our protocol was effective at 
producing primary OPCs that rapidly mature following the removal of the mitogenic 
factors bFGF and PDGF-AA. The only limitation with the protocol was that we tended 
to generate relatively low overall numbers of cells, therefore it was difficult to perform 
analyses on large numbers of the samples. 
6.5.2 The NgR1 receptor complex in OLG 
We imaged primary OPCs and OLs to determine whether NgR1 receptor complex 
proteins were present. Interestingly the OPCs that we imaged demonstrated a clear 
sign of NgR1 signal. Furthermore, we also imaged our OPCs for P75, with positive 
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ICC signal as well. NgR1+ staining in OPCs appeared to generally follow a bipolar 
distribution, although in some samples NgR1 appeared concentrated in the soma or 
localised to one side of the cell, based on DAPI+ staining. P75 distribution was more 
centred around the nucleus. However P75 also displayed a bipolar distribution, albeit 
less defined. These data clearly show that in mice primary OPCs two of the proteins 
involved in the tripartite NgR1 receptor complex (Mi et al., 2004; Ahmed et al., 2013) 
are present. Although this may not be the case with human OPCs, or even rat OPCs, 
this demonstrates that AMIGO3 and LINGO1 are very likely to be able to able to 
signal the NgR1 receptor in mouse OPCs. 
On top of our evidence of NgR1 and P75 in OPCs, we also demonstrated positive 
staining for NgR1 in differentiated OLs. However, the distribution did not follow the 
same pattern as in OPCs. NgR1 appeared in small globules which tended to be in 
small clumps, rather than spread throughout the soma as with the OPCs. It is 
possible that NgR1 appears in small collections on the membrane of OLs, however 
the data also points to a vesicular distribution. This suggests that NgR1 is being 
internalised and removed from the membrane, although more functional studies 
would be required to confirm this. Patch clamp analyses involving myelin derived 
proteins within the pipette internal solution would be interesting to examine whether 
the NgR1 complex functions similarly on mouse OLGs at different stages, and 
whether this function is similar to that observed in neurons (Morris et al., 2016; 
Zabala et al., 2018). 
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We also imaged our OPCs for AMIGO3 and LINGO1, with positive ICC signal for 
both proteins. AMIGO3 distribution was irregular and not spread evenly across cells, 
and LINGO1 was found to be located largely in the nucleus. It has to be highlighted 
however that neither AMIGO3 nor LINGO1 provided strong signal through ICC, with 
adjustments of minima and maxima pixel displays required to make the staining 
visible. It is possible that the antibodies do not show high signal in this model. 
However, this data also suggest that protein levels of AMIGO3 and LINGO1 were 
relatively low in our cells. Despite these issues, the data clearly shows that both 
AMIGO3 and LINGO1 are expressed in our cultured OLGs, demonstrating that all 
three components of the tripartite NgR1 receptor complex are present and 
presumably are able to function on mouse OLG. 
It would not be surprising to find the functional NgR1 receptor complex on OLG as 
this would provide a mechanism to prevent excessive myelination from taking place, 
assuming our hypothesis that AMIGO3 inhibits myelination is correct. It is well 
established that cues from axons are involved in the regulation of where and how 
much myelin is produced (Arancibia-Carcamo and Attwell, 2014). Despite this, 
signalling between OLG is likely to play a role in limiting the amount of myelin being 
produced, and hence interfering with the nodes of Ranvier. As NgR1 is activated by 
proteins derived from myelin, it is likely that neighbouring myelinated OLG processes 
will prevent new unmyelinated processes from binding to axons alongside the 
already developed myelin sheath. Despite our evidence of NgR1, P75 and 
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AMIGO3/LINGO1 being present on OLG, specifically in OPCs, we have not analysed 
the potential functions of these proteins. 
6.5.3 AMIGO3 in primary OPC development 
We next analysed the levels of AMIGO3 during maturation. Due to the relative low 
numbers of cells, and therefore low amount of samples we could collect, we decided 
to analyse the mRNA expression of AMIGO3 before and following maturation 
treatment. PLP mRNA expression was also analysed as a marker for myelin gene 
expression. We did not observe any change in the levels of AMIGO3 between D1 ( 1 
day after seeding primary OPCs and prior to maturation treatment) and D6 following 
the maturation treatment. This indicates that the levels of AMIGO3 transcripts do not 
alter during the maturation process. This presents an argument against the role for 
AMIGO3 in inhibiting the differentiation of OPCs. It is possible however that we have 
taken our observations at the wrong time point to observe this change. As such it 
would be interesting to observe if a similar trend occurs at earlier time points during 
the maturation process, rather than at a time point where most of the cells have 
become CC1+. We would expect to see AMIGO3 levels drop immediately after D1 
when the mitogenic factors, PDGF and bFGF, are removed, followed by a rise as the 
cells reach maturity. Our data may then suggest that AMIGO3 levels rise again after 
differentiation has occurred. 
6.5.4 Limitations 
Despite our attempts to reduce variability, there are a number of limitations with 
this investigation. Firstly, as discussed, our sample sizes were relatively small, as a 
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result of time and financial constraints. Repeats with larger sample sizes would help 
to provide a greater confidence with our results. It has to be noted that in our primary 
OPC studies, we were only able to maintain a sample size of 3 for each treatment 
group due to time constraints and limitations in the numbers of samples that we could 
obtain from one litter. To ensure that samples received the same treatment, studies 
were conducted with the cells grown from one litter of pups, therefore the number of 
cells and samples we received was directly correlated with the litter size. Ideally, we 
we would maintain a larger breeding colony and ensure a larger supply of pups 
however this was not possible for this study. 
Furthermore, in regards to our ICC study, we have not provided quantitative 
results. Cell counts should be performed to provide quantitation of the findings in this 
chapter. It would be interesting to examine the expression of our proteins of interest 
cells whilst co-staining for cell specific markers, such as CC1 and NG2. 
6.5.5 Further studies 
As we have determined that NgR1 is in fact present on mice OLG, it would now be 
interesting to determine whether AMIGO3 and LINGO1 are able to interact with the 
receptor complex and whether this will produce the characteristic RhoA responses in 
OLG cells. This could be analysed through Co-IP with AMIGO3/LINGO1 and 
NgR1/P75/TROY. A RhoA G-LISA assay would also be beneficial to determine the 
response of inhibiting AMIGO3 in cultured OLG to determine whether the traditional 
RhoA signalling pathway is active in these cells. 
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Another interesting point is that we have discussed previously is that AMIGO3 is 
both a heterodimer and homodimer. Although AMIGO3 levels do not appear to alter 
much within our cells during the maturation phase, it is possible that levels alter on 
neighbouring glia or neurons. In addition, a more detailed time course examining the 
expression of AMIGO3 mRNA should be conducted during and following the initiation 
of OPC differentiation. 
Finally, we have only examined the levels of AMIGO3 in during injury treatments 
(Chapter 4), or whilst encouraging primary OPCs to mature. As levels of AMIGO3 
have been shown to rise following trauma, it would be interesting to examine how 
levels of AMIGO3 alter following trauma induced during the differentiation process. It 
would be interesting to examine how trauma affects the primary OPCs ability to 
differentiate. It is possible that AMIGO3 has relatively minor relevance in the healthy 
model, but becomes more significant in a disease/injury state. As such, OPCs 
encouraged to mature following trauma could potentially have altered AMIGO3 
expression which could affect their ability to mature. 
6.5.6 Conclusions 
From this study, we can conclude that NgR1 and P75 are expressed on mouse 
primary OLGs, and that in OPCs, the NgR1 receptor complex is likely to be 
functional. In addition this work confirms that AMIGO3 is expressed by mouse OPC, 
and that LINGO1 appears to exhibit a nuclear localisation in these cells. Finally 
AMIGO3 levels did not alter during OPC differentiation although a finer temporal 















7.1 General conclusions 
7.1.1 AMIGO3 in models of myelination 
The purpose of this study was to determine the role of AMIGO3 in remyelination. 
As such, we examined the expression profile of AMIGO3 in models of myelination 
and remyelination. Namely, we examined the expression profile of AMIGO3 in the 
neocortex during postnatal development, following the stages of myelination, as well 
as in demyelinating disease models and in vitro cell cultures. 
Our data suggests that in both developmental stages of myelination and in EAE, 
that AMIGO3 is upregulated. Specifically in development, this upregulation of 
AMIGO3 drops immediately prior to the production of MBP, whereas our EAE model 
did not show clinical improvements whilst AMIGO3 protein levels remained raised. 
Although it should be highlighted that we were unable to quantify AMIGO3 in OPCs 
alone, these data provide a strong correlation between AMIGO3 expression and a 
reduced sign of OPC maturation and myelin production. 
Counter to our hypothesis, AMIGO3 levels did not change between primary OPCs 
and primary OPCs following maturation treatment. This suggests that AMIGO3 has 
no role in the maturation process, at least in this model as signs of maturation were 
observed. Furthermore, we observed a decrease in PLP mRNA when AMIGO3 was 
knocked down. This provides evidence of AMIGO3 actually playing a positive role in, 
at least, myelination and potentially maturation of OPCs. This particular experiment 
had a number of limitations in that we had a limited sample size which prevented 
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some of the control groups, most notably a sham treatment group, and that we did 
not observe a significant reduction in AMIGO3 transcript following KD treatment, 
therefore the data can only be deemed preliminary. If AMIGO3 actually promotes 
OPC maturation, then it is difficult to explain the increased expression prior to 
developmental maturation. This concept would also put it at odds with data from 
LINGO1 studies which demonstrate an inhibitory effect considering the similar 
mechanisms of action observed between the two analogous proteins (Chen et al., 
2006; Sun et al., 2015; Zhang et al., 2015a). This is further highlighted by the 
presence of the NgR1 receptor on our primary OPCs which both AMIGO3 and 
LINGO1 are known to be able to interact with and aid with activation of the NgR1 
receptor complex (Mi et al., 2004; Ahmed et al., 2013). 
Furthermore, it is interesting to note that AMIGO3 levels were not increased in our 
acute stage optic neuritis model. We did however fail to observe any sign of 
demyelination when MBP was imaged by IHC. This suggests that this model, despite 
showing some clinical signs of disease progression, caused a limited response within 
the CNS. As discussed (section 5.5.1), it is possible that our model was too mild to 
induce significant damage to the CNS, and thus AMIGO3 may require a more 
significant input to induce a response. 
7.1.2 The role of LRRs in trauma models 
Our data does highlight the link between EAE disease progression and OPC 
excitotoxicity. Excitotoxicity has been well documented in regards to neurons in EAE 
but limited work has been done in regards to excitotoxicity to OLG in EAE (Mehta et 
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al., 2013). Interestingly, it is known that OPCs are able to respond to glutamate, one 
of the main signalling proteins involved with excitotoxicity, and excessive glutamate 
binding induces signalling which leads to apoptosis of the cell (Sanchez-Gomez et 
al., 2011; Begum et al., 2018). Despite this, there is still a need to examine the 
effects of this excitotoxicity in regards to demyelinating diseases. Our data showing 
that AMIGO3 is upregulated following AMPA-CTZ induced excitotoxicity could pose a 
potential pathway which affects OPC behaviour following this trauma. This is 
hypothesised to pathologically inhibit effective maturation of the affected OPCs. As 
excitotoxicity is linked with a number of neurodegenerative disorders including spinal 
cord injury, stroke and Alzheimer’s disease, as well as MS and numerous others, our 
data highlights the potential damage and obstruction to OPC maturation that may be 
accompanying these diseases (Mehta et al., 2013). Our data also suggests that 
neuronal damage may be essential to induce the release of glutamate which in turn 
inhibits OPC differentiation (Pal, 2018). 
It is unclear whether our primary OPCs can be deemed a traumatic model or not 
as the cells have been dissected, which in itself is trauma. Despite this, the extended 
period of culturing is likely to return the OPCs to a resting state and prevent 
activation of trauma induced pathways. Conversely, the procedure of shaking the 
cells to relieve the OPCs from mixed glial cultures could induce some degree of 
trauma. Despite these arguments, it appears that the primary culture model is not a 
model of trauma, and therefore the cells have not received the potentially necessary 
cues to promote AMIGO3 expression.  
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Finally, in terms of excitotoxic trauma, we observed that LINGO1 protein levels 
actually went down in the acute following 5hrs treatment. This further demonstrates 
that AMIGO3 appears to be more prevalent in the early stages of disease, matching 
previous reports following spinal cord injury (Ahmed et al., 2013). 
We believe that these studies show that AMIGO3 is upregulated preferentially to 
LINGO1 following CNS and OPC trauma, potentially largely in the form of 
excitotoxicity. It is not until significant injury that AMIGO3 is upregulated in OPC. We 
suggest that this trauma induced upregulation of AMIGO3 then inhibits OPC 
development, whether directly or intercellularly between local neurons, OPC and 
other glia, resulting in the pathogenic inhibition of remyelination in demyelinating 
diseases. Furthermore, it appears that AMIGO3 plays a role in early stages of 
development, which we believe inhibits OPC maturation. At the onset of 
developmental myelination, AMIGO3 expression is reduced and does not play a role 
in OPC inhibition until significant injury has occurred. Our theory appears to have 
similarities with a recent theory that normal developmental regulators of myelination, 
such as PSA-NCAM, are re-expressed following trauma on stressed axons which 
repel and inhibit local OPCs (Podbielska et al., 2013). 
7.1.3 AMIGO3 mechanism of action in OLG 
There is yet to be any data demonstrating how AMIGO3 is able to signal within 
OLG. As discussed however, AMIGO3 has been previously shown to function via the 
NgR1 receptor complex in DRGNs as well as transfected COS7 cells containing all 
the machinery for the receptor complex (Ahmed et al., 2013). As such, our data 
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which demonstrated NgR1 and P75 protein expression in OPCs, two proteins 
involved with the NgR1 complex, as well as NgR1 in OLs present a possible 
mechanism. It was also interesting to note that NgR1 appeared to be internalised in 
the mature cells, presenting evidence that the receptor is no longer functional, or that 
it has a reduced function in mature cells. The receptor complex may still have a 
function whilst internalised, however our observations indicate that it would no longer 
be able to interact and therefore signal from interactions on the external surface of 
the cell. 
7.1.4 AMIGO3 in multiple sclerosis 
One of the interesting results from this study is the evidence that AMIGO3 protein 
levels actually appear to reduce, although not significantly, in MS lesion plaques and 
in the healthy white matter of MS patients. These data do however suggest that 
AMIGO3 may not be being expressed in the human disease, at least in the brain. 
Alternatively, it is still possible that levels of AMIGO3 would have been high in early 
stages of plaque formation, however due to the samples being post-mortem, we were 
only able to analyse healthy white matter or developed plaques. It should be noted 
that these samples were collected post-mortem and therefore there is a chance, 




7.2 Limitations and further studies 
7.2.1 Models of myelination 
We used a number of models to examine myelination and remyelination however 
these models all had their limitations. Firstly, with our EAE models, we were only able 
to examine AMIGO3 expression before and after significant disease progression. As 
we hypothesised that AMIGO3 is likely to act in the acute stages of disease, we 
wanted to develop early stages models, however our attempts appeared to result in 
very mild induction of disease and were accompanied by minimal signs of 
demyelination. It would have been interesting to examine the levels of AMIGO3 
throughout EAE progression when recovery was present. For example, as we 
observed AMIGO3 levels rise and then drop immediately before developmental 
myelination, it would be interesting to see if a similar pattern is observed in the 
remyelination stage after EAE induced demyelination. This was similarly the case 
with our OPC cultures, as by D6 when we analysed the levels of AMIGO3, cells were 
already demonstrating substantial CC1 expression, indicating their maturation. As O4 
is arguably a marker of pro-OLs, it would have been interesting to observe levels of 
AMIGO3 in correlation with O4 expression (Baccarini M et al., 2008; Neman J and de 
Vellis J, 2008). 
Due to our results appearing preliminary with our knock down studies, it would be 
essential to repeat these experiments to back up our results. Additionally, it would be 
interesting if the reduction in PLP transcript translates to a reduction in PLP and other 
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signs of myelination. Examining the production of myelin-sheets, an in vitro sign of 
myelin production through O4+ staining would be one example of how to examine the 
early stages of myelin production (Mi et al., 2005). 
Another potential model would be to develop co-cultures with neurons, to examine 
OPC ensheathment in relation to AMIGO3 expression. This would allow a quick and 
effective model for examining remyelination in vitro. DRGN would be the most 
effective neurons for these models due to the low degree of contaminants associated 
with their dissection and culturing (O'Meara et al., 2011). 
7.2.2 OPC trauma and AMIGO3 expression 
One of the interesting conclusions from this study was the observation that 
AMIGO3 proteins levels are raised in EAE and that this matches a similar raise 
observed in excitotoxicity induced trauma to Oli-neu. Despite the clear rise in 
AMIGO3 protein expression in Oli-neu following excitotoxicity, AMIGO3 protein was 
not raised in our LPC model of OPC trauma. This shows that AMIGO3 is only 
upregulated due to specific traumatic events and signalling pathways. As EAE, and 
MS, are multi-factorial, questions arise to which forms of cell trauma are required to 
activate the expression of AMIGO3 in vivo. As such, further studies would be 
valuable to determine which forms of trauma induce AMIGO3 expression and why 
AMIGO3 is not upregulated in LPC induced OPC trauma. This could lead to 
interesting studies determining the pathways through which AMIGO3 expression is 
upregulated and provide us with a greater insight in to when AMIGO3 therapies 
would be beneficial. 
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7.2.3 Functional AMIGO3 studies 
Although we have observed correlations between AMIGO3 transcript and protein 
expression in varying models of myelination and remyelination, we have failed to 
develop an effective causative study. Knock down or constitutively active studies of 
AMIGO3 expression in vivo would be instrumental in understanding the role of 
AMIGO3 in myelination and remyelination. For example, comparing the effects of 
altered AMIGO3 expression on the rate of myelination/MBP production in 
development, or on the ability of primary OPC cultures to differentiate. This would 
also be fascinating with our trauma models to definitively link the altered AMIGO3 
expression profiles that we observed, to direct cellular responses. 
The most effective and translational in terms of demyelination would have been to 
analyse the effects of the development of EAE when AMIGO3 levels have been 
altered or the protein has been inhibited. This could have been done again through 
genetic editing or similarly to LINGO1 studies, through developing an effective 
inhibitor for AMIGO3, presumably in the form of an anti-AMIGO3 antibody therapy. 
An inhibitor could be administered in disease models which would allow for direct 
comparisons to the human demyelinating diseases. As demyelination in MS and EAE 
is associated with breakdown of the BBB and AMIGO3 in CNS enriched (Kuja-
Panula et al., 2003; Chen et al., 2006; Bennett et al., 2010), antibody therapies would 
be effective for localised CNS treatment. Additionally, as we expect AMIGO3 to be 
only expressed at low levels away from the sites of trauma, there is likely to be 
minimal side effects in healthy tissue associated with AMIGO3 inhibitors. 
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As we have discussed briefly before, it is possible that AMIGO3 is able to interact 
with itself or with NgR1 receptor complex proteins intercellularly in a similar way as 
that proposed for LINGO1 (Jepson et al., 2012). This could be investigated through 
incubation with soluble AMIGO3 with OPC cultures, as well as through altering 
expression profiles of AMIGO3 in co-cultures systems, for example knocking down 
AMIGO3 expression in DRGNs and using the KD neurons in co-cultures with our 
primary OPCs.  
As we have identified NgR1 as a potential mechanism through which AMIGO3 
signalling could occur in OPCs, it would be vital to determine whether this signalling 
results in the same characteristic RhoA activation observed in neurons (Mi et al., 
2004; Ahmed et al., 2013). Furthermore, it would be interesting to investigate if there 
is any preferential binding for AMIGO3 or LINGO1 with the NgR1 complex, which 
could be easily tested through co-immunoprecipitation studies. 
7.2.4 Translation to human demyelinating diseases 
One of the major limitations with our studies is the use of murine OPCs and EAE 
to model remyelination in disease. Although EAE shares a number of similarities to 
MS, the majority of successful EAE designed therapies have proven to be ineffective 
as treatments for MS, most notably the results of the LINGO1 clinical trials for optic 
neuritis (Cadavid et al., 2017). Clearly, there must be significant variation between 
the model and the human disease. As we are purely examining the remyelination 
process, it could be argued that this is less relevant compared to inflammation and 
immune response research, however it still needs to be considered that more 
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translational models would be beneficial to determine that any responses that we 
observed are clinically relevant. As EAE has been developed in primates, this 
demonstrates a valuable further step in regards to developing AMIGO3 therapies 
(Slierendregt et al., 1995; Baker and Amor, 2014), however stronger data of the 
functional role for AMIGO3 is essential before progressing to these higher models of 
EAE. 
A final point that has to be acknowledged with our studies is whether remyelination 
will be effective. Remyelination is known to produce thinner myelin sheaths than 
those prior to demyelination, raising the question as to how effective the new myelin 
sheaths can be (Duncan et al., 2017). Despite this limitation, encouraging 
remyelination will clearly provide some benefit in the form of axonal protection and 
restoration of saltatory conduction, therefore further investigations into the role of 
AMIGO3 in remyelination, and specifically following trauma induced demyelination, 
could be vital in developing effective treatments for demyelinating diseases. 
7.3 Final conclusions 
From our data, it is clear that AMIGO3 is expressed in OLG, and specifically in 
OPCs. We have shown that AMIGO3 levels are relatively low and do not become 
apparent until trauma has been received to the CNS, with AMIGO3 protein rising in 
both whole CNS extracts and in specifically in OPCs. The NgR1 receptor complex is 
shown to be present on mouse OPCs highlighting that AMIGO3 and LINGO1 would 
be able to function through this signalling pathway. It still is yet to be determined what 
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the direct effects of AMIGO3 expression are in both OPCs and demyelinating 
diseases, however our data raises AMIGO3 as a promising potential future 
therapeutic for treating demyelinating disorders. Further work is essential to 
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